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Abstract
DNA damage contributes to cancer, aging, and heritable diseases. Ironically, DNA
damaging agents are also commonly used in current cancer treatment. We therefore
need robust, high throughput, and inexpensive tools for objective, quantitative DNA
damage analysis. The single cell gel electrophoresis (comet) assay has become a stan-
dard method for DNA damage analysis, however, it is not well suited for use in clinical
and epidemiological settings due to issues of low throughput, poor reproducibility, and
a laborious image analysis requirement. To overcome these limitations, we applied
microfabrication techniques to engineer an arrayed cell comet platform that maxi-
mizes the number of analyzable cells and provides spatial encoding for automated
imaging and analysis. Additionally, we developed complementary software that elim-
inates the inherent bias of manual analysis by automatically selecting comets from
the defined array. In its 96-well format, the so-called CometChip integrates with high
throughput screening technologies, further increasing throughput and removing user
error. This improved approach enables multiple cell types, chemical conditions, and
repair time points to be assayed in a single gel with improved reproducibility and
processing speed, while maintaining the simple protocol and versatility of the comet
assay to assess a wide range of DNA damage. Using the CometChip, we evaluated a
variety of DNA damaging agents, revealing repair profiles that can be used to gain
insight into biological mechanisms of damage sensitivities. We confirmed the ability
of the CometChip to identify deficiencies in four major DNA repair pathways, sup-
porting the use of the assay in determining pathway sensitivities that may be useful
in guiding treatment strategies that more selectively target cancerous cells and re-
duce side-effects. We also used the platform to evaluate potential inhibitors of DNA
repair, which are emerging as promising adjuvants in cancer management. Taken
together, the CometChip enables high throughput genotoxic evaluation of chemical
exposures, discovery of novel chemotherapeutic strategies, and measurement of DNA
repair kinetics for identification of susceptible populations and disease prevention.
The CometChip is a significant advancement in DNA damage and repair technology,
providing high throughput, objective, and quantitative measurements that have the
potential to become a new standard in DNA damage analysis.
Thesis Supervisor: Bevin P. Engelward
Title: Associate Professor
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Chapter 1
Introduction
DNA damage promotes cancers, aging, neurological disorders and heritable diseases
[1]. Unfortunately, exposure to genotoxins is unavoidable, as cells are continuously
exposed to inflammatory chemicals, reactive byproducts of metabolism, adverse heat
and pH, mechanical stress, exogenous chemicals, radiation, and other agents that
damage DNA through formation of base lesions, crosslinks, and strand breaks. These
lesions interfere with transcription and replication and can lead to mutations that
can alter protein function and gene regulation, thus potentially disrupting critical
cellular processes. To protect the genome from these deleterious effects, cells have
evolved a complex network of coordinated DNA repair pathways, each having speci-
ficity for a subclass of DNA damage [2]. Imbalances in these pathways can allow cells
to accumulate mutations that drive carcinogenesis through promotion of selective ad-
vantages such as unregulated cell growth [3]. This excessive cell division makes cancer
cells especially vulnerable to DNA damaging agents, thus providing the basis for the
frontline therapeutic strategies of radio- and chemotherapy [4, 5]. The study of DNA
damage is therefore important in understanding mechanisms of disease, identifying
harmful exposures, mitigating risk to susceptible populations, and guiding treatment
strategies; however, there has been minimal improvement made to methods of DNA
damage analysis in the past two decades. Available tools are limited in throughput
and reproducibility, their range of DNA lesion detection, and their capacity to mea-
sure both DNA damage and repair in a variety of cell types. We overcame these
limitations by applying microfabrication techniques to engineer a high throughput
platform for measurement of the integrated DNA damage response that is useful in
both a variety of clinical and research settings.
1.1 Cancer
The World Health Organization lists cancer as the leading cause of global mortality,
with an estimated 8 million deaths and nearly 13 million new cases diagnosed each
year [6]. Cancer is a large, heterogeneous class of disease states that results from the
accumulation of heritable modifications in tumor suppressor genes and oncogenes that
promote phenotypic evolution by providing cancerous cells with a selective advantage
to dominate local tissue through clonal expansion [3]. It is now well established that
mutations that effect proteins involved in the many pathways of DNA repair are crit-
ical to carcinogenesis, as they promote mutagenesis through genomic instability [7].
Carcinogenesis describes the multi-stage succession of clonal expansions in which cells
acquire traits that enable them to become immortal, grow uncontrollably, evading cell
cycle checkpoints and apoptotic signaling, form tumors with their own blood vessel
networks, evade immune responses, colonize surrounding normal tissue, and finally
infiltrate the bloodstream and metastasize [8].
Although some single-nucleotide polymorphisms in oncogenes and tumor suppres-
sor genes have been shown to increase susceptibility, the promotion and rapid pro-
gression of 95% of cancers is thought to be the consequence of environmental factors
rather than genetic predisposition [9]. More than a quarter of cancer deaths involve
the use of tobacco, another third are related to diet and lifestyle, and as much as
a fifth are attributed to infections [10]. The remaining cases stem from exposures
to environmental pollutants and radiation. The carcinogenicity of these agents is
derived from their ability to both damage DNA and create mico-environments that
promote proliferation and provide selective advantages to evolving tumor cells. For
example, cigarette smoke contains over 4,000 chemicals, many of which damage DNA
(e.g. formaldehyde, arsenic, etc.), but also elicits an inflammatory response, which
may advance carcinogenesis through the production of reactive oxygen species and
activation of survival signaling cascades that promote cellular growth and transfor-
mation [11]. A deep understanding of both exogenous and endogenous sources of
DNA damage is therefore critical in evaluating the effects and carcinogenic potential
of environmental exposures.
DNA damage is also an important mechanism in cancer therapy. The uncon-
trolled, rapid proliferation of cancer cells makes them sensitive to compounds that
are mutagenic or interfere with cell cycle progression [2]. This will be discussed in
greater detail in Section 1.3 once the context of DNA repair and its role in genomic
stability and cancer resistance is established.
1.2 DNA Repair
In response to DNA damage, cells maintain genomic integrity by initiating complex
responses, including the recruitment of DNA repair proteins, which can be grouped
according to the DNA lesions they repair. The four major pathways that are most
relevant to the aims of this thesis are: 1) base excision repair (BER), 2) nucleotide
excision repair (NER), 3) interstrand crosslink (ICL) repair (ICLR), and 4) non-
homologous end joining (NHEJ). Other mechanisms exist and continue to be dis-
covered, including homologous recombination (HR), direct reversal, mismatch repair
(MMR), and microhomology mediated end joining (MMEJ). Knowledge of these re-
pair mechanisms and the specific proteins involved is important for predicting the
consequences of genotoxic exposures, evaluating cancer susceptibilities, diagnosing
heritable disease, revealing sources of tumor resistance, identifying drug targets, and
developing novel treatment strategies. To develop an assay that is specific enough to
detect subtle deficiencies in DNA repair, but general enough to be useful in a variety
of applications, a comprehensive understanding of DNA repair is required. Here, an
overview of BER, NER, ICLR, and NHEJ is provided.
1.2.1 Base Excision Repair
It is estimated that the BER pathway is utilized over 10,000 times per cell per day
in order to service the endogenous nucleotide lesion burden [12]. BER targets small
chemical alterations of bases (e.g. deamination, oxidation, alkylation) that can inter-
fere with transcription or replication, or contribute to mutagenesis through nucleotide
mispairing. While the DNA damage itself can be problematic, removal of such aber-
rant bases also leads to potentially dangerous repair intermediates, such as single
strand breaks (SSBs), which are toxic if not repaired efficiently by downstream BER
[13, 14, 15, 16]. Polymorphisms in such proteins have been linked to increased cancer
susceptibility [17], indicating that even subtle imbalances in DNA repair have impor-
tant implications regarding genomic stability. Indeed, deficiencies in proteins from
all stages of the BER pathway have been linked to carcinogenesis [18, 19, 20].
One of the core aims of this project is to develop better ways of monitoring BER
and of testing the impact of BER proteins on repair kinetics. BER involves over
a dozen proteins and is initiated by lesion-specific DNA glycosylases that identify
and cleave the N-glycosyl bonds of improper bases to generate apurinic/apyrimidinic
(AP) sites [21]. Glycosylases are either monofunctional, removing only the nucleotide
base, or bifunctional, possessing both glycosylase activity and the ability to cleave
the DNA backbone 3' to the resulting AP site [22]. AP sites also frequently result
from spontaneous hydrolysis [23, 24]. For monofunctional glycosylase initiated repair
(Figure 1-1), the AP lyase activity is performed by an AP Endonuclease (APE)
[25]. In mammalian cells, APE-1 is the sole endonuclease responsible for nicking
the phosphodiester backbone to generate a free 3'OH on the normal nucleotide and
a 5' deoxyribose phosphate (5'dRP) blocking terminus on the abasic site [26]. The
resulting SSB can be processed by either short-patch BER, which replaces only the
aberrant nucleotide, or long-patch BER, which replaces 2-10 bases from the damaged
DNA strand [27]. For the sake of brevity, only the short patch BER pathway will
be discussed in detail. Polymerase beta (Pol3) is responsible for the rate-limiting
removal of the 5'dRP blocking lesion and also gap filling [28]. In cases where 3'
terminal processing is required, such as frank SSBs, additional gap tailoring proteins
are available (e.g. polynucleotide kinase-3'-phosphatase (PNKP)) [29]. To complete
the BER process, the 3'-OH and 5'-phosphate nick are sealed by a ligase (i.e. Ligase
I or Ligase III) in an ATP-dependent manner [30]. These are the basic steps in BER,
which has many points of entry and sophisticated subpathways for processing a wide
range of lesions.
1.2.2 Nucleotide Excision Repair
While BER removes specific base lesions, NER recognizes helical distortions result-
ing from bulky lesions that may involve multiple nucleotide bases (e.g. pyrimidine
dimers). NER was first observed in mammalian cells as unscheduled DNA synthe-
sis (UDS) in response to X-ray irradiation, i.e. incorporation of nucleotides in cells
not undergoing DNA synthesis [31]. Shortly after, cells from human patients suffer-
ing from the sunlight-sensitive and skin cancer-prone hereditary disease, xeroderma
pigmentosum (XP), were shown to have diminished capacity for UDS [32]. This
lead to the discovery of seven key NER proteins named XPA through XPG after
the XP disease. NER capacity has since been associated with other diseases (e.g.
Cockayne's syndrome and trichothyodystrophy) and susceptibility to numerous can-
cer types [33, 34, 35]. The repair pathway has also been implicated as a mechanism of
tumor drug resistance [36, 37]. As such, the study of NER offers insight into genomic
stability, cancer progression, and potential drug targets.
NER is divided into two subpathways, global genome NER (GG-NER) and
transcription-coupled NER (TC-NER), which differ in their mechanism of lesion de-
tection. GG-NER is initiated by the helix distortion recognition complex, XPC-
Rad23B, while TC-NER, as its name suggests, is initiated by blockage of the RNA
Polymerase II during transcription [38]. As shown in Figure 1-2, Both subpath-
ways proceed similarly, by unwinding the DNA at the site of damage with the XPD
and XPB helicase containing transcription/repair complex, transcription factor II H
(TFIIH). This allows XPA, RPA and XPG to join the complex and engage ERCC1-
XPF for initiating excision 5' of the DNA lesion. The resulting 3'-OH group acts as
a substrate for DNA polymerase and other factors, which fill in the 24-32 nucleotide
gap resulting from 3' excision by XPG. The nick is sealed by a ligase to restore the
original DNA sequence [39].
1.2.3 Interstrand Crosslink Repair
The use of DNA damaging chemotherapies was initiated by the success of the ICL
agent, nitrogen mustard (NM), after World War II (described in Section 1.3) [40].
Today, crosslinking agents such as cisplatin are still routinely used in the management
of numerous cancers; however, although highly successful upon administration, they
are ultimately limited by tumor resistance [41]. Mechanisms of resistance are largely
unknown due partially to an unavailability of assays to detect crosslinking lesions
[42]. We aim to provide an analysis platform with the utility to both classify ICL
agents and detect deficiencies in their repair.
ICLs, adducts that covalently bridge both DNA strands, are formed endogenously
by agents such as products of lipid peroxidation [43]. They are extremely cytotoxic,
disrupting replication and transcription, and causing strand breaks, chromosomal
aberrations, or cell cycle arrest [44]. Figure 1-4a is an example of a NM induced
crosslink formed between two guanine residues. The structure of ICLs can vary sig-
nificantly depending on the source of damage and the local sequence context of the
affected nucleotide bases. As a result, initiation of ICLR occurs through a variety of
mechanisms, including encounters with transcriptional machinery, collision with repli-
cation forks (Figure 1-4b), or recognition of helix deformation [45]. This diversity of
response demands coordination of multiple repair pathways in complicated processes
that are still largely unknown. Deficiencies in both NER and HR have been shown
to sensitize cells to ICLs [46, 47], implying a scenario in which HR repairs the DSB
resulting from the excision, or "unhooking," of each opposing lesion by NER. In sup-
port of this model, people suffering from Fanconia anemia (FA), a disease resulting
from mutations in genes including the critical HR gene, BRCA2, are hypersensitive
to crosslinking agents [48]. Furthermore, XP patients with deficiencies in XPF, one
of the two incision proteins of NER, have been shown to have defective "unhooking"
of ICLs [49]. A more complete understanding of ICLR and the coordination of the
many pathways involved is still required to manage treatment of ICLR related herita-
ble diseases such as FA [50]. In addition, crosslinking agents have become invaluable
in cancer treatment over the past 30 years, but their efficacy is often limited by ICLR
[51]. A better understanding of this complex mechanism will surely lead to new drug
targets and strategies to overcome tumor ICL resistance.
1.2.4 Non-homologous End Joining
In addition to excision repair, which will be explored in Chapters II and III, we also
aimed to improve methods for studying double strand break (DSB) repair. There are
two major DSB repair pathways: HR, which uses the sister chromatid as a template
to accurately resynthesize damaged DNA, and the more predominant, error-prone
pathway, NHEJ, which directly ligates severed DNA ends [2]. NHEJ is active in
all phases of the cell cycle and operates with a kinetic half-life of less than 30 min
[52, 53]. If NHEJ is deactivated, blunt ended DSBs can be resected to reveal short
microhomologies that guide ligation in a process known as MMEJ [52, 54]. MMEJ
and other 'alternative end joining' processes are unfavorable due to the required loss of
genetic material associated with resection [55, 56]. These back-up pathways operate
with slower kinetics (t1 / 2 > 2 hr) and are thereby dominated by the faster NHEJ
pathway [52, 57, 53].
An initiating step in NHEJ is recognition of the DSB by the Ku70/Ku8O het-
erodimer (Figure 1-3). The Ku heterodimer forms a ring-like structure that protects
the DSB ends from degradation [58, 59] and inhibits the initiation of alternate repair
pathways [52]. Multiple Ku proteins bind to a single DNA molecule and recruit the
catalytic subunit, DNA-PKcs, forming the DNA-dependent protein kinase (DNA-
PK) complex, which promotes strand alignment through trans-autophosphorylation
[60, 61, 62]. The activated DNA-PK undergoes a conformational change that fa-
cilitates accessibility, recruitment, and activation of ligation and processing factors
(i.e. XRCC4/Ligase IV complex and Artemis), as well as its subsequent release from
the DNA end [63, 64]. Deficiencies in DNA-PK lead to extreme radiosensitivity [65],
which has recently brought it attention as a potential target for adjuvant cancer treat-
ment. Chapter IV will explore the development of a DSB repair assay for evaluating
such treatment strategies.
1.3 DNA Damage and Repair in Cancer Therapy
Information concerning DNA damage and repair is not only important in the study
of cancer formation, but also in developing treatment strategies and understanding
mechanisms of resistance. There have been many recent advances in biotechnology,
but the three pillars of cancer treatment nevertheless remain: radiotherapy, surgery,
and chemotherapy. Ionizing radiation therapy has been employed for over a century
to combat cancer through direct collision with DNA or indirectly through the for-
mation of free radicals that damage DNA [4]. In the United States, radiotherapy is
given to nearly two-thirds of all cancer patients [66]. The main mechanism of action is
formation of toxic DSBs by direct induction or through endogenous cellular processes
such as DNA repair and replication, which are overactive in rapidly dividing cancer
cells [2]. Side-effects to healthy tissue are reduced through localized exposure and
by delivering radiotherapy in fractionated doses. For example, small doses may be
given every six hours, enabling normal tissue to repair, while rapidly dividing tumors
accumulate damage. Concurrent administration of chemotherapy treatment is effec-
tive in radiosensitizing tumors, and novel small molecule inhibitors of DNA repair are
emerging to further enhance the efficacy of radiotherapy [4].
Cancer cells are also preferentially sensitive to the cytotoxic effects of chemical
compounds that damage DNA or interfere with replication machinery. The success
of NM in the treatment of leukemia after World War II initiated the field of anti-
cancer chemotherapy and the evolution of three distinct categories of drugs: alkylat-
ing agents, antimetabolites, and antineoplastic antibiotics [40]. Nitrogen mustards are
bifunctional alkylating agents that form DNA crosslinks through affinity for the N7
position of guanine residues (Figure 1-5), which has relatively high nucleophilic po-
tential due to its relatively accessible position in the major groove of the double helix
[67]. DNA crosslinks are extremely cytotoxic because they block metabolic processes
such as replication and transcription [45]. Mono-alkylating agents such as methyl
methanesulfonate (MMS) and N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) cre-
ate N7-methylguanine, N3-methyladenine, and 0 6-methylguanine lesions (Figure 1-
5). The mutagenic potential of 0 6-methylguanine to mispair with thymidine is one
mechanism of alkylation toxicity. Interestingly, its toxicity is thought to result in part
through a process in which mismatch repair removes the mispaired thymidine in an
iterative and futile turnover of the daughter strand [68]. Direct removal of the lesion
by 0 6-methylguanine methyltransferase (MGMT) therefore provides a route of tumor
resistance [69]. N7-methylguanine and N3-methyladenine also contribute to alkyla-
tion toxicity, evidenced by the potency of MMS, in which less than 1% of the lesion
burden is 0 6-methylguanine. N7-methylguanine is relatively innocuous compared to
N3-methyladenine, which interferes with replication [67]. Both adducts additionally
destabilize the N-glycosidic bond, potentiating abasic site formation through hydrol-
ysis. Furthermore, their processing by BER forms SSB repair intermediates, which
if not repaired efficiently, are preferentially toxic to rapidly dividing cancer cells [70].
So while proficient BER acts as a mechanism of resistance to certain levels of alkyla-
tion, imbalances in the pathway can lead to accumulation of BER intermediates and
hypersensitivity to alkylation damage [71, 13, 14, 15, 16]. This was further illustrated
by Sobol, et al. who demonstrated that cells could be sensitized to alkylation damage
through accumulation of BER intermediates resulting from either overexpression of
the initiating glycosylase (i.e. alkyladenine glycosylase (AAG)) or inhibition of the
rate limiting polymerase step by Polo [14, 70]. The role of Pol# in protecting against
toxicity associated with accumulation of BER intermediates makes it an effective tar-
get to increase sensitivity of tumors to alkylation damage [15, 72, 73, 74]. Similarly,
small molecule inhibitors of upstream APE-1 activity have also been shown to result
in accumulation of toxic AP sites [75, 76, 77, 78]. Thus, a better understanding of
the role of DNA repair in tumorigenic resistance can guide treatment strategies and
help identify new targets of tumor susceptibility.
The use of inhibitors of DNA repair proteins is not limited to BER, but is
rather an emerging approach in cancer management to sensitize tumors to radio-
and chemotherapeutic approaches [79, 80, 81, 5]. Another compelling strategy is to
sensitize cells to DSBs through the inhibition of DNA-PK in NHEJ repair. This is
supported by studies demonstrating that cells lacking either subunit of the protein
kinase (i.e. Ku70/Ku8O heterodimer and DNA-PKcs) have increased radiosensitivity,
significant increases in chromosomal aberrations, and more MMEJ associated misjoin-
ing [82, 83, 84]. Such misrepairing is difficult to measure, as standard mammalian
assays provide information about residual DNA damage, but offer little insight into
mode of action and actual lesion burden. Indeed, whole-cell screening platforms to
identify small molecule inhibitors of NHEJ will be increasingly valuable to the phar-
maceutical industry as more companies add inhibitors of DNA-PK and other DNA
repair proteins into their preclinical pipelines [81].
1.4 Methods to Detect DNA Damage
Although effective methods for assessing DNA damage levels have been available
for decades, and it is well established that information about DNA damage levels
is highly useful both in the clinic and in population studies, measurements of DNA
damage and repair in human cells are far from routine. Currently available assays
are limited in throughput and often provide information about residual DNA damage
(e.g. chromosomal aberrations or mutations), but offer little insight into the actual
lesion burden or kinetics of repair. This section describes the strengths and limitations
of assays commonly used to evaluate DNA damage and repair, including unscheduled
DNA synthesis test (UDS), pulse field gel electrophoresis (PFGE), gamma-H2AX
assay, the chromosomal aberration (CA) test, sister chromatid exchange (SCE) assay,
and micronucleus (MN) assay. The single cell gel electrophoresis (comet) assay will
be described in detail in Section 1.5. Better genotoxicity tools that directly measure
DNA damage must be developed in order to perform epidemiological studies that
both reveal the impact of variations in DNA repair capacity and guide development
of valuable biomarkers of cancer susceptibility. In addition, the United States Food
and Drug Administration (FDA) is searching for new strategies that can provide
greater detail concerning mechanism of genotoxicity at early stages of drug discovery
to eliminate the cost and requirement of rodent models in later stages of development
[85].
1.4.1 Unscheduled DNA Synthesis Test
Unscheduled DNA synthesis (UDS) refers to the replication of DNA during NER. By
culturing cells in the presence of radionucleotides, the amount of UDS resulting from
an exposure of interest can be quantified as an indicator of DNA damage. Scintil-
lation counters cannot discriminate semi-conservative replication from UDS in a cell
suspension, so autoradiography is required to visually quantify the extent of UDS,
excluding cells undergoing synthesis based on their high radionucleotide content. This
process is extremely laborious and neither directly nor selectively measures the re-
moval of a specific type of damage. However, at this time, the UDS test is the only
functional test to directly measure NER activity on the entire genome without the
use of antibodies [86]. It has therefore been adopted by the FDA as a supplementary
in vivo test in rats to evaluate the extent of liver genotoxicity [85].
1.4.2 Pulsed Field Gel Electrophoresis
Constant field gel electrophoresis is an invaluable technique in molecular biology
to separate DNA fragments based on their size, but is limited to the range of 100
base pairs (bp) to 50 Kbp. PFGE was developed to measure large fragments of
DNA resulting from DSBs. By periodically changing the direction of the electric
field, fragments as long as 10 Mbp can be separated. The concept behind PFGE is
that larger molecules take longer to reorient in the alternating electric field and can
therefore be separated from shorter fragments that are able to more quickly change
direction. Pulse times are optimized so that DNA molecules of a targeted size spend
most of their time reorienting. At the end of the long electrophoresis process (>30
hr), the fragments of DNA that have migrated into the gel are stained, cut from
the gel, and quantified using scintillation counting. This radiation requirement limits
the applications of PFGE, because cells must be pre-incubated for 24 hr to allow
incorporation of radiolabeled nucleotides into their genome. Other limitations of the
assay include a 17 hr lysis, in addition to the 30 hr electrophoresis, which significantly
reduces throughput [87].
1.4.3 Gamma-H2AX Assay
Phosphorylation of histone variant H2AX is an early signaling event in response to
DSB induction, and detection of '7-H2AX has emerged as a sensitive indicator for DSB
quantification [88, 89, 90, 91]. The formation and disappearance of 7-H2AX has been
shown to correlate linearly with DSBs induced by radiation doses as low as 1 mGy [92].
The sensitivity and low cell requirement of the -y-H2AX assay are favorable for use
in biodosimetry and cancer staging, and higher throughput versions of the assay are
emerging for the evaluation of novel cancer therapies [93, 94, 95, 96]. However, as an
indirect and non-specific marker of DSB repair, the -- H2AX assay is inappropriate for
precise analysis of repair kinetics [89]. For example, the -y-H2AX assay is inaccurate
for measurement of NHEJ inhibition, because H2AX phosphorylation is dependent
on the activity of DNA-PK and other phosphatidylinositol 3-kinase (P13K) related
kinases (PI3KKs) [97]. Furthermore, the disappearance of the -- H2AX signal may
not correlate precisely with DSB repair [98, 89, 99]. One hypothesis is that y-H2AX
continues to mark DSBs after completion of NHEJ in order to signal further processing
and chromatin remodeling [100]. Other explanations are that the dephosphorylation
of -y-H2AX is simply limited by the concentration and activity of the phosphatase
(i.e. PP2A) [101]. What is clear is that as an indirect marker of DSB disappearance,
7-H2AX is limited in its utility for precise analysis of repair kinetics.
1.4.4 Chromosomal Aberration Test and Sister Chromatid
Exchange Assay
Chromosomal aberrations are a very severe form of DNA damage and are associated
with heritable diseases and tumorigenesis. Improperly repaired DSBs can result in
chromosomal breaks, gaps, fusions, deletions, translations, and inversions [2]. Al-
though many of these structural aberrations cause cell death, they also serve as indi-
cators of DNA damage in neighboring cells that may not be lethal, but may instead
have profound genetic consequences. The FDA approves the chromosomal aberration
(CA) test as the frontline method for determining carcinogenicity [85]. To analyze
aberrations, cells are fixed in metaphase using a microtubule inhibitor such as col-
cemid. The cells are then harvested and added to a hypotonic solution in order to
burst the cells open and enhance separation of the chromosomes. The chromosomes
are then stained and evaluated under a microscope for easily identifiable aberrations
such as dicentric and ring chromosomes, breaks, gaps, and aneuploidy [102]. The
CA test is a direct marker of genotoxicity and a powerful predictor of carcinogenic
potential [103], but does not provide mechanistic information and may not detect
nonlethal exposures with mutagenic potential. Limitations in the assay include the
requirement of in vitro cell cultivation, a laborious analysis process, and an inability
to directly measure DNA repair.
Sister chromatid exchange (SCE) describes the process whereby genetic material
is exchanged between two identical chromatids through HR during mitotic repair
of DSBs [104]. SCEs are a biomarker for chromosomal recombination, but their
frequency has not been shown to correlate with cancer risk [103]. The assay is time
consuming, requiring two consecutive cell cycles to incorporate bromodeoxyuridine
(BrdU), a mutagenic analogue of thymidine, for visualization of exchange events.
Chromatids in which only one strand incorporated BrdU stain dark with Giemsa,
while those with two rounds of synthesis stain lighter [105]. The SCE assay is limited
by its requirement of two rounds of mitosis, detection of only damage repaired by
HR, and manual image analysis requirement, which is labor intensive and subject to
bias. In addition, the endpoint is not accurate for ionizing radiation and some other
damaging agents, because BrdU is highly reactive and can itself contribute to the
formation of SCEs [106].
1.4.5 Micronucleus Test
Chromosomal breakage or spindle damage during the metaphase/anaphase transition
of mitosis can result in improper chromosomal integration into the daughter nucleus.
Chromosomal fragments that remain in the mother cell form micronuclei (MN) that
can be visualized through fluorescent staining and counted as a measure of relative
genotoxic activity. The assay can be performed in vivo on the erythrocytes of mice,
which lack a nucleus, making identification of micronuclei straight forward [107]. This
version of the assay is recommended by the FDA for genotoxicity screening, because
it can detect a wide spectrum of changes in chromosomal integrity, including aneu-
ploidy. For in vitro studies, most cell types can be assayed using an actin inhibitior
(i.e. cytochalasin-B) to prevent cytokinesis in order to count micronuclei in bionu-
cleated cells. The in vitro MN test is an indirect measure of DSBs with relevance
only in mitotic cells. The assay has minimal quantitative capacity and provides no
information concerning specific types of DNA damage or DNA repair. Furthermore,
it requires a laborious imaging and analysis process [108].
1.5 Comet Assay
Over the past two and a half decades, the comet assay has become a standard method
for detecting base lesions and DNA strand breaks with sensitivity down to sponta-
neous damage levels [109]. The comet assay is inexpensive, requires a relatively few
number of cells, and has the versatility to measure a range of DNA lesions, in a variety
of cell types [110]. In the traditional gel electrophoresis protocol (Figure 1-6), cells are
embedded in agarose on a slide and a lysis solution is used to dissolve cell membranes
and disrupt nucleosomes, leaving a nucleoid of negatively charged, supercoiled DNA.
An alkaline electrophoresis buffer (pH > 13) is used to unwind the DNA and expose
SSBs and alkali-labile sites. An electrical current is then applied across the slide to
pull relaxed loops and fragments of DNA toward the positive anode. The resulting
morphology resembles a celestial comet when imaged using a fluorescent nucleic acid
stain. Image processing software or manual analysis is used for DNA damage quan-
tification under the governing principle that damaged DNA migrates more readily
into the so-called "comet tail" than undamaged DNA, which remains tightly wound
within the "comet head" [111].
While most genotoxicity assays probe a fairly specific repair process - e.g. y-H2AX
assay measures an early signal in DSB repair and UDS measures the incorporation of
radionucleotides during NER - the comet assay directly measures DNA strand breaks,
giving it the versatility to detect several different classes of DNA damage through
simple modifications in protocol. The alkaline version of the assay detects SSBs, but
also abasic and alkali labile sites, which have also been shown to be mutagenic [112].
DSBs can be quantified by using a neutral buffer [113, 111], ICLs can be detected as a
decrease in comet tail length after radiation induced damage [114], and specific base
lesions can be assessed using lesion specific glycosylases [115]. The comet assay also
directly detects the disappearance of strand breaks, which can be used to precisely
measure kinetics of the integrated DNA repair response to a given exposure [12, 116].
There are over 4,000 publications using the comet assay with diverse applications,
including investigating DNA damage levels associated with cigarette smoke and other
environmental genotoxins [117, 118, 119, 120], determining the roles of specific DNA
repair proteins [82, 46, 121, 122, 20, 48] and the influence of their polymorphisms
[123, 124, 125, 126, 127], predicting cancer susceptibility [128, 129, 116], establishing
biomarkers for use in nutritional studies [130, 131], and understanding the connection
between oxidative stress and disease [132, 133, 134, 135]. In addition, the assay
is a strong candidate for clinical applications such as determining radiosensitivity
of tumors [136], and evaluating chemotherapeutic options [137]. The comet assay
requires relatively few cells and can performed in both in vitro and in vivo studies
[138], making it an attractive option for preclinical pharmaceutical screening [139,
140, 141, 142, 143, 144].
Higher throughput detection of DNA damage is important in classification of
chemicals, pharmaceutical screening and the development of novel cancer therapies.
The FDA currently recommends the following standard three stage test battery for
genotoxicity: 1) bacterial reverse mutation test (i.e. Ames test), 2) in vitro test
for chromosomal aberration in mammalian cells (i.e. CA ), and 3) in vivo test for
chromosomal aberrations in rodent hematopoietic cells (i.e. CA or MN). At the
5th International Workshop on Genotoxicity Testing (IWGT) in 2009, the use of the
comet assay as an in vitro test was discussed, because it does not require proliferation
and measures a wide range of DNA damage [145]. Furthermore, the comet assay has
been shown to have similar sensitivity to the MN Test, while providing more specific
information on mode of action [146, 147, 148]. The comet assay may be used in
combination with the MN Test to eliminate false negatives from the Ames Test and
eliminate unnecessary, costly in vivo rodent studies [149]. The FDA has recommend
the in vivo comet assay as a follow-up test [143, 85] and it has been shown that the
comet assay can be effectively combined in the same animal with the in vivo MN Test
to provide additional safety testing on critical target organs [150].
As a stand-alone test, issues relating to specificity and sensitivity of the comet
assay need to be addressed before it is accepted by the regulatory framework [137].
One issue in terms of its utility as a standard gentoxicity assay is that the comet assay
does not detect aneugenic effects and epigenetic mechanisms of DNA damage such
as effects on cell-cycle checkpoints [110]. Other limitations include low throughput,
slide-to-slide variability, limited parameter control, and image processing and analysis
that are laborious, time consuming, and often biased [151, 152].
Many researchers have attempted to overcome these weaknesses in order to un-
lock the true potential of the comet assay as a high throughput, robust technique for
measure of the integrated DNA damage response. Their approaches, however, have
focused on improving a single variable rather than providing a complete solution.
For example, Trevigen Inc. (Gaithersburg, MD) commercialized a high throughput
version that enables 96 samples to be assayed on a single glass slide. Although this
approach simplifies electrophoresis and imaging, it still requires a logistically challeng-
ing preparation procedure, because all samples must be counted and exposed prior to
plating. The development of a multichamber plate (MCP) by Stang, et al. overcomes
this requirement by enabling multiple cell samples or chemical concentrations to be
treated in a 96-well format. Because the multichamber plate does not address issues
associated with random distribution of cells in wells, four wells are required per sample
(-25 cells per well), reducing the throughput from 96 to 24 samples per plate [153].
Furthermore, the approach applies only to adherent cells and requires an optimized
seeding time for each cell type ranging from 2-4 hr with potential of over-adherence,
which results in abnormal comet morphologies. This incubation requirement limits
its utility for assessing primary cells. Another group focused on improving the repro-
ducibility of the comet assay by incorporating BrdU labeled reference cells. Although
this approach was important in identifying the contribution of subtle gel differences
in slide-to-slide variation, it drastically reduced throughput by requiring the use of
antibody detection and additional imaging of BrdU labeled control cells [154]. Many
other groups have addressed specific issues such as imaging bias [155, 156], analy-
sis algorithms [157, 158], statistical issues [159], interlab variability [160, 161], and
protocol standardization [133, 162].
The major goal of this project was to overcome the limitations of throughput
and reproducibility while maintaining the core strength of the comet assay, namely,
a straight forward and inexpensive protocol with the ability to operate in a variety
of modes for sensitive detection of a range of DNA lesions and their repair on a
single cell basis. Shown in Figure 1-6, the comet assay protocol can be divided into
seven steps according to the guidelines established by the International Workshop
of Genotoxicty Test Procedures (IWGTP) [140]: slide preparation, lysis, alkaline
unwinding, electrophoresis, neutralization, staining and imaging, and comet scoring.
By exploring each step of the comet assay protocol, the sources of these limitations are
revealed and an engineering approach is defined that not only improves throughput
and reproducibility, but extends the utility of the comet assay for novel applications
in new research settings.
Slide Preparation: Slide preparation is a time consuming and laborious proce-
dure. Slides must be pre-coated in agarose and cell samples must be counted in order
to optimize the seeding concentration. Cell samples are then mixed in agarose, added
to the pre-coated slides, cover-slipped to form a consistent layer, and allowed to settle
to a uniform focal plane. Each sample requires a single slide, making it difficult to
process more than 20-30 conditions at a time. This large slide requirement makes
evaluating multiple chemical conditions a logistical challenge, so many researchers
first expose cells in microtiter plates, which leads to savings in time and chemicals
[163]. However, the subsequent trypsinization and slide preparation allows for DNA
repair, which may contribute to issues in reproducibility. Trypsinization and centrifu-
gation may also be damaging to the cells [164]. Lysis: Lysis is a straightforward step
in which slides are placed in a cold, high salt, alkaline pH (>13) detergent solution
to osmotically rupture cells and disrupt their nuclear membrane, leaving a tightly
wound nucleoid of DNA. One issue with lysis is that agarose gels can be lost from
the glass slides. Alkaline unwinding: The alkaline unwinding step denatures DNA,
exposing SSBs and alkali labile sites. This step is excluded in the neutral version of
the assay for detection of DSBs. Electrophoresis: Electrophoresis draws the neg-
atively charged loops and fragments of DNA toward the anode, producing a "tail"
that is used as a measure of DNA damage. The main limitation of this step is the
volume of the electrophoresis box, which limits the number of slides that can be run
simultaneously and therefore under identical DNA migration conditions. Neutral-
ization: Tris buffer (pH 7.5) is used to neutralize slides from their alkaline state in
preparation for DNA staining. Staining and imaging: A fluorescent DNA stain of
choice (e.g. SYBR Gold) is used for visualization of comets. Imaging contributes the
most to limitations in throughput. Slides are imaged individually under fluorescent
microscope at a rate of approximately 10-15 per hour [111]. The optimal number of
comets per visual field is "no more than a few," according to the IWGTP [140]. This
restriction minimizes the number of unanalyzable comets resulting from overlap, but
requires the imaging of numerous visual fields to obtain the minimum 50 comets that
are sufficient for statistical analysis [165]. Imaging is generally a manual process and
slides have to be switched by hand. Automated imaging systems with slide feeders are
becoming more prevalent, but are expensive and often limited in imaging efficiency
due to difficulty of autofocusing on cells that are randomly distributed at multiple
focal planes within the agarose. Comet scoring: A number of comet parameters
can be derived from dimensional analysis of the comet "head" and "tail." In the
alkaline version of the assay, both the proportion of DNA that migrates from the
head (% tail DNA) and the distance it travels (tail length) correlate linearly with
DNA damage. The use of % tail DNA, as a normalized parameter, is an unambigu-
ous measure, minimizes inter-laboratory differences due to discrepancies in protocol
(e.g. electrophoresis time), and is linearly related to DNA break frequency over a wide
range of damage levels [140, 152]. In the neutral version of the assay, tail length is the
preferred measure, because it best captures the presence of DNA fragments resulting
from DSBs [111]. Scoring can be conducted manually using visual analysis or through
the use of commercially available software. Although visual scoring has been shown
to give reliable, quantitative results [158], the method is laborious and prone to bias
even when conducted by a skilled operator [156]. Semi-automated computer algo-
rithms, such as the Komet Software (Andor Technology, Belfast, Northern Ireland),
automatically calculate parameters, providing a more rigorously quantitative analy-
sis; however, such programs still require user selection of comets, which is tedious and
potentially subjective. For high throughput applications, fully automated analysis is
the logical approach, because it is fast and minimizes user involvement. Currently
available software packages (e.g. Metafer, Metasystems, Germany) are prohibitively
expensive and imperfect in that they can introduce error by not registering highly
damaged comets, miscalculating head-to-tail thresholds, and by analyzing improper
objects, overlapping comets, etc. [158].
In summary, the main limitations of the comet assay, low throughput and repro-
ducibility, are factors of two key limitations: the use of one slide per condition, and the
random distribution of cells in the agarose gel. The slide requirement directly limits
throughput by demanding significant handling with inefficient use of chemicals and
reagents. The slide requirement also makes for a logistically challenging protocol with
many opportunities for human error, as well as error that is inherent to using multiple
gels, and running multiple electrophoresis chambers. The slide number also translates
to a laborious imaging requirement. As others have demonstrated, this limitation can
be overcome by housing all conditions on a single slide (Trevigen) [153]. However,
this does not overcome the random distribution of cells within the agarose, which
leads to inefficient use of slide surface area, and complications for automated imaging
(i.e. focusing, comet identification) and automated analysis (i.e. overlapping comets).
This limitation can be overcome by patterning cells in a two-dimensional array, which
would maximize the number of comets per unit area, enabling simultaneous analysis
of all conditions on a single slide for improved throughput and reproducibility. A cell
array would also benefit the imaging process by maximizing the number of comets
per visual field, eliminating overlapping comets, and reducing the focal range. Lastly,
this approach would simplify automated analysis, because each cell would have a
specific address and objects not found within the cell matrix could be disregarded as
contamination. Our goal was to use microtechnology to reinvent the comet assay as a
single cell microarray platform for high throughput DNA damage and repair analysis.
1.6 Patterning techniques
Microfabrication describes a collection of processes developed by the semi-conductor
industry to produce miniature structures. In the past twenty years, these techniques
have fueled innovation in biological engineering by enabling single-cell analysis. Cells
are increasingly appreciated as heterogeneous entities, each with the potential to
initiate disease. Understanding how cells respond one by one is important in diag-
nosing and understanding disease progression, as well as drug targeting. "Lab-on-a-
chip" applications also minimize the amount of reagents that are required, increase
throughput, enable faster analysis and integration with sequential processes, and re-
duce waste. Microfabrication is used to create well-, trap-, pattern-, and droplet-based
devices for a wide range of single-cell technologies, including fluorescence-activated
cell sorting, cytotoxicity evaluation, polymerase chain reaction, proteomic and ge-
nomic analysis, and the study of cellular interactions, dynamics, mechanics, division,
differentiation, morphology, etc. [166].
Photolithography, illustrated in Figure 1-7, is a powerful technique for the minia-
turization of biological tools, because it provides the micrometer precision necessary
to capture single cells. The founding principle is that ultraviolet (UV) radiation
permanently crosslinks photoresist (i.e. SU-8) onto a silicon substrate for design of
fluidic channels, wells, or other features. Polydimethylsiloxane (PDMS) is a silicone-
based polymer that can be poured over a silicon-SU-8 device and allowed to harden
into a durable microfeature device for direct use or as a reusable stamp for pattern-
ing of biomolecules in a process termed soft lithography. These technologies can be
implemented to pattern cells through a variety of approaches, including bimolecular
micropatterning, mechanical trapping, and microwell separation [166].
Soft lithography can be used to pattern surfaces with biomolecules (e.g. fibronectin
or collagen) for directed cell adhesion. This technique enables high resolution pat-
terning that is ideal for surface interaction studies, but is limited to adherent cell
types [167]. Continuous flow microfluidic devices enable the analysis of cells with
precise control over their microenvironment. For this application, a PDMS device is
permanently bonded to glass using RF plasma techniques in order to form hydropho-
bic microchannels. Pumps and valves can be used to introduce specific reagents and
mechanical traps can be utilized to separate cells for individual analysis. Although
in principle, microfluidic devices offer a powerful, self-contained solution to cell pat-
terning, they are inherently difficult to operate, because flow rates are dependent
on the properties of the entire system and are thereby drastically affected by liquid
properties (e.g. viscosity) and other factors (e.g. bubble formation) [166]. The use
of microwells to capture single cells is the least challenging approach, and has been
achieved in a variety of materials (e.g. PDMS, poly(ethylene glycol), polystyrene)
[168, 169, 170]. Well size can be varied to accommodate one or more cells, which
are captured by gravitational settling. Passive seeding leads to potential issues in
cell loading efficiency. Another drawback is an inability to measure instant cellular
responses to reagents due to limitations in practical liquid dispensing techniques [170].
1.7 Specific Aims
DNA damage is a critical risk factor for cancer, aging, and heritable diseases [21, 171,
1], and it is the underlying basis for most frontline cancer therapies [5]. Increased
knowledge about DNA damage and repair would facilitate disease prevention, identi-
fication of individuals at increased risk of cancer, discovery of novel therapeutics, and
better drug safety testing. Despite their obvious translational impact, most DNA
damage assays have not changed significantly in more than two decades, and thus
are not compatible with modern high throughput screening (HTS) technologies. To
better assess the biological impact of damage, we need data that reflect the integrated
effect of multiple DNA repair pathways and subpathways, in response to a range of
DNA lesions, measured in an accurate and high throughput fashion.
This thesis describes our work aimed at transforming the well-established comet
assay into a high throughput, reproducible assay for experimental, clinical, and epi-
demiological applications. The governing hypothesis was that by patterning cells
using microfabrication technologies, we could both increase the number of samples
assayed on a single device through miniaturization, and improve the quality and ef-
ficiency of analysis by utilizing automated imaging systems and developing software
that takes advantage of spatial optimization of cells. We envisioned other advantages
to an arrayed based comet assay, including the ability to precisely measure DNA
repair kinetics on a single device, integrate the platform with standard HTS tech-
nologies, and multiplex endpoints such as cell viability to extend the utility of the
assay.
Chapter II describes the development of a strategy to microarray single cells in
agarose gel. We explored several distinct methods of cellular patterning, including
the use of microfluidic trapping and collagen island adhesion. The requirement of
molten agarose proved to be a barrier to a microfluidic approach. Collagen adhesion
was successfully used to pattern primary rat hepatocytes for increased throughput
radiation studies, but was ultimately abandoned due to limitations in throughput
and cell type accommodation [172]. The use of microwells enabled an inexpensive,
straightforward and reproducible method for patterning numerous cell types. As
anticipated, the use of patterning enabled multiple conditions to be assayed on a
single gel and allowed us to develop software that automatically locates and analyzes
comets based on their distinct locations in the array. Taken together, these advantages
resulted in both increased throughput and reproducibility.
Ultimately, we want to provide an assay that is useful both in epidemiological ap-
plications, such as identifying susceptible populations, and in clinical practice, such
as determining tumor sensitivities and guiding treatment strategies. It was therefore
important to determine the assay's detection thresholds for various DNA damaging
agents and confirm its ability to detect known deficiencies in repair. In the work
described in Chapter III, we further increased throughput by improving our micro-
fabrication process and adapting the technology to a 96-well version known as the
CometChip, which integrates with standard HTS technologies. This enabled simul-
taneous evaluation of multiple cell types, chemical conditions, and repair time points
on a single device. We demonstrated the usefulness of the CometChip for detection
of a variety of DNA damaging agents, revealing the ability of the assay to detect
subtle differences in lesion specific repair, which may be useful in characterizing the
genotoxic effects of chemical agents. We also identified deficiencies in three excision
repair pathways, providing support for existing mechanistic models of DNA repair,
and supporting the use of the platform in applications such as the development of
biomarkers of disease susceptibility.
In Chapter IV, we applied our single cell patterning approach to the neutral
version of the comet assay for detection of DSB repair, which is known to be an im-
portant mechanism in tumor resistance and therefore a potential target for adjuvant
chemotherapy. Currently available assays for DSB detection are limited in through-
put and specificity and offer minimal information concerning kinetics of repair. In
contrast, the CometChip measures physical DSBs for direct detection of repair. We
demonstrated an ability to identify multiple genetic deficiencies in NHEJ and sensi-
tively evaluate a set of clinically relevant inhibitors of DSB repair. In total, this work
represents a signficant advance in DNA damage and repair assessment technology.
The CometChip enables high throughput, objective analysis of a variety of DNA le-
sions for potential use in applications such as the development of predictive assays
for untested compounds, and enables direct measurement of DNA repair, which may
be useful for the development of clinical assays.
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Chapter 2
Single cell trapping and DNA
damage analysis using
microwell arrays
2.1 Abstract
With a direct link to cancer, aging, and heritable diseases as well as a critical role in
cancer treatment, the importance of DNA damage is well established. The intense
interest in DNA damage in applications ranging from epidemiology to drug develop-
ment drives an urgent need for robust, high throughput, and inexpensive tools for
objective, quantitative DNA damage analysis. We have developed a simple method
for high throughput DNA damage measurements that provides information on mul-
tiple lesions and pathways. Our method utilizes single cells captured by gravity into
a microwell array with DNA damage revealed morphologically by gel electrophore-
sis. Spatial encoding enables simultaneous assays of multiple experimental conditions
performed in parallel with fully automated analysis. This method also enables novel
functionalities, including multiplexed labeling for parallel single cell assays, as well
as DNA damage measurement in cell aggregates. We have also developed 24- and
96-well versions, which are applicable to high throughput screening. Using this plat-
form, we have quantified DNA repair capacities of individuals with different genetic
backgrounds, and compared the efficacy of potential cancer chemotherapeutics as in-
hibitors of a critical DNA repair enzyme, human AP endonuclease (APE-1). This
platform enables high throughput assessment of multiple DNA repair pathways and
subpathways in parallel, thus enabling new strategies for drug discovery, genotoxicity
testing, and environmental health.
2.2 Introduction
DNA damage is a critical risk factor for cancer, aging, and heritable diseases [1, 2, 3],
and it is the underlying basis for most frontline cancer therapies [4]. Increased knowl-
edge about DNA damage and repair would facilitate disease prevention, identification
of individuals at increased risk of cancer, discovery of novel therapeutics, and better
drug safety testing. Despite their obvious translational impact, most DNA damage
assays have not changed significantly in more than two decades, and thus are not
compatible with modern high throughput screening technologies. In order to better
assess the biological impact of damage, we need data that reflect the integrated effect
of multiple DNA repair pathways and subpathways, in response to a range of DNA
lesions, measured in an accurate and high throughput fashion.
The single cell gel electrophoresis or "comet" assay is based on the principle that
relaxed loops (induced by single strand breaks (SSBs)) and DNA fragments migrate
farther in an agarose gel than undamaged DNA [5, 6, 7, 8]. The alkali comet as-
say sensitively detects a range of DNA lesions, including strand breaks (single and
double), as well as alkali sensitive sites. Although most base lesions are not directly
detected, base adducts can be detected when converted to abasic sites or SSBs with
the addition of purified DNA repair enzymes [7, 8, 9, 10, 11]. The comet assay has
been used in a variety of applications, including genotoxicity testing, human biomon-
itoring and epidemiology, environmental health, and basic research on DNA damage
and repair [7, 8, 12, 13, 14, 15, 16, 17, 18, 19]. Compared with other DNA damage
assays [20, 21, 22], the comet assay is relatively inexpensive, is very sensitive, and can
assess the integrated cellular response to many kinds of DNA lesions simultaneously
[7, 8, 19].
Wider acceptance of the comet assay has been limited, however, by low through-
put; poor reproducibility between slides, users, and laboratories; and image process-
ing and analysis methods that are laborious, time-consuming, and potentially biased.
The need for improvement is widely recognized, and previous approaches include re-
ducing space requirements for electrophoresis (CometAssay 96, Trevigen), using a
multiwell format for treating samples [23], incorporating internal controls [24, 25], or
improving imaging [26]. These methods address individual issues, but do not provide
a comprehensive solution for DNA damage analysis.
Here we present a high throughput platform for DNA damage analysis with the
sensitivity and versatility of the comet assay. We spatially register cells by capturing
them into a microwell array patterned directly into agarose (Figure 2-1). This pas-
sive patterning method requires only gravity to capture cells and introduces minimal
external stress. Array registration allows multiple experimental conditions to be spa-
tially encoded on a single slide. Additionally, the microwells provide a new method
for assessing DNA damage in collections of cells or cell aggregates. The arrays also
facilitate fully automated imaging and analysis, requiring no user input or special
equipment.
In order to facilitate the high throughput analysis of drugs, patient samples or
other experimental conditions, we have also developed 24- and 96-well implementa-
tions of the microwell array, which can be integrated with standard high throughput
screening (HTS) techniques. We have validated this platform in two key applica-
tions. By incorporating multiple cell types and multiple DNA repair time points on
a single plate, we directly compare DNA repair kinetics between human lymphocytes
from individuals with different genetic backgrounds. We also demonstrate how this
assay could be used in the context of drug screening by comparing the performance
of potential inhibitors of base excision repair (BER).
2.3 Materials and Methods
2.3.1 Cell Culture
TK6 human lymphoblasts were cultured in suspension in RPMI 1640 with L-glutamine
and supplemented with 10% horse serum. OVCAR-8 human ovarian cancer cells were
cultured in RPMI 1640 with L-glutamine and supplemented with 10% fetal bovine
serum (FBS). Human B-lymphocyte lines from the NIGMS Human Genetic Cell
Repository were obtained from the Coriell Institute. The lines GM15268, GM15242
and GM15224 were cultured in suspension in RMPI 1640 with L-glutamine and sup-
plemented with 15% FBS. Primary hepatocytes were isolated from 2- to 3-month-old
adult female Lewis rats (Charles River Laboratories, Wilmington, MA) weighing
180-200 g. Detailed procedures for hepatocyte isolation and purification have been
described [27, 28]. Hepatocyte culture medium consisted of DMEM with high glucose,
10% (vol/vol) FBS, 0.5 units/ml insulin, 7 ng/ml glucagon, and 7.5 mg/ml hydro-
cortisone. All cell culture media were supplemented with 100 units/ml penicillin-
streptomycin. Cytoplasmic staining of live cells in Figure 2-1c was done with Cell-
Tracker (Green CMFDA and Orange CMRA, Invitrogen, Carlsbad, CA) according
to the manufacturer's instructions.
2.3.2 Microwell Fabrication
The microwell molds were fabricated by lithographically patterning SU-8 photoresist
(SU-8 2000 series, MicroChem Corp, Newton, MA) according to the manufacturer's
instructions. Briefly, SU-8 was spun to the desired thickness onto silicon wafers. Soft-
baking the resist was followed by broadband UV exposure through a transparency
mask, which included transparent circular features of the desired microwell diameter
on a dark background. Post-exposure bake and development in propylene glycol
monomethyl ether acetate revealed the patterned SU-8 microposts. Micropost depth
and width were varied from 20 - 50 mm to optimize well filling for various cell types.
Microwells were cast from the molds as shown in Figure 2-la. Molten 1% normal
melting point (NMP) agarose (Omnipur Agarose, Invitrogen Corp, Carlsbad, CA)
was applied to a sheet of GelBond film (Lonza, Basel, Switzerland) and the mold was
allowed to float on top until the agarose set. PBS was added to assist in carefully
removing the mold without tearing the microwells. Hydrated gels could be stored at
4C for several weeks until ready for use.
2.3.3 Comet Slide Preparation
As shown in Figure 2-la, cells were allowed to settle gravitationally into the microwells
by incubating for 15 min in complete growth media. Afterwards, the gel was gently
rinsed twice with PBS while holding the gel surface at a 150 angle. Most unwanted
cells are washed away because they do not adhere readily to agarose, while cells
trapped inside the wells are protected from the fluid shear [29, 30]. Finally, 1%
low melting point (LMP) agarose (Ultrapure, Invitrogen, Carsbad, CA) in PBS was
applied to the surface and allowed to gel at 4C for 10 min to seal the cells within the
microwells. To prepare traditional comet slides, as described by Olive and Binath
[31], a suspension of cells was prepared and mixed 1:1 with 2% LMP agarose in PBS
at 37'C to make a final concentration of 50,000 cells/ml in 1% LMP agarose. A total
volume of 0.25 ml of cell-agarose suspension was applied to 3 cm x 4 cm GelBond
slides on a 37'C slide warmer. Coverslips were applied to level the gels, while the
cells were allowed to settle for 10 min. Finally, the slides were placed at 4C for 10
min to allow the agarose to set, and the coverslips were removed.
2.3.4 Multiwell Comet Arrays
The multiwell version of the comet platform was prepared by sealing a microwell gel
between a glass plate and a bottomless 24-well plate (Greiner Bio-One, Monroe, NC)
(Figure 2-5a). Cells were then loaded into each well as described above and sealed
with 1% LMP agarose.
2.3.5 Exposure to Ionizing Radiation
Cells were exposed to IR after encapsulation in agarose for both traditional comet and
microwell comet array assays. Cells were irradiated using 250 kVp X-rays at 1 Gy/m
(Philips RT-250). After exposure cells were placed in lysis buffer (10 mM Tris-HCl,
100 mM Na 2EDTA, 2.5 M NaCl, 1% Triton X-100) at pH 10 and 4C. In order to
evaluate repair kinetics on a single multiwell "CometChip", wells were synchronized
during lysis after repairing in media for varying time intervals. This protocol required
a 37'C lysis for 0 min and 30 min repair time points. For this we used a special lysis
buffer formulation (50 mM Tris-HCl, 1 mM Na 2EDTA, 20 mM NaCl, 0.1% sodium
dodecyl sulfate (SDS) at pH 8.0). After the final repair time, all samples were placed
into standard lysis solution with 1% Triton X-100 at 4C.
2.3.6 Comet Assay
The comet assay was performed using a modified version of the alkaline comet protocol
as described by Singh et al. [6]. After a minimum of 1 hr in lysis, comet slides were
placed into an electrophoresis chamber and covered with alkaline unwinding buffer
(0.3 M NaOH and 1 mM Na 2EDTA) for 40 min, followed by 30 min electrophoresis
at 1 V/cm and a total current of 300 mA. The slides were then neutralized twice for
10 min in fresh buffer (0.4 M Tris-HCl at pH 7.5) and stored at 4C until ready to
be stained and analyzed.
2.3.7 Fluorescence Imaging and Comet Analysis
Slides were stained with SYBR Gold (Invitrogen Corp, Carlsbad, CA) according to the
manufacturer's instructions and imaged on a Nikon 80i upright microscope fitted with
a scanning stage. For microwell comets, NIS-Elements software (Nikon Instruments,
Melville, NY) was used to automatically step the stage between frames and capture
images. Images were then automatically analyzed using custom software designed
in MATLAB (The Mathworks, Natick, MA). As shown in Figure 2-2, this software
automatically filters images for comets located on a rectangular grid. The software
sums each comet image in the vertical direction to map the 2D image to a 1D profile.
The upper 10% of the comet image is empty and is used to calculate the background
level, which is subtracted from the comet line profile. The beginning and end of
the comet are determined using user-definable thresholds. The head/tail division is
readily identified as an inflection point in the line profile, immediately following the
head. Once the beginning, end, and head/tail division are known, typical comet
parameters are calculated using standard methods [32, 31]. Traditional comet slides
were scored using a commercial comet analysis software package (Komet 5.5, Andor
Technology, Belfast, UK). All DNA damage is reported as % Tail DNA, which is the
ratio of fluorescence in the comet tail to the total comet fluorescence.
2.4 Results
2.4.1 Micropatterned Cell Arrays
The traditional comet assay uses cells randomly dispersed in agarose. Random cell
placement leads to several problems, including difficulty in locating cells automatically
and large numbers of unanalyzable cells due to overlap. Spatial registration of cells
in a defined array obviates these problems and allows spatial encoding of multiple
experimental conditions on the same slide, and cell spacing can be tuned in order to
maximize the number of conditions per slide.
Several methods currently exist for patterning cells, including dielectrophoresis
[33], hydrostatic trapping [34], and microwell cell traps [35, 36, 37]. Of these meth-
ods, only microwells capture cells passively, eliminating the need for external energy
sources and introducing minimal external stress on cells. Current microwell material
systems, however, including polydimethyl siloxane (PDMS) and polyethylene glycol
(PEG) are not compatible with DNA electrophoresis. We have developed a method
that uses a microfabricated stamp to pattern microscopic wells, directly into hy-
drated agarose (Figure 2-la). The stamp consists of microposts (Figure 2-1b), which
are photolithographically defined and can be varied in width and depth to optimally
accommodate specific cell types (see Methods). Molten agarose sets around the posts,
and the stamp is removed to form arrayed microwells in the agarose gel. Cells are
then trapped in the wells using gravity. Captured cells are protected from rinsing
shear so that excess cells are easily rinsed away, leaving the captured cells patterned
into a defined array. Figure 2-1c shows patterned cells that have been labelled with
a fluorescent cytoplasmic stain. The resulting arrays typically show > 90% filling.
By directly patterning the agarose gel, we have created a system that is fully
compatible with the comet assay (Figure 2-1d). Figure 2-le shows that the mor-
phology of the resulting comets is comparable to that seen in the traditional comet
assay [8]. There is a well-defined head consisting of tightly wound and high molecular
weight DNA. The head is followed by a comet tail, which consists of relaxed loops
and fragments. This is further demonstrated in Figure 2-1f, which shows microwell
comets from varying doses of ionizing radiation (IR). Typical comet morphology is
also seen in the dose response, with heads growing dimmer and tails growing longer
and brighter with increasing dose.
One potential application of the microwell array is multiplexing cell types or con-
ditions using colors or other labels. Cell multiplexing is demonstrated in Figure 2-1c,
where two groups of cells, one stained red and the other green, have been loaded
simultaneously into the microwell arrays. Fluorescent images of the cells are taken
before lysis, and the color information can be recorded for each cell position and
correlated with the final comet output.
2.4.2 Automated Imaging and Analysis
Imaging traditional comets is both laborious and tedious. Complications include
sparse comet distribution, unanalyzable cell clumps, as well as random debris, which
require users to distinguish analyzable objects. Automated imaging systems do exist,
but they are expensive and either require manual comet selection or machine learning
algorithms, which can be biased in their training. Comet analysis requires accurately
discerning the transition from comet head to comet tail, which demands complex im-
age analysis that can produce erroneous results. The microwell arrays obviate these
problems and provide a simple route to automated imaging and analysis. We use a
standard fluorescence microscope with automated stage (see Methods) combined with
a suite of custom analysis software (Figure 2-2), which utilizes simple algorithms to
identify and analyze comets. Our software selects comets based on array registration,
which eliminates problems with overlapping comets and debris. Further, because of
the microwell fabrication method, all cells are located in a single focal plane, which
eliminates the need for users to adjust the focus for each individual comet. Finally,
the fixed head size provided by the microwell geometry simplifies the problem of iden-
tifying the head/tail transition, ensuring accurate determination of comet parameters
(Figure 2-2). The result is the capability to fully automate imaging and analysis with
no user intervention and with no special equipment or complex software.
2.4.3 Spatially-Encoded Microwell Comet Assay
A major advantage of the micropatterned array is the ability to increase through-
put by spatially encoding multiple dosing conditions on the same slide. As shown
in Figure 2-3a, using a moving shield to dynamically protect areas of the sample,
different regions of the same comet slide can be treated with unique doses of IR, a
key cancer therapeutic that has been well-characterized with the comet assay. To
test the robustness of this platform for measuring DNA damage, we performed an IR
dose response for human lymphoblast cells using either the traditional comet assay
scored using commercial software or our spatially-encoded microwell assay scored us-
ing our automated analysis tools. The results, shown in Figure 2-3b, show consistent
linear dose responses to IR in both implementations of the assay, demonstrating the
efficacy of our platform for DNA damage analysis. Additionally, all IR doses for the
microwell comets were incorporated on the same microscope slide. Due to differ-
ences in experimental protocols (see Methods), we did not compare absolute levels
of damage between the two assays. Additionally, the microwell size can be tuned
to accommodate virtually any cell type. For example, using different microwell sizes
and spatial encoding of 10 IR doses, human lymphoblasts, ovarian cancer cells and
primary hepatocytes were analyzed (Figure 2-3c). These data demonstrate efficacy
for generating dose-response curves for multiple cell types.
2.4.4 Self-Calibrating Microwell Comets
In the traditional comet assay, single cell suspensions are required. Remarkably, the
simple innovation of microwells overcomes this limitation by physically restraining
the DNA within the walls of the microwell following lysis, giving rise to a uniform
and analyzable comet head. The uniform head size combined with an analysis that is
normalized to the total amount of DNA makes the microwells self-calibrating. This
feature means that any number of cells can be combined in a microwell and analyzed
as a single comet, providing a new method for assessing DNA damage in small clusters
of cells. Figure 2-4a shows human lymphoblast cells captured in wells with a range
of diameters. The smallest wells (19 pm diameter) typically capture single cells,
while the largest wells (54 pm diameter) can capture more than 10 cells. Figure 2-
4b demonstrates that comets remain morphologically consistent over a range of IR
damage and microwell diameters. The consistency with single cell comets is also
reflected in the quantitative analysis (Figure 2-4c). Further, all IR doses and well
sizes were combined on the same microscope slide, demonstrating a 20-fold higher
throughput than the traditional comet assay. Absolute levels of DNA damage appear
to decrease with increasing microwell size, which could be the result of incomplete
DNA migration from the larger wells. Longer electrophoresis times or a stronger field
could increase DNA migration.
2.4.5 Multiwell Comet Array
In order to measure DNA damage induced by different chemicals, or among different
samples of cells, we created a multiwell version of our micropatterned comet array
(Figure 2-5a). Figure 2-5a illustrates the 24-well version of the assay, where the floor
of each well is a patterned array of agarose microwells. Cells are loaded into the
microwells and, once embedded in agarose, can be treated with chemical damaging
agents, lysis solution, or repair media. After treatment, the multiwell structure can
be removed, leaving only the cells embedded in agarose. The "CometChip" can then
be carried through the standard comet assay protocol, enabling 24 or 96 samples
to be run simultaneously. Importantly, this platform is fully compatible with our
automated imaging and analysis tools.
There is significant interest in determining the extent of variation in DNA damage
sensitivity and repair capacity between populations and individuals [38, 24]. Although
it is extremely sensitive, the traditional comet assay is impractical for most large-scale
studies. Our multiwell CometChip, however, allows all samples and repair times to
be analyzed simultaneously. Further, by including all replicates and conditions in
the same agarose slab, this platform reduces the noise introduced by slide-to-slide
variation. When comparing between wells of a 96-well plate, we observe an 8.8%
coefficient of variation (CV) in the population medians (Figure 2-6), which is less
than the observed CV between slides in the traditional assay [25]. As a proof of
concept, we used the 96-well platform to evaluate the repair capacity in response
to IR of three B-lymphocyte lines (Coriell Research Institute) from individuals with
different genetic backgrounds. The experiment is shown schematically in Figure 2-5b.
All three cell lines, non-treated controls, and three repair time points (0 min, 30 min,
60 min) were performed on a single plate by lysing cells in wells adjacent to cells that
were allowed to repair at 37 C. As shown in Figure 2-5c, nearly all of the damage
is repaired within 30 min of treatment with IR for all cell types. Additionally, it
appears that no significant difference exists between the repair capacities of these cell
lines for IR-induced damage. In contrast, these same cells were previously shown to
have significantly different sensitivities to a methylating agent (N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG)) [39]. While the majority of IR-induced DNA damage is
repaired by the BER pathway [4] (Figure 2-7a), the cytotoxicity of MNNG is largely
due to 06 -methylguanine, which is primarily repaired by direct reversal. Thus, these
cells show different repair capacities for different repair pathways.
2.4.6 Small Molecule Inhibitors of Human AP Endonuclease
DNA damaging agents are the frontline treatment for most cancers, but cells have
numerous DNA repair mechanisms, which can limit therapeutic efficacy or contribute
to resistance [4]. Inhibiting DNA repair has therefore the potential to sensitize cancer
cells to treatment and is now a common theme in cancer therapy research [4]. The
BER pathway (Figure 2-7a) has received particular interest because of its relevance
to numerous types of cancer therapies, including IR and monofunctional alkylators
[4]. Following removal of a damaged base by a monofunctional DNA glycosylase, the
major human apurinic/apyramidinic (AP) endonuclease, APE-1, is responsible for
cleavage of AP sites prior to processing by downstream BER machinery (Figure 2-7a)
[40]. Inhibition of APE-1 activity blocks the BER pathway and leads to accumulation
of AP sites, which can be highly cytotoxic [41, 42]. From a clinical perspective, APE-
1 overexpression has been observed in numerous cancer types [43]. Additionally,
reduced expression of APE-1 using RNA interference has been shown to sensitize
cells to treatment by numerous therapeutic agents [44, 45, 46, 47]. Small molecules
that inhibit the AP endonuclease activity of APE-1 could thus be extremely valuable
in combination therapies for treating cancer.
Several small molecules have previously been identified as potential inhibitors of
APE-i's AP endonuclease activity [48, 49, 50]. Cytotoxicity of these molecules was
evaluated by clonogenic surviva lwhich does not illuminate the mechanism by which
the molecules are cytotoxic. The comet assay can directly reveal abasic sites that
accumulate due to APE-1 inhibition. As a proof of concept screen, we utilized the
96-well CometChip to test three potential small molecule inhibitors of APE-1: 7-
nitro-IH-indole-2-carboxylic acid (NCA) [51], myricetin (MYR) [49] and 6-hydroxy-
DL-DOPA (DOPA) [49]. Cells treated with either DOPA (Figure 2-7b) or MYR
(Figure 2-7c) show a dose-dependent increase in DNA damage levels, presumably as
a result of the accumulation of BER intermediates that is expected from the high
levels of spontaneous BER (estimated to be > 10,000 BER events per day [10]). All
concentrations of these two molecules tested show a significant increase in damage over
the controls. At 50 pM the damage induced by myricetin was so severe as to saturate
the assay. Although there may be some direct damage resulting from these small
molecules, the findings agree well with the observation of abasic site accumulation
by Simeonov et al. [49]. In contrast, cells treated with the candidate molecule NCA
(Figure 2-7d) do not show greatly increased damage, as compared to control. Only
the highest concentration (50 pM) shows a statistically significant (21%) increase in
damage over the control, whereas DOPA and MYR induce a 48% and 50% increase
in damage, respectively, at 10-fold lower concentrations. Interestingly, two studies
have reported no effect on cell survival when using NCA with DNA damaging agents
[49, 52]. Our results suggest that NCA may have some effect on cells, but both DOPA
and MYR are far more potent. As potent inhibitors of APE-1, these molecules could
potentially be used in combination therapies to treat tumors more aggressively.
2.5 Discussion
We present a new technique for measuring DNA damage that combines sensitivity,
versatility, high throughput, and ease of use. This platform has potential to impact
a broad range of applications in the laboratory and clinic. Having the capacity to
handle dozens of conditions in parallel will shed light on how cells respond to multiple
classes of DNA damaging agents, acted upon by a variety of DNA repair pathways
and subpathways. With increased granularity in the human DNA repair landscape,
it should become possible to reveal novel predictive biomarkers and prognostic indi-
cators.
A major strength of the comet assay is its versatility. It has been used to study a
variety of cell types and species from all three biological kingdoms [17]. The microw-
ell arrays further increase the versatility of this assay by enabling new capabilities,
including cell multiplexing and analysis of cell aggregates. Cell multiplexing could be
used to analyze multiple readouts from the same cell. This could be useful in several
contexts, including antibody labeling of mixed populations or determining viability
of cryo-preserved primary samples on a single cell basis. The microwells also facili-
tate DNA damage analysis in small cell aggregates (Figure 2-4). Cell aggregates are
common in research and the clinic, in the form of tissue samples, tumor spheroids
or embryos, and embryonic stem cells. Maintaining cell-cell contact is often neces-
sary to preserve important features of the sample, such as autocrine signaling and
tight junctions that might influence cellular response to DNA damage. The microwell
technique allows for DNA damage quantification in such samples, potentially without
sacrificing important biological information.
We present here the first demonstration of a platform in which multiple cell types,
repair time points, DNA damaging agents, DNA repair enzymes or inhibitors, and
other conditions can be assayed simultaneously and in combination. Unlike other high
throughput comet assay implementations ([23] and Trevigen), the multiwell platform
is compatible with any cell type, whether cultured adherently or in suspension, and
also incorporates significant improvements in imaging and analysis. Further, we pro-
vide the ability to assay repair kinetics on multiple cell types without introducing
slide-to-slide variation, which could be critical for revealing subtle biological effects.
The 8.8% CV observed between individual wells of a 96-well plate is less than the
reported variation between individual comet slides using the traditional assay [25],
and this could potentially be reduced further by including internal controls [25].
This platform has potential for both epidemiology and drug screening applications.
Our findings on the repair kinetics of B-lymphocyte lines highlight the importance
of measuring repair capacities through multiple pathways and by different agents,
and they demonstrate the utility of a high throughput approach. For drug screening,
the platform offers an integrated readout of multiple biological pathways. Specific
subsets of DNA lesions can be detected by the application of DNA repair enzymes
that convert otherwise undetectable damaged bases into detectable SSBs or AP sites.
Modifications in the basic comet protocol provide increased specificity, thus enabling
testing of therapeutics that damage DNA or that target DNA repair pathways. Ad-
ditionally, the 96-well platform integrates with standard HTS techniques making it
well-suited for drug development.
2.6 Conclusions
With the ability to measure acute DNA damage levels as well as repair kinetics, the
comet assay is uniquely relevant to a variety of biological and clinical applications.
The significant improvements afforded by this platform make the measurement of
DNA damage easier and more readily applicable. Further, the approach is simple
and scalable, offering a route to mass produce gels and distribute them in a manner
similar to DNA and protein electrophoresis. This would bring critical information
about DNA damage and repair to researchers and clinicians in a range of fields, and
the use of this knowledge to facilitate disease prevention and treatment could be fully
realized. Through the integration of traditional methods in biology and engineering,
the platform described here represents a significant technological advance, providing
high throughput, objective, and quantitative measurements that have the potential
to become a new standard in DNA damage analysis.
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Figure 2-1: Single Cell Gel Electrophoresis Array. (a) Microwell fabrication.
A microfabricated stamp is placed onto molten agarose. Agarose is cooled to set,
and the stamp is removed. Cells are loaded into wells by gravitational settling, and
an agarose overlay covers the cells. (b) Scanning electron micrograph of SU-8 posts
patterned onto a silicon substrate. (c) Two populations stained red and green, loaded
into wells concurrently, are shown by cytoplasmic staining. (d) Comet assay. Cells
are treated with DNA damaging agent. Cells are lysed in the gel, exposing the DNA.
The DNA is unwound and electrophoresed under alkaline conditions. Relaxed loops
and low molecular weight fragments migrate out of the packed chromatin, forming a
comet tail. (e) Arrayed microwell comets. (f) Microwell comets with varying doses
of IR damage. Horizontal scale bars are 100 pm.
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Figure 2-2: Comet Analysis Pipeline. Images of comets are acquired automati-
cally. Identification software recognizes comets in a defined array. Image of arrayed
comets before and after identification are shown. Identified comets are labelled with
blue crosses. Scale bar is 100 pm. Finally comet analysis software identifies beginning
and end of comet as well as head/tail division (dashed vertical lines) and calculates
comet parameters. A comet is shown along with its corresponding line profile from
which the comet parameters are calculated.
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Figure 2-3: Spatially-Encoded Comet Assay. (a) Method for spatially encod-
ing IR doses on the same microscope slide. A moving lead shield exposes different
regions of the slide to IR for varying lengths of time. (b) Comparison of IR dose
response between traditional comet slides scored using commercial software and mi-
crowell comets scored using automated software. Each data point is the median of 50
individual comets. (c) IR dose responses for TK6 human lymphoblasts, OVCAR-8
human ovarian carcinoma cells, and freshly isolated primary rat hepatocytes. Rep-
resentative images are shown from 10 Gy dose for each cell type. Box plots show
median of 50 comets as a red line and the lower and upper quartiles as a blue box.
Whiskers show extent of furthest data points within 150% of interquartile range.
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Figure 2-4: Self-Calibrating Microwells. (A) Fluorescence image of (from left to
right) 19, 25, 29, 33, 40 and 54 pm diameter microwells filled with propidium iodide
stained TK6 human lymphoblasts. (b) Morphological and (c) quantitative IR dose
response of TK6 cells loaded into different sized microwells on the same slide. White
scale bar in (b) is 25 pm. Each data point in (c) is the median of 50 comets.
100
(a)
-- -(b)
0 Gy
1 Gy
10 Gy
o 19 pm
a 21 pm
-A 40 m
(a) Mechanical Force
Bottomless Plate
Microwells
GielBond
Glass Plate
(b) (c) 315224
30 m15242
--- 15268
IR 0 zu
~20
z
-c 10
Repair+ i -
0 NT 0 30 60
Repair Time (m)
Figure 2-5: Multiwell Comet Array. (a) Assembly of multiwell comet array.
Agarose gel with microwells is sandwiched between a glass substrate and a bottomless
multiwell plate and sealed with mechanical force. Arrayed microwells comprise the
bottom of the multiwell. A large field scan of one well of a 24-well plate is shown
with a fish-eye magnification (2X) of a small region. White scale bar is 2 mm. (b)
Schematic of repair study with representative comets. Cells are treated with IR and
allowed to repair in media at 374C before lysis. (c) Repair kinetics of human B-
lymphocyte lines GM15224, GM15242 and GM15268 after treatment with 7.5 Gy IR.
Non-treated (NT) cells were not exposed to IR. Bars and error bars represent averages
and standard deviations, respectively, of three independent experiments with at least
50 comets scored for each condition in each experiment.
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Figure 2-6: Well-to-Well Variation. Distribution of comets from individual wells
of a 96-well plate. TK6 human lymphoblast cells were loaded into the microwell array
and treated with 5 Gy IR in the 96-well format. Data from 25 wells are shown. Each
box represents 100 individual comets. Outliers not shown.
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Figure 2-7: Potency of APE-1 Inhibitors. (a) Schematic of short patch BER for
repairing methylated bases. The base is removed by a monofunctional glycosylase,
and APE-1 cleaves the backbone 5' to the resulting abasic site. The new base is
inserted by DNA polymerase, the 5' flap is removed by a dRpase, and the nick is
sealed by a DNA ligase. (b - d) Human lymphoblasts (TK6) treated with increasing
doses of (b) 6-hydroxy-DL-DOPA (DOPA), (c) myricetin, or (d) 7-nitro-iH-indole-
2-carboxylic acid (NCA). Each data set is a representative from three independent
experiments. Box plots for NCA and DOPA include 150 individual comets per con-
dition. 100 comets per condition are shown for MYR. Assay readout was saturated
at 50 pM MYR. Notches represent 95% confidence interval of medians, determined
using Kruskal-Wallis nonparametric analysis of variance. Boxes with non-overlapping
notches represent different populations with at least 95% confidence.
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Chapter 3
Evaluation of Multiple Chemical
Conditions and Detection of DNA
Repair Deficiencies using the
CometChip
3.1 Abstract
DNA damage, whether environmentally or endogenously induced, can be both cy-
totoxic and mutagenic and is an important risk factor for many diseases, including
cancer [1]. It is now well established that heritable DNA repair deficiencies can pro-
mote cancer, and the list of DNA repair genes that are critical in cancer prevention
includes genes from every major DNA repair pathway [2]. Ironically, DNA damage is
also important as the primary mechanism in most frontline cancer therapies. Thus,
the ability to assess DNA damage and repair levels in populations or in individuals is
important for predicting cancer susceptibility as well as response to therapies. How-
ever, available technologies for assaying DNA damage and repair suffer from being
low throughput. Therefore, an assay that can accurately measure DNA damage lev-
els in a robust and automated way would be highly valuable in applications such as
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human biomonitoring, epidemiology, and drug development. We have recently devel-
oped the CometChip, which enables parallel analysis of DNA damage in multiple cell
samples. Here, we set out to validate the use of the CometChip for high throughput
measurement of DNA repair after exposure to a variety of DNA damaging agents.
The CometChip enables the precise analysis of DNA repair kinetics, which may be
useful in advancing models of DNA repair, and identifying new drug targets. Further-
more, we demonstrate an ability to detect deficiences in base excision repair (BER),
nucleotide excision repair (NER), and interstrand crosslink repair (ICLR), supporting
the use of the CometChip both for mechanistic studies of DNA repair as well as for
use in health related applications.
3.2 Introduction
The integrity of our genome is maintained by a complex network of proteins that
continuously monitor our DNA for strand breaks, base mispairing, and the presence
of base damage that might disrupt replication or transcription, and consequently
promote cell mutation or death. It is now well established that deficiencies in DNA
repair proteins are critical to carcinogenesis, as they promote genomic instability.
The so-called "mutator phenotype" is a hallmark of cancer that enables tumor cells to
outcompete normal cells through the accumulation of traits providing advantages such
as proliferation and resistance to cell death [3, 4]. Initiation of a mutator phenotype
may result from inherited mutations in DNA repair genes [5, 2]. Ironically, DNA
damage is also a frontline mechanism in cancer treatment, as rapidly dividing tumor
cells are more sensitive to agents that interfere with replication and transcription [6].
Understanding DNA repair capacity and the coordination of proteins in the various
pathways is therefore important not only in predicting cancer susceptibility, but also
in evaluating tumor sensitivity and guiding cancer treatment.
To learn more about DNA repair capacity, we set out to develop better assays for
specific DNA repair paths. There are two main pathways for excision of damaged
DNA nucleotides: base excision repair (BER) for single base lesions and nucleotide
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excision repair (NER) for helix-distorting bulky damage. The BER pathway is initi-
ated by a variety of glycosylases that remove specific base lesions through hydrolysis
of their N-glycosidic bond. For example, alkyladenine DNA glycosylase (AAG) pro-
tects the cell from numerous damaging agents through removal of a wide range of
substrates [7, 8]. Glycosylases are further categorized based on whether they possess
the bifunctional activity to cleave the phosphodiester DNA backbone. Bifunctional
glycosylases can perform base excision and lyase in a concerted reaction, while mono-
functional glycosylase initiated BER requires the 5'dRP lyase activity of Pol#, which
is known to be rate limiting [9]. In either case, initiation of BER leads to BER inter-
mediates (i.e. single strand breaks (SSBs), abasic sites) that may be more toxic and
mutagenic to the cell than the initial DNA lesion if not repaired efficiently [8, 10]. So,
for example, while AAG deficient cells are hypersensitive to alkylation damage [11],
overexpresssion of AAG results in a build up of toxic 5'dRP blocking lesions due to
the rate limiting kinetics of polymerase beta (Polo) gap tailoring [12, 13, 14]. This ac-
cumulation effect can also result from or be enhanced by inhibiting or knocking down
expression of Pol#, or other downstream repair proteins, such as AP Endonuclease
(see Chapter 2) or a ligase (e.g. Ligase III) [15]. People with BER gene polymor-
phisms have increased susceptibility to cancer and numerous cancers are found to
contain BER deficiencies [16, 17, 18, 2]. Thus, proper coordination of BER proteins
is critical for genomic stability and disruption of this balance may lead to carcino-
genesis.
Understanding the coordination and balance of BER proteins is also important
to understanding tumor resistance and guiding chemotherapeutic intervention. For
example, the use of radiation and temozolmoide, a potent alkylating agent, has sig-
nificantly increased the life expectancy of glioblastoma patients in recent years, but
the development of tumor resistance prevents their sustained success [19, 20]. Temo-
zolomide efficacy is largely attributed to the formation of 0 6 -methylguanine lesions,
which are efficiently removed in the direct reversal process by 0 6-methylguanine
methyl-transferase (MGMT). While MGMT serves as a common path to resistance
in gliomas [20], strategies to both overcome resistance or provide alternate path-
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ways to chemosensitivity are of great interest. One such strategy is to target BER,
which is responsible for the efficient removal of the majority of alkylation damage
(i.e. N7-methyguanine, N3-methyladenine) [21]. In addition to AP Endonuclease,
which was explored in Chapter 2, Pol# is being studied as a potential target for ad-
juvant chemotherapy [22, 23]. Determining the roles of key BER proteins may allow
for strategic disruption of this process in order to provide enhanced chemosensitivity
to resistant tumors [24, 25]. Additionally, information about BER imbalances may
advance biological models of DNA repair and generate insights into tumor sensitivity
and treatment [26].
The study of NER is equally relevant to human health, as NER capacity has
been shown to be an important factor in cancer susceptibility and mutations in many
NER genes are associated with diseases, most notably, xeroderma pigmentosum (XP)
and Cockayne's syndrome [27]. NER describes the process in which more than 30
proteins coordinate to remove bulky lesions through the incision of a 24-32 nucleotide
long sequence surrounding the damage [28]. There are a number of XP conditions
resulting from deficiencies in proteins named for the disease. For example, deficiencies
in XPF, which makes the incision 5' to the lesion, and XPG, which makes the 3'
incision, result in hypersensitivity to ultraviolet sun light (UV) and increased risk of
skin cancer [29]. XPB is part of the helicase complex that unwinds DNA for XPF
to make the 5' incision. Although not directly responsible for incision, deficiencies in
other NER proteins, such as XPB, result in XP symptoms and other genetic diseases
such as trichothiodystrophy [29]. Therefore, determining the relative contributions of
NER proteins to DNA damage clearance is important for understanding mechanisms
of disease progression.
DNA interstrand crosslinks (ICLs), are extremely cytotoxic, because they cova-
lently link the two strands of DNA, preventing strand separation and blocking DNA
replication and transcription [30]. ICLR is therefore a critical process, as further evi-
denced by its association with numerous diseases and cancers [31, 32, 33]. Components
of various DNA repair pathways, including NER and homologous recombination, have
been shown to participate in ICLR, but details of the mechanism remain largely un-
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known [34]. This may be due, in part, to a lack of available tools for ICL detection. A
high throughput ICLR assay may therefore help advance biological models and could
assist in disease diagnosis and also in designing treatment strategies, as ICL agents
are highly efficacious against many cancers. As an example, metastatic testicular
germ cell cancer, which was once a fatal disease, is now curable in 80% of patients
due to increased ICL sensitivity of tumors with low levels of XPF expression [35, 36].
Other tumors are resistant to ICL agents, reinforcing the potential clinical value of a
robust ICLR assay [37].
Quantitative assessment of DNA damage and repair is important in both epidemi-
ological and clinical applications [38, 39, 40, 41, 42], but there is a lack of tools that
are available to evaluate repair kinetics, as most DNA damage assays detect artifacts
of damage, such as the incorporation of nucleotides, but reveal minimal information
concerning damage induction and the kinetics of repair [43]. In contrast, the alkaline
comet assay provides a relatively accurate analysis of multiple pathways of DNA re-
pair, by directly measuring the formation and disappearance of single strand breaks
(SSBs) and alkali labile sites, which arise both from direct damage and as repair in-
termediates [44]. Figure 3-1 illustrates the various lesions of detection as well as the
concept of directly measuring the repair process through visualization of repair inter-
mediates. The ability of the comet assay to detect subtle variations in repair capacity
is central to its utility as an epidemiological tool [45, 46, 47], but the assay has not
been widely adopted by epidemiologists and clinicians due to its low throughput and
laborious analysis requirement.
In order to increase throughput and robustness of the comet assay, we developed
the 96-well CometChip, which provides the capacity to simultaneously assess inter-
individual differences in DNA damage or DNA repair. Prior to performing larger scale
human studies, it is important to characterize the range and conditions under which
various DNA repair pathways are active. Here, we used cell lines with known genetic
deficiencies in BER, NER, and ICLR to evaluate the potential of the CometChip
for assessment of repair efficiency using model chemical agents. The results of the
studies described demonstrate the versatility of the CometChip for detection of a
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variety of DNA lesions and support its use for high throughput applications that
require assessment of multiple cell types, chemical conditions, and repair time points.
We used transgenic cell lines to provide meaningful insight into BER coordination and
support existing mechanistic models of NER in the repair of bulky and ICL lesions.
This work demonstrates the usefulnes of the CometChip for assessment of numerous
DNA repair deficiencies, supporting its use in a applications such as the development
of biomarkers of disease susceptibility, development of predictive assays for untested
compounds, and development of clinical assays for optimizing treatment regimens.
3.3 Materials and Methods
3.3.1 Cell Culture
TK6 human lymphoblastoids were cultured in suspension in RPMI 1640 with L-
glutamine and supplemented with 10% horse serum. The glioblastoma cell lines were
kindly supplied by Dr. Robert Sobol (Department of Pharmacology Chemical Bi-
ology, Pittsburgh University). Wild type glioblastoma cells were cultured in alpha
MEM (MediaTech Manassas, VA), 10% fetal bovine serum (FBS) (Atlanta Biologics,
Lawrenceville, GA), antibiotic/antimycotic (Sigma), gentamycin, and L-glutamine
(Sigma). The transgenic cell lines with polymerase beta knockdown (Pol#KD), alky-
ladenine DNA glycosylase overexpressed (AAGOE), or Pol# KD with AAG OE (Pol-
BKD/AAGOE) were cultured in the same media with 1 pg/mL puromycin (Sigma)
added to select for shRNA expressing cells. XPGWT, XPG/E791A, and XP-G hu-
man fibroblasts were kindly gifted by Dr. Orlando D Schirer. The wild type Chinese
hamster ovary (CHO) cell line (AA8) and CHO cell lines deficient in XPB (UV23)
and XPF (UV41) were kindly gifted by Dr. Larry H. Thompson (Lawrence Livermore
National Laboratory). Both CHO and human fibroblast cell lines were cultured in
DMEM (Invitrogen) supplemented with 10% FBS (Atlanta Biologicals, Atlanta, GA).
All cell culture media were supplemented with 100 units/ml penicillin-streptomycin.
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3.3.2 Microwell Fabrication
Figure 3-2 illustrates 96-well CometChip fabrication using a PDMS mold. Briefly, 15
mL of molten normal point agarose was applied to gel bond (Lonza, Switzerland) in
a 150 mm dish. The agarose was allowed to gel with the PDMS mold on top. PBS
was added to aid in removal of the mold, which revealed patterned microwells across
the surface of the gel. After the bottomless 96-well plate was applied, at least 10,000
cells were added to each multiwell and allowed to settle by gravity in complete growth
media at 37'C, 5% CO2. Excess cells were aspirated after 15 min and the bottomless
plate was removed in order to enclose the arrayed cells in a layer of 1% low melting
point agarose.
3.3.3 Analysis of BER Repair Kinetics
One CometChip loaded with exponentially growing TK6 lymphoblastoid cells was
used per chemical treatment. All chemicals were prepared immediately prior to ex-
posure. Hydrogen peroxide (H20 2) was diluted to 25 pM in 4C phosphate buffered
saline (PBS). Methyl methanesulfonate (MMS) was obtained from Sigma and diluted
in PBS to concentrations of 10, 100, and 1000 pM. N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG) was dissolved in dimethylsulfoxide (DMSO) and diluted to concentrations
of approximately 1, 10, 20 tM in PBS. For each chemical concentration, cells were
treated in triplicate for 30 min at 4C. The chemicals were then aspirated and the
CometChip wells were rinsed twice with PBS before adding complete media and al-
lowing cells to repair in the incubator at 370 C, 5% CO 2. To evaluate repair kinetics,
40C lysis buffer was added at each time point for 15 min to stop repair activity and
then removed to prevent the conversion of heat labile sites. At the completion of the
final time point, the multiwell plate was removed and the entire gel was submerged
in 40C lysis buffer over night.
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3.3.4 4NQO Exposure and Ultraviolet Irradiation
Human fibroblasts with either functional XPG (XPGWT), XPG deficiency (XP-
G), or a mutation abolishing catalytic activity (XPG/E791A) were loaded into a
single CometChip, which was cut into 3x3 well pieces and exposed to 500 nM 4-
Nitroquinoline 1-oxide (4NQO) (Sigma) in 4C PBS. Each 3x3 gel contained all three
cell types in triplicate and was allowed to repair individually for 0, 1, 2, or 4 hr in
complete growth medium in the incubator. The same protocol was used to assess
ultraviolet radiation damage. 3x3 well gels were individually exposed to 0 to 10 J/m 2
using a 254 nm UVC Lamp (UVG-11, UVP, Upland, CA) calibrated with a UVX
Radiometer (UVP, Upland, CA) to 0.5 ± 0.1 J/m 2 /s. Cells were allowed to repair
for three hours in order to assess NER using the comet assay.
3.3.5 Interstrand Crosslinking Assay
Exponentially growing AA8 (wild type), UV41 (XPF-/-), and UV23 (XPB-/-) CHO
cells were loaded into the 96-well version of the CometChip. Three plates were pre-
pared for measurement of interstrand crosslinking repair (ICLR) efficiency: a non-
treated plate and 0 and 24 h time points. The ICLR version of the comet assay
was then performed as described by Spanswick, et al. [48]. Briefly, wells of the
CometChip were treated with 20 pM nitrogen mustard (NM) in FBS-free medium or
medium without NM for 1 hr at 37'C. The wells were then washed three times with
PBS and medium was replaced with fresh complete medium. The multiwell plates
were then removed and the CometChip gels were allowed to incubate for the required
post-incubation repair time. At the time of analysis, each gel was put in cold PBS on
ice and irradiated with 12 Gy of gamma-radiation from a cesium-137 source. The gels
were then immediately submerged in cold lysis solution overnight before performing
the standard comet assay protocol. The degree of DNA interstrand crosslinking re-
pair was calculated as the relative increase in % DNA in tail compared to both the
untreated (0%) and NM treated (100%) control samples at 0 hr.
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3.3.6 Fluorescence Imaging and Comet Analysis
After electrophoresis, gels were neutralized in 0.4 M Tris, pH 7.5 (3x5 min). Slides
were then stained with SYBR Gold (Invitrogen). Images were captured automat-
ically using an epifluorescent microscope and analyzed automatically using custom
software written in MATLAB (The Mathworks). Traditional comet slides were scored
manually using Komet 5.5 (Andor Technology).
3.4 Results
3.4.1 96-well CometChip
Currently available assays to measure DNA damage and repair are limited in through-
put, which acts as a barrier to their use in epidemiological studies. We recently devel-
oped the CometChip to enable DNA damage assessment of multiple conditions and
cell types on a single platform and increase processing speed through integration with
automated analysis platforms [49]. To further increase throughput, we developed the
CometChip technology into a 96-well version by replacing the use of silicon/SU-8
microwell stamps with PDMS. This represented a significant advance, because nu-
merous molds can be made from a single master, and PDMS molds are more durable
than silicon/SU-8, because they are made from a single material rather than two. In
addition, PDMS is pliable and hydrophobic, which simplifies its removal from agarose
and allows for the creation of a microwell patterned surface large enough to cover the
area of an entire microtiter plate.
The 96-well version integrates with high throughput screening (HTS) technolo-
gies, such as robotic liquid handling systems and automated imaging platforms. To
demonstrate this ability, we loaded a CometChip with TK6 lymphoblastoids and used
an automated liquid handler (Digilab, Holliston, MA) to deliver a range of H20 2 con-
centrations (Figure 3-3). These data support the ability of the CometChip to be
integrated with HTS equipment, where larger sets of chemicals could be administered
to cells in an automated fashion. The data also show the range of H20 2 damage de-
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tection, revealing a dose of 25 pM as an appropriate exposure for assessment of base
excision repair kinetics because it produces a large signal without saturation. This is
consistent with doses used by other groups in clinical assessments of BER capacity
[50, 51].
3.4.2 Evaluation of Base Excision Repair Kinetics
The alkaline comet assay detects the presence of SSBs and also alkali labile sites
(e.g. abasic sites), making it especially well suited for the measure of BER kinetics
[44]. Using the CometChip, multiple cell types and conditions can be assayed on
a single device, increasing throughput, reducing volume of chemicals required, and
significantly decreasing labor and experimental noise [49]. Furthermore, multiple
repair time points can be precisely assessed by lysing cells in wells adjacent to cells
undergoing further repair incubation. To test the multiwell platform for measuring
BER kinetics, we exposed TK6 lymphoblastoid cells to 25 pM H202 and allowed
repair for up to two hours with time increments as short as five min. The entire
experiment was conducted on a single chip at 00 C, in order to minimize the initiation
of repair during exposure. We similiarly exposed TK6 cells on a separate CometChip
to three concentrations of both MMS and MMNG. Figure 3-4a shows that H202
induced damage is completely repaired in less than 30 min with kinetics similar to
the repair of radiation induced damage [52, 49]. In contrast, alkylation damage
induced by MMS and MNNG persists signficantly longer, as seen in Figure 3-4b and
Figure 3-4c, respectively. With regard to measuring BER with the comet assay, we
must consider the contribution of repair intermediates, even at the initial time point,
due to the rapid glycosylase activity during treatment [3]. The decrease in signal
can then be interpreted as a measure of the net excision of base lesions and the
repair of intermediates [53]. Interestingly, the rate of BER, seen as the slope of each
repair curve, appears to be consistent among concentrations of the same chemical,
suggesting a tightly controlled coordination of BER protein activities.
To directly compare the repair kinetics between H202, MMS, and MNNG, the
data for the highest concentration of each chemical were normalized relative to its
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initial damage level (Figure 3-5). The first interesting result is a significantly faster
repair of H2 0 2 induced damage compared to both MMS and MNNG, (t1 / 2 ~ 15,
60, and 120 min, respectively). This variation can be attributed to differences in
the major glycosylase used to initiate BER. H2 0 2 , like irradiation, induces a large
proportion of oxidized base lesions, which are excised by a bifunctional glycosylase (i.e.
OGG1), eliminating the requirement of gap tailoring by Polo. In contrast, alkyation
induced damage is primarily excised by a monofunctional glycosylase (i.e. AAG) with
strand scission by AP Endonuclease, and therefore requires the rate limiting dRP
lyase activity of Polo [9, 52, 54]. Interestingly, we observe variation in repair rate
between MMS and MNNG, which have simliar alkylation lesion spectra. The main
difference between the two chemicals is that MNNG induces 7% 0 6 -methylguanine
lesions through SN1 attack, while MMS is known to act through an SN2 mechanism
and form less than 1% 06 adducts [55]. 06 -methylguanine is repaired through direct
reversal by methylguanine methyltransferase (MGMT), but the lesion has been shown
to induce many cellular responses that may help to explain the reduced rate of repair
[56, 57]. Interestingly, the relative toxicities of H2 0 2 , MMS, MNNG are in agreement
with the relative rates in which the damage they induce is repaired. Taken together,
the CometChip enables precise assessment of repair kinetics that may be useful not
only in characterizing chemical exposures, but also in interpreting mechanisms of
toxicity.
3.4.3 Detection of BER deficiency
We used transgenic glioblastoma cell lines to more closely examine the role of key
BER proteins in the repair of alkylation damage. The use of MMS, a model alkylat-
ing agent, enables a focused study of BER, as it induces a relatively low proportion
of 0-methylguanine adducts, and instead induces mainly N -methylguanine and N3_
methyladenine lesions [55]. We used the CometChip to assess the repair capacities
of glioblastoma cell lines with deficiencies in both BER initiation (i.e. AAG) and/or
progression/completion (i.e. Polo). LN428 cells were generously gifted by the Labo-
ratory of Dr. Robert Sobol (University of Pittsburg). The cell lines were engineered
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through shRNA lentiviral integration to overexpress AAG (LN428 AAGOE), or to
have knock-down expression of Polo (LN428 Pol#KD), or to both overexpress AAG
and have knock-down expression of Pol# (LN428 Pol#KD/AAGOE). This combina-
tion of genotypes enabled us to modulate the rate of BER initiation versus progression
in order to investigate the processing tolerance of Pol# and the ability to detect a
BER deficiency using the CometChip platform.
To determine if the CometChip can be used to detect BER deficiencies, we ex-
posed all four LN428 genotypes to 1 mM MMS and measured their repair over 2
hr using a single device (Figure 3-6). The results suggest equivalent repair kinetics
in WT, Pol#KD, and AAOE cells, with only the combined AAGOE and Pol#KD
genotype resulting in a persistent damage signal. This implies that an increase in
BER intermediates resulting from AAOE is tolerated by Polo. There does appear to
be a slight increase in comet signal in the AAGOE cells at 120 min, suggesting Polo
saturation, but this difference was not found to be statistically significant. The data
also imply that Po#KD can tolerate BER intermediates, which conflicts with results
from similar studies that showed a significant accumulation of BER intermediates by
comet assay in Pol#KD cells [58, 52]. This suggests either an alternative route of
repair for AAG initiated intermediates or inherently low AAG expression. In fact,
LN428 glioblastoma cell lines have been shown to possess undetectable AAG expres-
sion by Western blot [58, 59]. This additional information helps clarify the Pol#KD
result, emphasizing that it is the balance of many coordinated proteins in the BER
pathway that must be considered when evaluating the impact of BER deficiencies
[60].
An important limitation to consider is the inability to detect absolute levels of
alkylation damage using the CometChip in this format. Instead, the comet signal
represents the level of BER intermediates resulting from the net excision of base
lesions and the repair of intermediates. As such, a repair deficiency, such as low
expression of AAG, which is known to promote sensitivity to alkylating agents [61],
can go undetected by the comet assay. It would therefore be interesting to probe the
absolute levels of alkylation damage using post-lysis enzymatic treatment (e.g. AlkA)
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[62]. The adoption of this procedure might enable a more sensitive detection of Pol#,
AAG, and other BER protein deficiencies. However, even in its standard format, the
CometChip provides a quick method to directly measure repair intermediates, which
have been shown to contribute significantly to the toxicity of methylation damage
[8, 10, 63].
3.4.4 Detection of NER deficiency
Imbalances in NER are associated with both increased cancer susceptibility and
chemotherapeutic resistance [64]. Dual incision by key proteins, XPF and XPG,
is especially critical, because their improper coordination can result in potentially
toxic repair intermediates (Figure 3-8) [65]. Many traditional assays measure the
incorporation of repaired nucleotides (i.e. unscheduled DNA synthesis (UDS)), which
is highly laborious and cannot be used for detection of initial damage levels or dual
incision repair intermediates. While the comet assay does not directly detect the pres-
ence of NER substrates (i.e. bulky lesions), their incision, both partial and complete,
is revealed by an increase in comet signal [66]. In collaboration with the laboratory
of Dr. Orlando Schirer, we set out to determine if the CometChip is capable of
detecting NER deficiencies and also investigate the mechanism of dual incision.
To explore the role of XPG in the dual incision process, we used three human
fibroblast cell lines: XPGWT has functional XPG activity, XPG/E791A is catalyti-
cally inactive, and XP-G is deficient [67]. We exposed all three cell types in a single
CometChip to 4NQO, which is known to induce bulky adducts that are repaired by
NER [68]. Wild type cells repaired the majority of the damage within four hours
(Figure 3-7). In contrast, a significant amount of damage remained in both XPG de-
ficient cell lines. According to the dual incision model, XP-G deficient cells are unable
to make either the 3' incision by XPF or the 5' incision by XPG, while XPG/E791A
cells are capable of making the 3' incision by XPF but not the 5' incision by XPG
[65]. The theoretical intermediates that are detectable at later time points are shown
in Figure 3-8. According to previous studies, we expected to see one-sided incision
in the XPG/E791A cells and no significant accumulation of repair intermediates in
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the XP-G cell line. The results show significant differences in the repair response of
the three genotyptes, but offer little mechanistic insight. The results, however, agree
with Staresincic et al. [65], who found residual XPG activity in the XPG/E791A cells
and also described the ability of XP-G cells to initiate NER and conduct some UDS.
It would be interesting to further compare CometChip results to previous results by
evaluating cells with deficiencies in XPF, as XPF has been shown to be required for
incision by XPG, and XP-F cells were shown to have even less UDS than XP-G [65].
We would therefore expect an XPF deficiency to have even less damage induction
than XP-G cells.
In an attempt to further reveal the XPG deficiencies, we used 254 nm ultraviolet
light (UVC), which is known to induce pyrimidine dimers, which are specifically re-
paired by NER. UVC also induces SSBs and other oxidative lesions [66]. To increase
the specificity of our signal for NER, we evaluated damage levels after 3 hr, when
we expected most BER mediated repair to be complete and the signal to therefore
be more representative of the NER intermediates proposed in Figure 3-8. The re-
sults show a dose dependent increase in damage levels in XPGWT cells, which is
consistent with a dose dependent increase in prymidine dimers (Figure 3-9). In XP-G
cells, the comet signal was independent of UV dose, which supports the dual incision
hypothesis that XPG is required for both 3' and 5' incisions. Lastly, the XPG/E791A
cells were found to be extremely sensitive to UV radiation, as would be expected
by accumulation of one-sided incision. Although this approach does not provide di-
rect measurement of NER, it represents a novel approach to identify dual incision
deficiencies.
3.4.5 Detection of ICL deficiency
ICL agents represent the oldest class of DNA damaging chemotherapies and are still
used in treatment of numerous cancers, although they are largely limited by tumor
resistance [69]. In order to test the efficacy of the CometChip to detect a deficiency in
ICLR, we administered NM to three CHO cell lines: AA8 (wild type), UV41 (XPF-
/-), and UV23 (XPB-/-). The extent of "unhooking" was determined according to
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Spanswick, et al. as seen in Figure 3-10 and described in Materials and Methods [70].
Figure 3-11 demonstrates complete "unhooking" by wild type and XPB-/- cells after
24 hr repair. In contrast, there was significantly less ICLR in the XPF-/- cells. This
is in agreement with findings by De Silva, et al. [71], and serves as a proof of principle
for the use of the CometChip to screen for ICL resistance or potential ICL activity
in drug discovery. In addition, the CometChip can be used to assess roles of various
NER proteins in ICLR and thereby advance mechanistic models that are still largely
incomplete in human cells [34].
3.5 Conclusion
We explored the versatility of the alkaline CometChip to measure repair from a vari-
ety of DNA damaging agents known to produce oxidized and alkylated base lesions,
bulky adducts, strand breaks, and DNA crosslinks, etc. Our data demonstrate the
potential use of the alkaline Comet Chip in applications such as preclinical drug screen-
ing or evaluating sensitivities to chemotherapeutical agents. A comparison between
similarly acting alkylating agents (i.e. MMS and MNNG), revealed differential repair
kinetics, raising the importance of relative glycosylase activities and perhaps even
suggesting differences in the kinetics between BER sub-pathways. To explore this
concept, we investigated the effect of multiple BER deficiencies in the repair of MMS
induced damage. An imbalance in Pol# was detected only by enhancing BER ini-
tiation, revealing the importance of coordination between multiple BER proteins in
maintaining pathway balance. Lastly, we demonstrated an ability to detect multiple
genetic deficiencies in two other DNA repair pathways (NER and ICL), supporting the
use of the CometChip in identifying susceptible populations and guiding treatment
strategies.
Collectively, this work serves as proof of principle for the use of the CometChip in
studies to advance mechanistic models of DNA repair and also as a high throughput
tool for evaluating genotoxicity of multiple chemical conditions or assessing DNA
repair through numerous pathways. The CometChip may be useful in public health,
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as there is increasing evidence supporting a correlation between DNA repair capacity
and cancer incidence [2, 72, 73]. In addition, effective individualized therapies require
knowledge of the sensitivity of a particular tumor. The versatility of the CometChip,
its straight forward and inexpensive protocol, and its ability to integrate with high
throughput screening and analysis platforms give it value in a variety of research
settings.
120
References
[1] J. H. J. Hoeijmakers, "Dna damage, aging, and cancer," N Engl J Med, vol. 361,
pp. 1475-85, Oct 2009.
[2] R. Hakem, "Dna-damage repair; the good, the bad, and the ugly," EMBO J,
vol. 27, pp. 589-605, Feb 2008.
[3] L. A. Loeb and B. D. Preston, "Mutagenesis by apurinic/apyrimidinic sites,"
Annu Rev Genet, vol. 20, pp. 201-30, Jan 1986.
[4] D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation,"
Cell, vol. 144, pp. 646-74, Mar 2011.
[5] L. A. Loeb, "A mutator phenotype in cancer," Cancer Research, vol. 61,
pp. 3230-9, Apr 2001.
[6] J. H. Hoeijmakers, "Genome maintenance mechanisms for preventing cancer,"
Nature, vol. 411, pp. 366-74, May 2001.
[7] K. Larson, J. Sahm, R. Shenkar, and B. Strauss, "Methylation-induced blocks
to in vitro dna replication," Mutat Res, vol. 150, pp. 77-84, Jan 1985.
[8] L. M. Posnick and L. D. Samson, "Imbalanced base excision repair increases
spontaneous mutation and alkylation sensitivity in escherichia coli," J Bacteriol,
vol. 181, pp. 6763-71, Nov 1999.
[9] R. W. Sobol, R. Prasad, A. Evenski, A. Baker, X. P. Yang, J. K. Horton, and
S. H. Wilson, "The lyase activity of the dna repair protein beta-polymerase
121
protects from dna-damage-induced cytotoxicity," Nature, vol. 405, pp. 807-10,
Jun 2000.
[10] R. W. Sobol, M. Kartalou, K. H. Almeida, D. F. Joyce, B. P. Engelward, J. K.
Horton, R. Prasad, L. D. Samson, and S. H. Wilson, "Base excision repair in-
termediates induce p53-independent cytotoxic and genotoxic responses," The
Journal of biological chemistry, vol. 278, pp. 39951-9, Oct 2003.
[11] B. P. Engelward, A. Dreslin, J. Christensen, D. Huszar, C. Kurahara, and
L. Samson, "Repair-deficient 3-methyladenine dna glycosylase homozygous mu-
tant mouse cells have increased sensitivity to alkylation-induced chromosome
damage and cell killing," EMBO J, vol. 15, pp. 945-52, Feb 1996.
[12] F. Calleja, J. G. Jansen, H. Vrieling, F. Laval, and A. A. van Zeeland, "Mod-
ulation of the toxic and mutagenic effects induced by methyl methanesulfonate
in chinese hamster ovary cells by overexpression of the rat n-alkylpurine-dna
glycosylase," Mutat Res, vol. 425, pp. 185-94, Apr 1999.
[13] M. Rinne, D. Caldwell, and M. R. Kelley, "Transient adenoviral n-methylpurine
dna glycosylase overexpression imparts chemotherapeutic sensitivity to human
breast cancer cells," Molecular Cancer Therapeutics, vol. 3, pp. 955-67, Aug
2004.
[14] R. Trivedi, K. Almeida, J. Fornsaglio, S. Schamus, and R. Sobol, "The role of
base excision repair in the sensitivity and resistance to temozolomide-mediated
cell death," Cancer Research, vol. 65, no. 14, p. 6394, 2005.
[15] D. K. Srivastava, B. J. Berg, R. Prasad, J. T. Molina, W. A. Beard, A. E.
Tomkinson, and S. H. Wilson, "Mammalian abasic site base excision repair.
identification of the reaction sequence and rate-determining steps," The Journal
of biological chemistry, vol. 273, pp. 21203-9, Aug 1998.
122
[16] E. L. Goode, C. M. Ulrich, and J. D. Potter, "Polymorphisms in dna repair genes
and associations with cancer risk," Cancer Epidemiol Biomarkers Prev, vol. 11,
pp. 1513-30, Dec 2002.
[17] J. B. Sweasy, J. M. Lauper, and K. A. Eckert, "Dna polymerases and human
diseases," Radiat Res, vol. 166, pp. 693-714, Nov 2006.
[18] T. Sliwinski, P. Ziemba, Z. Morawiec, M. Kowalski, M. Zadrozny, and J. Blasiak,
"Polymorphisms of the dna polymerase beta gene in breast cancer," Breast Can-
cer Res Treat, vol. 103, pp. 161-6, Jun 2007.
[19] R. Stupp, W. P. Mason, M. J. van den Bent, M. Weller, B. Fisher, M. J. B.
Taphoorn, K. Belanger, A. A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann,
R. C. Janzer, S. K. Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J. G. Cairncross,
E. Eisenhauer, R. 0. Mirimanoff, E. 0. for Research, T. of Cancer Brain Tu-
mor, R. Groups, and N. C. I. of Canada Clinical Trials Group, "Radiotherapy
plus concomitant and adjuvant temozolomide for glioblastoma," N Engi J Med,
vol. 352, pp. 987-96, Mar 2005.
[20] J. Zhang, M. F. G. Stevens, C. A. Laughton, S. Madhusudan, and T. D. Brad-
shaw, "Acquired resistance to temozolomide in glioma cell lines: molecular mech-
anisms and potential translational applications," Oncology, vol. 78, pp. 103-14,
Jan 2010.
[21] N. J. Curtin, L.-Z. Wang, A. Yiakouvaki, S. Kyle, C. A. Arris, S. Canan-
Koch, S. E. Webber, B. W. Durkacz, H. A. Calvert, Z. Hostomsky, and D. R.
Newell, "Novel poly(adp-ribose) polymerase-1 inhibitor, ag14361, restores sen-
sitivity to temozolomide in mismatch repair-deficient cells," Clin Cancer Res,
vol. 10, pp. 881-9, Feb 2004.
[22] S. H. Wilson, W. A. Beard, D. D. Shock, V. K. Batra, N. A. Cavanaugh,
R. Prasad, E. W. Hou, Y. Liu, K. Asagoshi, J. K. Horton, D. F. Stefanick,
P. S. Kedar, M. J. Carrozza, A. Masaoka, and M. L. Heacock, "Base excision
123
repair and design of small molecule inhibitors of human dna polymerase ," Cell
Mol Life Sci, vol. 67, pp. 3633-47, Nov 2010.
[23] A. S. Jaiswal, S. Banerjee, H. Panda, C. D. Bulkin, T. Izumi, F. H. Sarkar, D. A.
Ostrov, and S. Narayan, "A novel inhibitor of dna polymerase beta enhances the
ability of temozolomide to impair the growth of colon cancer cells," Mol Cancer
Res, vol. 7, pp. 1973-83, Dec 2009.
[24] J. K. Horton and S. H. Wilson, "Hypersensitivity phenotypes associated with
genetic and synthetic inhibitor-induced base excision repair deficiency," DNA
Repair, vol. 6, pp. 530-43, Apr 2007.
[25] E. M. Goellner, B. Grimme, A. R. Brown, Y.-C. Lin, X. hong Wang, K. F.
Sugrue, L. Mitchell, R. N. Trivedi, J. bo Tang, and R. W. Sobol, "Overcoming
temozolomide resistance in glioblastoma via dual inhibition of nad+ biosynthesis
and base excision repair," Cancer Research, vol. 71, pp. 2308-17, Mar 2011.
[26] J. N. Sarkaria, G. J. Kitange, C. D. James, R. Plummer, H. Calvert, M. Weller,
and W. Wick, "Mechanisms of chemoresistance to alkylating agents in malignant
glioma," Clin Cancer Res, vol. 14, pp. 2900-8, May 2008.
[27] J. Slyskova, A. Naccarati, V. Polakova, B. Pardini, L. Vodickova, R. Stetina,
J. Schmuczerova, Z. Smerhovsky, L. Lipska, and P. Vodicka, "Dna damage and
nucleotide excision repair capacity in healthy individuals," Environ. Mol. Muta-
gen., Apr 2011.
[28] 0. D. Schirer, "Dna interstrand crosslinks: natural and drug-induced dna
adducts that induce unique cellular responses," Chembiochem, vol. 6, pp. 27-
32, Jan 2005.
[29] K.-M. Thoms, C. Kuschal, and S. Emmert, "Lessons learned from dna repair
defective syndromes," Exp Dermatol, vol. 16, pp. 532-44, Jun 2007.
124
[30] P. J. McHugh, V. J. Spanswick, and J. A. Hartley, "Repair of dna interstrand
crosslinks: molecular mechanisms and clinical relevance," Lancet Oncol, vol. 2,
pp. 483-90, Aug 2001.
[31] L. J. Niedernhofer, A. S. Lalai, and J. H. Hoeijmakers, "Fanconi anemia
(cross)linked to dna repair," Cell, vol. 123, pp. 1191-1198, Dec 2005.
[32] P. H. Clingen, C. F. Arlett, J. A. Hartley, and C. N. Parris, "Chemosensitivity
of primary human fibroblasts with defective unhooking of dna interstrand cross-
links," Exp Cell Res, vol. 313, pp. 753-60, Feb 2007.
[33] P. R. Andreassen and K. Ren, "Fanconi anemia proteins, dna interstrand
crosslink repair pathways, and cancer therapy," Curr Cancer Drug Targets, vol. 9,
pp. 101-17, Feb 2009.
[34] P. A. Muniandy, J. Liu, A. Majumdar, S.-T. Liu, and M. M. Seidman, "Dna
interstrand crosslink repair in mammalian cells: step by step," Crit Rev Biochem
Mol Biol, vol. 45, pp. 23-49, Feb 2010.
[35] J. R. W. Masters and B. K6berle, "Curing metastatic cancer: lessons from tes-
ticular germ-cell tumours," Nat Rev Cancer, vol. 3, pp. 517-25, Jul 2003.
[36] S. Usanova, A. Pi6e-Staffa, U. Sied, J. Thomale, A. Schneider, B. Kaina, and
B. K6berle, "Cisplatin sensitivity of testis tumour cells is due to deficiency in
interstrand-crosslink repair and low erccl-xpf expression," Mol Cancer, vol. 9,
p. 248, Jan 2010.
[37] A. J. Deans and S. C. West, "Dna interstrand crosslink repair and cancer," Nat
Rev Cancer, vol. 11, pp. 467-80, Jan 2011.
[38] A. Memisoglu and L. Samson, "Contribution of base excision repair, nucleotide
excision repair, and dna recombination to alkylation resistance of the fission yeast
schizosaccharomyces pombe," J Bacteriol, vol. 182, pp. 2104-12, Apr 2000.
125
[39] K. H. Chen, D. K. Srivastava, and S. H. Wilson, "Relationship between base ex-
cision repair capacity and dna alkylating agent sensitivity in mouse monocytes,"
Mutat Res, vol. 487, pp. 121-6, Dec 2001.
[40] V. J. Spanswick, C. Craddock, M. Sekhar, P. Mahendra, P. Shankaranarayana,
R. G. Hughes, D. Hochhauser, and J. A. Hartley, "Repair of dna inter-
strand crosslinks as a mechanism of clinical resistance to melphalan in multiple
myeloma," Blood, vol. 100, pp. 224-9, Jul 2002.
[41] P. Wynne, C. Newton, J. A. Ledermann, A. Olaitan, T. A. Mould, and J. A. Hart-
ley, "Enhanced repair of dna interstrand crosslinking in ovarian cancer cells from
patients following treatment with platinum-based chemotherapy," Br J Cancer,
p. 7, Sep 2007.
[42] C. Li, L.-E. Wang, and Q. Wei, "Dna repair phenotype and cancer susceptibility-
a mini review," Int J Cancer, vol. 124, pp. 999-1007, Mar 2009.
[43] V. Valdiglesias, E. Pisaro, J. Mendez, and B. Laffon, "Assays to determine dna
repair ability," Journal of Toxicology and Environmental Health, Part A, vol. 74,
pp. 1094-1109, Aug 2011.
[44] A. R. Collins, "The comet assay for dna damage and repair: principles, applica-
tions, and limitations," Mol Biotechnol, vol. 26, pp. 249-61, Mar 2004.
[45] V. Calini, C. Urani, and M. Camatini, "Comet assay evaluation of dna single-
and double-strand breaks induction and repair in c3h1Ot1/2 cells," Cell Biol
Toxicol, vol. 18, pp. 369-79, Jan 2002.
[46] F. Faust, "The use of the alkaline comet assay with lymphocytes in hu-
man biomonitoring studies," Mutation Research/Reviews in Mutation Research,
vol. 566, pp. 209-229, May 2004.
[47] M. Shahidi, H. Mozdarani, and P. E. Bryant, "Radiation sensitivity of leukocytes
from healthy individuals and breast cancer patients as measured by the alkaline
and neutral comet assay," Cancer Letters, vol. 257, pp. 263-73, Nov 2007.
126
[48] V. Spanswick, J. Hartley, T. Ward, and J. Hartley, "Measurement of drug-
induced dna interstrand crosslinking using the single cell gel electrophoresis
(comet) assay," Methods in molecular medicine, vol. 28, pp. 143-154, 1999.
[49] D. K. Wood, D. M. Weingeist, S. N. Bhatia, and B. P. Engelward, "Single cell
trapping and dna damage analysis using microwell arrays," Proc Natl Acad Sci
USA, vol. 107, pp. 10008-13, Jun 2010.
[50] R. A. El-Zein, C. M. Monroy, A. Cortes, M. R. Spitz, A. Greisinger, and C. J.
Etzel, "Rapid method for determination of dna repair capacity in human periph-
eral blood lymphocytes amongst smokers," BMC Cancer, vol. 10, p. 439, Jan
2010.
[51] F. Caple, E. A. Williams, A. Spiers, J. Tyson, B. Burtle, A. K. Daly, J. C.
Mathers, and J. E. Hesketh, "Inter-individual variation in dna damage and base
excision repair in young, healthy non-smokers: effects of dietary supplementation
and genotype," Br J Nutr, vol. 103, pp. 1585-93, Jun 2010.
[52] J. K. Horton, M. Watson, D. F. Stefanick, D. T. Shaughnessy, J. A. Taylor,
and S. H. Wilson, "Xrccl and dna polymerase beta in cellular protection against
cytotoxic dna single-strand breaks," Cell Res, vol. 18, pp. 48-63, Jan 2008.
[53] B. A. Sokhansanj, G. R. Rodrigue, J. P. Fitch, and D. M. Wilson, "A quantitative
model of human dna base excision repair. i. mechanistic insights," Nucleic Acids
Research, vol. 30, pp. 1817-25, Apr 2002.
[54] D. Svilar, E. M. Goellner, K. H. Almeida, and R. W. Sobol, "Base excision repair
and lesion-dependent subpathways for repair of oxidative dna damage," Antioxid
Redox Signal, vol. 14, pp. 2491-507, Jun 2011.
[55] M. D. Wyatt and D. L. Pittman, "Methylating agents and dna repair responses:
Methylated bases and sources of strand breaks," Chem. Res. Toxicol., vol. 19,
pp. 1580-94, Dec 2006.
127
[56] B. Kaina, "Mechanisms and consequences of methylating agent-induced sces and
chromosomal aberrations: a long road traveled and still a far way to go," Cyto-
genet Genome Res, vol. 104, pp. 77-86, Jan 2004.
[57] D. I. Beardsley, "N-methyl-n'-nitro-n-nitrosoguanidine activates cell-cycle arrest
through distinct mechanisms activated in a dose-dependent manner," Molecular
Pharmacology, vol. 68, pp. 1049-1060, Jul 2005.
[58] R. W. Sobol, D. E. Watson, J. Nakamura, F. M. Yakes, E. Hou, J. K. Hor-
ton, J. Ladapo, B. V. Houten, J. A. Swenberg, K. R. Tindall, L. D. Samson,
and S. H. Wilson, "Mutations associated with base excision repair deficiency
and methylation-induced genotoxic stress," Proc Natl Acad Sci USA, vol. 99,
pp. 6860-5, May 2002.
[59] J. bo Tang, D. Svilar, R. N. Trivedi, X. hong Wang, E. M. Goellner, B. Moore,
R. L. Hamilton, L. A. Banze, A. R. Brown, and R. W. Sobol, "N-methylpurine
dna glycosylase and dna polymerase beta modulate ber inhibitor potentiation of
glioma cells to temozolomide," Neuro-oncology, Mar 2011.
[60] R. N. Trivedi, X. hong Wang, E. Jelezcova, E. M. Goellner, J. bo Tang, and R. W.
Sobol, "Human methyl purine dna glycosylase and dna polymerase beta expres-
sion collectively predict sensitivity to temozolomide," Molecular Pharmacology,
vol. 74, pp. 505-16, Aug 2008.
[61] B. Engelward, G. Weeda, M. Wyatt, J. Broekhof, J. de Wit, I. Donker, J. Allan,
B. Gold, J. Hoeijmakers, and L. Samson, "Base excision repair deficient mice
lacking the aag alkyladenine dna glycosylase," Proc Natl Acad Sci USA, vol. 94,
no. 24, p. 13087, 1997.
[62] A. R. Collins, M. Dusinskai, and A. Horski, "Detection of alkylation damage
in human lymphocyte dna with the comet assay," Acta Biochim Pol, vol. 48,
pp. 611-4, Jan 2001.
128
[63] M. L. Rinne, Y. He, B. F. Pachkowski, J. Nakamura, and M. R. Kelley, "N-
methylpurine dna glycosylase overexpression increases alkylation sensitivity by
rapidly removing non-toxic 7-methylguanine adducts," Nucleic Acids Research,
vol. 33, pp. 2859-67, Jan 2005.
[64] D. Leibeling, P. Laspe, and S. Emmert, "Nucleotide excision repair and cancer,"
J Mol Hist, vol. 37, pp. 225-38, Sep 2006.
[65] L. Staresincic, A. F. Fagbemi, J. H. Enzlin, A. M. Gourdin, N. Wijgers,
I. Dunand-Sauthier, G. Giglia-Mari, S. G. Clarkson, W. Vermeulen, and 0. D.
Schdrer, "Coordination of dual incision and repair synthesis in human nucleotide
excision repair," EMBO J, vol. 28, pp. 1111-20, Apr 2009.
[66] C. Alapetite, T. Wachter, E. Sage, and E. Moustacchi, "Use of the alkaline
comet assay to detect dna repair deficiencies in human fibroblasts exposed to
uvc, uvb, uva and gamma-rays," International Journal of Radiation Biology,
vol. 69, pp. 359-69, Mar 1996.
[67] M. Wakasugi, J. T. Reardon, and A. Sancar, "The non-catalytic function of xpg
protein during dual incision in human nucleotide excision repair," The Journal
of biological chemistry, vol. 272, pp. 16030-4, Jun 1997.
[68] C. J. Jones, S. M. Edwards, and R. Waters, "The repair of identified large dna
adducts induced by 4-nitroquinoline-1-oxide in normal or xeroderma pigmento-
sum group a human fibroblasts, and the role of dna polymerases alpha or delta,"
Carcinogenesis, vol. 10, pp. 1197-201, Jul 1989.
[69] R. B. Scott, "Cancer chemotherapy-the first twenty-five years," Br Med J, vol. 4,
pp. 259-65, Oct 1970.
[70] V. J. Spanswick, J. M. Hartley, and J. A. Hartley, "Measurement of dna in-
terstrand crosslinking in individual cells using the single cell gel electrophoresis
(comet) assay," Methods Mol Biol, vol. 613, pp. 267-82, Jan 2010.
129
[71] I. U. D. Silva, P. J. McHugh, P. H. Clingen, and J. A. Hartley, "Defining the
roles of nucleotide excision repair and recombination in the repair of dna inter-
strand cross-links in mammalian cells," Molecular and Cellular Biology, vol. 20,
pp. 7980-90, Nov 2000.
[72] T. Paz-Elizur, Z. Sevilya, Y. Leitner-Dagan, D. Elinger, L. C. Roisman, and
Z. Livneh, "Dna repair of oxidative dna damage in human carcinogenesis: po-
tential application for cancer risk assessment and prevention," Cancer Letters,
vol. 266, pp. 60-72, Jul 2008.
[73] F. Marcon, "Assessment of individual sensitivity to ionizing radiation and dna
repair efficiency in a healthy population," Mutation Research/Genetic Toxicology
and Environmental Mutagenesis, vol. 541, pp. 1-8, Nov 2003.
130
DNA Damage
51iliii Ill III 11111 llI~1lIl 111111L111L[
Repair Initiation
DNA Repair
Intermediates
BER
TM
-mtmnr-
NER
,mmummT .....mr
ICLR
Mutations
Toxicity
Detectable by Comet Assay
Repair Completion Example- Polo, Ligase
Exml:o4,Lgs
II IIl||II| |III IIII| | 111 1 |111111
Repaired DNA
Figure 3-1: Detection of DNA Repair Intermediates. The alkaline comet assay
detects single strand breaks and alkali labile sites. Its use for detection of base lesions
is therefore dependent on their excision by DNA repair enzymes and their repair by
downstream enzymes. Examples of detectable repair intermediates for BER, NER,
and ICLR are provided.
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Figure 3-2: 96-well CometChip Fabrication using PDMS Mold.
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Figure 3-3: Evaluation of Hydrogen Peroxide using Automated Dosing by
Robotic Liquid Handler. (a) Morphologies of patterned comets resulting from
exposure to 0, 25, and 100 pM H20 2. (b) H2 0 2 dose response administered using
robotic liquid handler. Box plots show median of 50 comets as a red line and the
lower and upper quartiles as a blue box. Whiskers show extent of farthest data points
within 150% of interquartile range. Red pluses indicate outliers.
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Figure 3-4: Evaluation of Repair Kinetics of Multiple Chemicals. For each
chemical, all concentrations and repair time points conducted on a single CometChip.
(a) Repair of damage induced by H2 0 2 . (b) Repair of damage induced by MMS. (c)
Repair of damge induced by MNNG.
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Figure 3-5: Comparison of TK6 Repair Kinetics from Damage Induced by
MNNG, MMS, and H 2 0 2. 1000 tM MNNG and 25 pM MMS were evaluated on
the same CometChip (t 1 / 2 ~ 120 and 90 min, respectively). H2 0 2 assessment was
conducted on a separate CometChip ( t1 / 2 ~ 15 min).
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Figure 3-6: Detection of a Base Excision Repair Deficiency using 96-well
CometChip. (a) Repair of all four LN428 glioblastoma genotypes, WT, Pol#KD,
AAGOE, and AAGOE/Pol#KD, evaluated on a single CometChip. Cells were ex-
posed to 1 mM MMS and allowed to repair for 0, 30, 60, 90, 120 min. (b) Damage
levels in WT, Pol#KD, and AAGOE decreased at similar rates over 120 min, while
the AAGOE/Pol3KD cells had a persistent damage signal over the entire evaluation
period. Significance determined by Student's t-test.
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Figure 3-7: Analysis of Repair Kinetics of XPG Mutants Exposed to 4NQO.
All three human fibroblast cell lines were exposed to 500 nM 4NQO and repair was
assessed over a 4 hr period. XPG/E791A (green) cells are catalytically inactive for
XPG and XP-G cells (blue) are XPG deficient.
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Figure 3-8: Theoretical Nucleotide Excision Repair Products for XPG Mu-
tants. (a) Wild type cells are expected to completely repair NER damage. (b) XP-G
cells lack both 3' and 5' incision activities and are expected to produce minimal NER
intermediates. (c) XPG/E791A cells lack 3' incision activity but have functional 5'
activity and are expected to accumulate intermediates through one-sided NER.
138
100 .- - - -.Human Fibroblasts
80 3 hour Repair XPG(E791A)
Supports 5'incision; no 3'incision
1- 60 V V
z
C 40- XPG
0X0 No5'or3'incision
20 -
n=3
0 -
0 2 4 6 8 10
UV Dose (J/m2)
Figure 3-9: Analysis of Nucleotide Excision Repair Products Formed in
XPG Mutants Exposed to UV Radiation. XPG/E791A (green), WT (red),
and XP-G (blue) human fibroblasts were exposed to a range of UVC exposures and
allowed to repair for 3 hr before analysis by comet assay. All cell types were evaluated
in triplicate on a 3x3 well CometChip at each UV dose.
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Figure 3-10: Protocol to Evaluate Crosslinking Repair using the CometChip.
WT, XPB-/-, and XPF-/- CHO cells were exposed to 20 pM NM for 1 hr. Cells were
allowed to repair for 0 or 24 hr. Immediately before lysis, cells were exposed to 12
Gy irradiation. The extent of unhooking was determined as the relative increase in
comet signal in cells repaired for 24 hr versus 0 hr.
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Figure 3-11: Evaluation of Interstrand Crosslinking Repair in NER Mutants.
(a) Relative unhooking capacity was calculated for WT, XPB-/-, and XPF-/- CHO
cells as 100, 95, and 30%, respectively. (b) After 24 hr of repair, WT and XPB-
/- cells had significantly greater damage (resulting from unhooking activity) than
XPF-/- cells when challenged with a 12 Gy dose.
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Chapter 4
Single Cell Microarray Enables
High Throughput Evaluation of
DNA Double Strand Breaks and
DNA Repair Inhibitors
4.1 Abstract
Many cancer chemotherapy agents and radiation therapy act through the formation
of DNA double strand breaks (DSBs), which are preferentially toxic to uncontrolled,
rapidly dividing cancer cells. DSB repair capacity is therefore a therapeutic target
for adjuvant chemotherapy. Currently available assays to detect double strand breaks
are limited in throughput and specificity and offer minimal information concerning
the kinetics of repair. We present the CometChip, a high throughput (HT) arrayed
platform that enables assessment of DNA DSB levels and repair capacity in mul-
tiple cell types and assay conditions in parallel and integrates with standard HT
screening (HTS) technologies. We confirm the ability to detect multiple genetic defi-
ciencies in DSB repair and evaluate a set of clinically relevant chemical inhibitors of
non-homologous end joining. While other repair assays measure residual damage or
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indirect markers of damage, the CometChip detects physical DSBs in a HT format,
and serves as a novel discovery tool for identification of modulators of DNA damage
induction and repair capacity.
4.2 Introduction
Mammalian cells have evolved mechanisms of DNA damage repair owing to endoge-
nous processes such as generation of reactive oxygen species and VDJ recombination,
and rely predominantly upon two major pathways of DSB repair: non-homologous
end joining (NHEJ) and homologous recombination (HR) [1, 2, 3]. Ionizing radiation
(IR) and radiomemetic chemicals are frontline tools in cancer management [4, 5].
One of their main mechanisms of action is the formation of toxic DSBs, which act
as a signal to promote cell death. DSB repair has been identified as an underlying
mechanism of drug resistance and is therefore important in guiding treatment strate-
gies that more selectively target cancerous cells and reduce side-effects [6, 7]. One
emerging approach is to sensitize tumors by inhibiting their DNA repair response
system, e.g. NHEJ [8, 9, 10, 11]. A major challenge in identifying such inhibitors
is that currently available DNA damage assays are limited in throughput, and often
provide information about residual damage (e.g. chromosomal aberrations or signal-
ing events), but offer little insight into the actual lesion burden or kinetics of repair.
Better methods to measure DSBs are needed to assess DNA repair capacity in tumor
cells and to identify novel pharmaceutical compounds that modulate DNA damage
repair. Here, we describe a novel HT approach that enables direct physical detection
of DSBs.
Currently, one of the most broadly used DSB assays is the gamma-H2AX assay,
which relies upon detection of phosphorylated serine 129 of the histone variant H2AX
('--H2AX), an early signaling event in response to a DSB. Although the -- H2AX as-
say is remarkably sensitive [12, 13], H2AX phosphorylation is separable from DSBs,
in part due to its dependence on the activity of ATM, DNA-PK and other phos-
phatidylinositol 3-kinase (P13K) related kinases (PI3KKs) [14]. Another approach is
144
to directly measure DSBs based on their physical properties. Physical detection is the
basis for alkaline elution and single cell gel electrophoresis (the comet assay), both
of which rely upon changes in the mobility of intact versus broken DNA. While the
alkaline elution method suffers from being technically difficult and slow, the comet
assay is gaining in popularity [15]. When performed at neutral pH, the quantity of
DSBs in a cell is proportional to the distance and the amount of DNA that migrates
during electrophoresis [16]. Although the neutral comet assay can directly analyze
DSBs, the specificity and statistical precision of the assay are limited. Additionally,
the standard technique is laborious, making HTS difficult.
To overcome problems in reproducibility and throughput of the comet assay, we
recently developed the CometChip [17]. The CometChip exploits single cell pattern-
ing using microwell arrays, which enables spatial encoding and increases throughput
and consistency. Here, we have adapted the CometChip to accommodate a 96-well
device (with microwells at the base of each 96 well; Figure 4-1) that can be integrated
with HTS tools, including fully automated imaging and analysis. Furthermore, we
show that this new 96-well format suppresses variability among samples. In addition
to increasing throughput and reliability, we used established protocols to adapt the
CometChip for HT physical detection of DSBs in mammalian cells, wherein DSBs
are directly measured via analysis of comet tail length following single cell gel elec-
trophoresis. Using cell lines harboring specific defects in DSB repair and a set of
compounds with known effects on DNA repair, we show that the CometChip can be
used to detect DSBs and furthermore that is offers a useful screen for DSB repair
inhibitors. The neutral CometChip is straightforward to implement, and compatible
with HTS, thus providing a valuable tool for researchers, clinicians and epidemiolo-
gists.
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4.3 Materials and Methods
4.3.1 Cell Culture
TK6 human lymphoblastoid cells were cultured in suspension in RPMI medium 1640
with L-glutamine (Invitrogen) supplemented with 10% horse serum (Invitrogen). Chi-
nese hamster ovary (CHO) cell lines were cultured in Dulbeccos modified Eagles
medium (Invitrogen) supplemented with 10% fetal bovine serum (Atlanta Biolog-
icals, Atlanta, GA). All cell culture media were supplemented with 100 units/mL
penicillin-streptomycin (Invitrogen). CHO-Ki and xrs-6 CHO cells were kindly sup-
plied by Larry H. Thompson (Lawrence Livermore National Laboratory) and irs-20
CHO cells were a generous gift by Dr. Joel S. Bedford (Colorado State University).
All genotypes were confirmed by Western blot (data not shown).
4.3.2 Microwell Fabrication
Negative molds were fabricated from silicon wafers (WaferNet, San Jose, CA) that
were lithographically patterned with SU-8 photoresist microwells (SU-8 2025, Mi-
crochem, Newton, MA), following a protocol similar to Wood, et al. [17]. Poly-
dimethylsiloxane (PDMS, Dow Corning, Midland, MI) was cast on the negative sil-
icon mold and baked for 1 hr at 50 'C according to the manufacturers instructions.
After 1 hr the PDMS was removed to reveal patterned microposts of approximately
50 pm depth and 30 pm width. Molten 1% normal melting point agarose (Omnipur,
Invitrogen) was applied to a sheet of GelBond film (Lonza, Basil, Switzerland) and
the PDMS mold was allowed to float until the agarose set. The PDMS mold was
removed, leaving a 300 pm thick gel with arrayed microwells. The microwell gel was
then clamped between a glass plate and a bottomless 96-well titer plate (Greiner
BioOne).
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4.3.3 Multiwell Preparation
Figure 4-1b illustrates CometChip loading. At least 10,000 cells were added to each
multiwell and allowed to settle by gravity in complete growth media at 37'C, 5%
CO2. Excess cells were aspirated after 15 min and the bottomless 96-well plate was
removed in order to enclose the arrayed cells in a layer of 1% low melting point
agarose. Traditional comet slides were prepared as previously described [16].
4.3.4 Exposure to Ionizing Radiation
Microwell gels were either irradiated all at once in the multiwell format or cut and
exposed in smaller pieces. A Cobalt-60 irradiator (Gammacell 220 Excel, MDS Nor-
dion, Canada) was used to deliver 0-100 Gy of IR at an approximate rate of 120
Gy/min. Cells were irradiated in 4 'C phosphate buffered saline (PBS). To evaluate
repair kinetics, wells were synchronized by cell lysis after repairing damage in media
for varying time intervals. In the evaluation of NHEJ deficient cells, all time points
(0, 30, 60, 90, 120 min) were conducted on a single multiwell plate. For the screen
of NHEJ repair inhibitors, each condition (nontreated, 0 and 60 min) was run on a
separate gel. For the dose response assessment, a single CometChip was divided into
six 3x2-well pieces for exposure to varied levels of IR.
4.3.5 Treatment with Chemicals
Bleomycin (Bioworld, Dublin, Ohio) was dissolved in PBS and was exposed to cells
for 1 hr at 4 'C. All chemical conditions, controls, and replicates were conducted on
a single multiwell plate. All repair inhibitors were purchased from Tocris (Ellisville,
Missouri). NU7441, NU7026, and P1103 hydrochloride were prepared in dimethyl
sulfoxide (DMSO) and Wortmannin, LY294002, Compound 401, and DMNB were
prepared in ethanol. All inhibitors were stored at -20 'C until immediately before
use. The inhibitors were diluted to 50 pM in complete growth medium and exposed
in triplicate wells of the 96-well plate for 1 hr at 37'C, 5% CO 2. CHO-K1 cells in
1% DMSO and untreated xrs-6 and irs-20 cells were used as controls. The inhibitors
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were replaced with 4C PBS during irradiation and fresh inhibitor was applied during
evaluation of repair kinetics.
4.3.6 Neutral Comet Assay
The comet assay was performed using a modified version of the neutral comet protocol
as previously described [18]. Briefly, gels were lysed for four hours at 43'C (2.5M
NaCl, 100 mM Na2EDTA, 10 mM Tris, 1% N-Lauroylsarcosine, pH 9.5 with 0.5%
Triton X-100 and 10% DMSO added 20 min before use). For evaluation of repair
kinetics of NHEJ deficient cells, lysis was synchronized in the multiwell plate at 37'C
and then completed at 43'C. After lysis, the slides were washed three times for 30 min
with the electrophoresis buffer (90 mM Tris, 90 mM Boric Acid, 2 mM Na 2EDTA,
pH 8.5). Electrophoresis was conducted at 4C for 1 hr at 0.6 V/cm and 6 mA.
4.3.7 Fluorescence Imaging and Comet Analysis
After electrophoresis, gels were neutralized in 0.4 M Tris, pH 7.5 (3x5 min). Slides
were then stained with SYBR Gold (Invitrogen). Images were captured automat-
ically using an epifluorescent microscope and analyzed automatically using custom
software written in MATLAB (The Mathworks). Traditional comet slides were scored
manually using Komet 5.5 (Andor Technology). ANOVA analysis was conducted to
determine statistical significance between irradiation doses (Fig. 2) and a Student's
t-test was used to evaluate relative repair differences between cells (Fig. 3-5).
4.3.8 y-H2AX Assay
Wild type (CHO-Ki) and DNA-PKcs-/- (irs-20) CHO cells were seeded in 6-well
plates and allowed to grow to confluency over night. Media containing 50 PM NU7441
inhibitor was added to wild type cells for 1 hr at 37'C, 5% CO 2. All plates except the
untreated control were exposed to 100 Gy in the Cobalt-60 irradiator (Gammacell 220
Excel, MDS Nordion, Canada). Cells were allowed to repair for (0, 1, 2, 4, 8 hr) in
either fresh medium or medium supplemented with NU7441. Cell samples were lysed
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at each time point (4% SDS, 0.12 M Tris-HCl pH 6.8 with Photostop tab (Roche)
and complete Mini tabs (Roche)), scraped from the dish, and stored in eppendorf
tubes for '--H2AX analysis by Western blot. Briefly, samples were sonicated and run
in the HT E-Page gel system (Invitrogen) and transferred using the iBlot Blotting
System (Invitrogen). -- H2AX was visualized using anti-y-H2AX rabbit monoclonal
antibody (Cell Signaling Technology) and normalized to actin levels using anti-actin
mouse monoclonal antibody (Sigma).
4.4 Results
4.4.1 High Throughput Neutral Comet Assay
Currently available assays for detecting DSBs are limited in throughput and speed of
analysis, attributes that are critical for large-scale pharmaceutical discovery projects.
The multiwell CometChip enables multiple different cell samples or chemical condi-
tions to be assayed on a single agarose gel (Figure 4-1). Briefly, cells are arrayed in
microwells in an agarose gel by gravity, and subsequently cultured, treated, lysed,
and electrophoresed using traditional comet protocols [16, 18]. The resulting pat-
terned comets at the base of each 96 well (Figure 4-2a) can be imaged manually on a
fluorescent microscope or in an automated fashion using any imaging platform. One
advantage of the arrayed microwell approach is that the comets are optimally pat-
terned at the same focal depth with no overlap, enabling ten or more comets to be
captured and automatically analyzed in a single image. Images are analyzed using
unbiased, fully automated software, increasing the processing rate from a maximum
of 50 samples a day to over 400.
Here, we set out to evaluate the sample to sample noise using the CometChip
versus the traditional assay. To assess sample to sample variation on the neutral
CometChip, TK6 lymphoblastoid cells were exposed to 100 Gy IR and analyzed for
DSBs. Images were captured in an automated fashion and automatically analyzed
using software described by Wood, et al. [17]. We found a coefficient of variance
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of approximately 15% between the 96 wells of the CometChip compared to around
20% between ten slides of the traditional assay. Figure 4-6 illustrates the improved
throughput and well-to-well variability of the neutral CometChip. It is noteworthy
that it was not practical to process 96 slides for a direct comparison; had we done so,
the experimental noise for the traditional approach would likely have risen. Taken
together, being able to process 96 samples in parallel on a single platform, rather
than on separate slides, helps to reduce experimental noise.
To compare the sensitivity and dose response of the CometChip to the traditional
neutral comet assay, we performed a dose response analysis following exposure to IR.
Extent of damage was evaluated by measuring comet tail length (pn), because among
the standard comet parameters, it was found to best correlate with radiation dose
(Figure 4-7d). A comparison of the traditional assay and the CometChip revealed
that both approaches yield a linear dose response over the 100 Gy range (Figure 4-2b).
As expected, the absolute values between the two assays appear to vary somewhat due
to differences in experimental protocols. Importantly, the CometChip appears to be
more sensitive at higher doses, as reflected by the regression statistics (R2 = 0.99 and
R2 = 0.85 for microwell and standard comets, respectively). This increased sensitivity
may result from the improved morphology of the microwell comet, since the DNA is
constrained by the walls of the microwells, thus providing a more distinct head-to-tail
cutoff and thus more reliable assessment of comet tail length (Figure 4-7a).
HT screens are most useful when a very small volume is required per sample,
thus minimizing the amount of test agent required. An important feature of the
CometChip is the ability to evaluate conservative volumes of multiple chemical con-
ditions in parallel (while approximately 2 ml is generally required for on-slide treat-
ment using the traditional method, only 100 pl is required using the CometChip).
Furthermore, all chemical conditions can be conducted on the CometChip, elimi-
nating the need for cell plating and post-exposure centrifugation and trypsinization
required by other HT versions of the comet assay [19], [Trevigen, Inc.]. To further
assess the efficacy of the neutral CometChip for evaluating chemical exposures, we
assayed bleomycin, a glycopeptide antibiotic that efficiently introduces DSBs and is
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used in the treatment of numerous cancers [20, 21, 22]. To analyze bleomycin-induced
DSBs, more than 300 comets were pooled from six replicate wells and the resulting
data fit a linear dose response with R2 = 0.999 (Figure 4-2c). Together, these data
show that the CometChip can be used effectively to measure DSBs following multiple
chemical exposure conditions in parallel.
4.4.2 Detection of a Repair Deficiency
In order to assess the specificity of the neutral comet assay for DSBs, we set out
to compare DSB repair kinetics among cell lines with known genetic deficiencies
in NHEJ. An early step in the NHEJ pathway is recognition of the DSB by the
Ku70/Ku8O heterodimer. The Ku heterodimer recruits the DNA-PK catalytic sub-
unit (DNA-PKcs) to form the DNA-PK complex, which promotes strand alignment
and recruitment of factors involved in end-processing and ligation (Figure 4-3a)
[23, 24]. We used mammalian cells specifically mutated in either Ku80 (xrs-6) or
DNA-PKcs (irs-20) to see if cells lacking critical genes in NHEJ show a repair deficit
when analyzed on the CometChip. Cells were exposed to 100 Gy IR and the mul-
tiwells corresponding to the zero min time point were immediately lysed, while the
remaining wells were filled with growth medium and allowed to repair over the course
of 120 min. Wild type cells demonstrated a fast recovery within the first hour, while
both the Ku80 and DNA-PKcs deficient cells showed a severe repair defect, with most
of the damage still remaining after two hours (Figure 4-3b). These data show that
the assay is effective for detection of DSBs, which is consistent with previously pub-
lished studies of Ku80 and DNA-PKcs deficient cells using similar methods [24, 25].
Interestingly, even in the absence of DNA-PK activity, there is some residual clear-
ance of DNA damage, which is likely due to alternative DSB repair pathways that
are revealed in the absence of NHEJ [1, 26]. Nevertheless, most of the IR-induced
comet signal persists in the DNA repair defective cell lines, indicating that most of
the IR-induced comet signal is due to DSBs.
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4.4.3 Comparison of CometChip and the -y-H2AX assay
One potential advantage of the CometChip is that it enables direct physical mea-
surement of DSBs, rather than detection of a signaling events triggered by DSBs.
A potential shortcoming of the latter approach is that conditions that inhibit either
phosphorylation or dephosphorylation of -H2AX could lead to false negative or false
positive results, respectively. To directly compare CometChip and 'y-H2AX, we stud-
ied repair following exposure to 100 Gy IR using both wild type and DNA-PKcs-/-
cell lines. Physical breaks were assessed by CometChip and levels of 'y-H2AX were
determined by Western blot, as shown in Figure 4-4a and Figure 4-4b, respectively.
For the CometChip, there is a significant induction of DSBs followed by rapid clear-
ance to baseline within two hours of exposure in the wild type cells. There is almost
no DSB repair capacity in the DNA-PKcs-/- cells, which is consistent with the es-
sential role of DNA-PK in NHEJ [27]. In contrast, for the -y-H2AX assay, there is
a clear induction of H2AX phosphorylation reflecting apparent DSBs in wild type
cells, but the signal induction is delayed by 30-60 min after appearance of DSBs, and
persists for more than six hours after DSBs have been completely repaired according
to the CometChip analysis. Thus, disappearance of the -y-H2AX signal clearly lags
behind repair of actual physical DSBs, leading to a false positive result. Additionally,
the levels of DSBs according to the -y-H2AX assay are significantly reduced in the
DNA-PKcs-/- cell line, which is consistent with results showing that DNA-PK con-
tributes to phosphorylation of H2AX [14]. Thus, despite there being equal levels of
damage when assessed physically, there is a false negative result when assessed using
an indirect measure of DSBs. Taken together, these data demonstrate the value of
physical detection of DSBs rather than assessment of a response to the damage, to
avoid both false positive and false negative results. Furthermore, they support the
use of the CometChip for analysis of small molecule inhibitors of DNA-PK and other
DSB repair proteins.
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4.4.4 Screen of DNA-PK Inhibitors
Evaluating DNA-PK inhibitors that could be useful in the clinic is a potentially
valuable application of CometChip technology, as inhibitors of DSB repair are of
particular interest in the clinic as radio- and chemotherapy sensitizers. To test the
efficacy of the CometChip, we screened a subset of leading DNA-PK inhibitors, listed
in Table 4-1. Wortmannin and LY294002 are benchmark PI3KK inhibitors that
have been shown to sensitize cancer cells to DNA damaging agents via inhibition
of DNA-PK dependent DSB repair [28, 29]. NU7441, NU7026, and Compound 401
were developed as LY294002-like inhibitors with improved specificity for DNA-PK
[30, 31, 32]. DMNB and P1103 represent the range of other DNA-PK inhibitors, with
DMNB having high selectivity and relatively low inhibitory efficiency for DNA-PK
(i.e. 15000 nM), and PI103 having nanomolar potency for numerous PIKKs.
CHO-K1 (wild type) cells were loaded into a 96-well CometChip and exposed
in triplicate wells to 50 pM of each inhibitor. This concentration represents the
half maximal effective concentration (EC50 ) of LY294002, which can be greater than
1000-fold higher than the half maximal inhibitory concentration (IC50 ) due to cellular
penetration, competition with ATP, and the high abundance of cellular DNA-PK [33].
The use of the multi-well plate minimized the volume requirement of each inhibitor to
50 pL and reduced the complexity of the experiment to just three CometChips. All
steps including cell loading, repair inhibition, irradiation, and repair took less than
three hours to complete. Imaging was greatly reduced in terms of labor requirement
through automation.
NU7441 is being pursued as a potential adjuvant in cancer treatment due to its
ability to increase efficacy of both chemo- and radio-therapy in tumor-bearing mice
through selective inhibition of DNA-PK [34]. Figure 4-5 shows the relative repair 1 hr
after exposure compared to wild type for each inhibitor and cell type. All inhibitors
except for the less potent, DMNB, displayed inhibition of DSB repair at an efficiency
comparable to or greater than the cells with DNA-PK genetic deficiencies. Inhibitors
with multiple PI3KK targets had a more pronounced effect on DSB repair. For
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example, P1103, which has low specificity but ten-fold greater potency for DNA-PK
than NU7441, resulted in complete inhibition of repair. Inhibition of mammalian
target of rapamycin (mTOR) has recently been shown to significantly inhibit NHEJ,
which might explain the increased efficacy of several of the DNA-PK inhibitors [35].
Most notably, Compound 401 is highly specific to DNA-PK and mTOR, and was
found to completely inhibit DSB repair. Thus, the CometChip can be used to both
identify inhibitors of DSB and provide information regarding their relative potencies.
4.5 Discussion
Here, we have described a HT method to directly assess DSBs resulting from both
radiation and a chemotherapeutic agent and we show the DSB repair kinetics for
multiple cell samples analyzed in parallel. In addition to its utility in screening
compounds, the CometChip can also potentially be used for personalized medicine.
DNA damaging agents are central to non-surgical cancer treatment and as adjuvants
to surgery, but their clinical efficacy varies considerably among individuals. The
CometChip provides a relatively inexpensive and fast method of measuring DSB
repair capacity, which could be used to assess patient sensitivity and tumor resistance
in order to design optimal therapeutic strategies that minimize side-effects.
We have shown that the CometChip has a distinct advantage over the y-H2AX
assay, in particular for evaluating DNA-PK or other PI3KK inhibitors, since it di-
rectly measures DNA damage. Further, the CometChip readout reflects the inte-
grated response of multiple DNA repair pathways and sub-pathways, as opposed to a
biomarker that may otherwise be influenced by the compound being assessed [14, 36].
DNA-PK inhibitors and other drugs that target DNA repair proteins have emerged
as promising adjuvants in combinational therapy, and whole-cell screening platforms
to characterize such compounds will be increasingly valuable to the pharmaceutical
industry as more companies add them to their advanced preclinical pipelines [10].
The morphology of neutral comets differs from that of alkaline comets and is often
criticized for reducing the sensitivity and reproducibility of the assay 4-7a. Single
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strand breaks relax supercoiled DNA, resulting in a 'halo' that makes it difficult
to decipher the head-to-tail threshold [16]. One advantage of the arrayed comet
platform is that the DNA conforms to the morphology of the microwell, producing a
distinct and reproducible comet head and tail. This feature may explain the increased
sensitivity of the CometChip at higher doses compared to the traditional comet assay
as determined by ANOVA analysis. Another contributing factor may be the reduced
variability in the CometChip. In addition to increased sensitivity, a major advantage
of the CometChip is the reduction of labor, and therefore human error, resulting
from the ability to conduct all samples and controls on a single device that integrates
with HTS technologies and automated imaging and analysis platforms. Additionally,
the multiwell format minimizes the required amount of reagent, which is important
in terms of cost savings when evaluating expensive chemotherapeutic compounds.
This increase in throughput not only has potential applications in drug screening
and personalized medicine, but it also can be used to better classify environmental
pollutants and understand the risk they represent to exposed populations.
We had previously shown that the CometChip is compatible with multiple cell
types. Here, we extended this work, evaluating the DSB repair kinetics of three
cell types on a single CometChip and demonstrating detection of two functionally
different deficiencies in DNA-PK (Fig. 3). The ability to detect such deficiencies is
important in predicting treatment response and managing cancer resistance.
In addition to NHEJ and HR, DSBs can also be repaired by alternative mecha-
nisms, such as single strand annealing (SSA) and microhomology mediated endjoining
(MMEJ) [2, 26]. In the case of HR, we do not anticipate detecting a significant impact
from this pathway during the early time points, since NHEJ is significantly faster than
HR [1]. Likewise, SSA and MMEJ are significantly slower than NHEJ, and are thus
kinetically separable. The ability of the CometChip to measure precise end joining
kinetics is critical in understanding the integrity of repair, as the deleterious MMEJ
pathway masks NHEJ deficiencies at times greater than two hr [26].
The irs-20 CHO cell line contains a defect in the DNA-PKcs that disrupts its kinase
domain, while maintaining its DNA-binding activity [36]. Detection of this deficiency
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supports the use of the CometChip for screening potential adjuvant therapies known
to inhibit the phosphorylation activity of DNA-PK. We found the potent DNA-PK
inhibitor, NU7441, to induce equivalent levels of repair inhibition as the irs-20 mutant
(Fig. 4). Compounds with lower specificity for DNA-PK demonstrated stronger
inhibition profiles, revealing the importance of other PI3KKs in DSB repair mediation.
This is best exemplified by LY290042, which has relatively less potency for DNA-
PK than the other inhibitors (Table 4-1), but had a dramatic effect on DSB repair
capacity. The increased efficacy of LY290042 over Wortmannin may also result from
its ability to competitively inhibit the active site of DNA-PKcs, as opposed to the
non-competitive nature of Wortmannin [37]. Further differences in efficacies may
be due to off-target interactions with mTOR, as previously discussed [35], or P13K,
which has recently been shown to influence DSB repair through interaction with
other PI3KKs (e.g. ataxia telangiectasia mutated (ATM)) [38]. In support of this
hypothesis, NU7026, a highly selective inhibitor, has significantly less potency for
mTOR and negligible affinity for P13K, and did not have as profound of an effect
as NU7441 (Fig. 5). It will be interesting to further explore this concept through
evaluation of specific inhibitors of mTOR, such as PP242 and PP30 [35]. There
are limited tools to investigate the direct effect of the PI3KK signaling cascade and
other chromatin remodeling processes on DSB repair. Chromatin modifications are
gaining attention for their role in carcinogenesis and for their potential as targets for
pharmaceutical intervention [39, 40]. CometChip studies are currently underway to
assess other PI3KK-targeting compounds, such as ATM (i.e. KU55933), as well as
histone deacetylase (HDAC) inhibitors, a promising new class of small molecules in
cancer treatment [41].
In conclusion, the CometChip is an effective tool for directly measuring the induc-
tion of DSBs. The 96-well format enables multiple cell types and chemical conditions
to be assayed in parallel with improved processing speed to that of the traditional
comet assay. Using both a genetic approach and a chemical inhibitor of DNA repair,
we demonstrated that the assay is sensitive for DSB detection and showed that the
assay improves reproducibility and enhances throughput by nearly an order of magni-
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tude compared to the traditional assay according to [16]. Furthermore, the platform
directly measures DSB repair kinetics, enabling the detection of end joining deficien-
cies and the evaluation of inhibitors of DSB repair. The CometChip may therefore
be useful in a variety of clinical settings.
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Figure 4-1: 96-well CometChip: Single Cell Microarray Platform. (a) As-
sembly of multiwell comet array. Agarose gel with microwells is sandwiched between
a glass substrate and a bottomless multiwell plate and sealed with mechanical force.
Approximately 300 arrayed microwells comprise the bottom of each multiwell. (b)
Loading and chemical dosing of cell samples in multiwell. One cell sample is loaded in
each multiwell and cells settle by gravity into the arrayed microwells. The bottomless
plate is removed in order to aspirate excess cells and enclose the cells in agarose.
The bottomless plate is replaced in order to treat each multiwell with a chemical
condition.
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Figure 4-2: Arrayed Microwell Comet Assay for Detection of Double Strand
Breaks. (a) Arrayed microwell comets from untreated TK6 human lymphoblasts and
TK6 cells exposed to 100 Gy gamma irradiation. Scale bar is 100 Am. (b) Com-
parison of irradiation dose response between traditional comet slides scored using
commercial software and microwell comets scored using automated software. Each
data point is the average of three independent experiments, where the median tail
length (pim) of 100 individual comets was used to represent the extent of DNA dam-
age. (c) Bleomycin dose response conducted on multiwell platform with each data
point representing the median tail length (pLm) of at least 300 comets pooled from six
multiwells.
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Figure 4-3: Detection of NHEJ Deficiencies. (a) Simplified model of non-
homologous endjoining. The Ku70/Ku8O heterodimer binds to the DNA ends formed
by a DSB and recruits DNA-PKcs to form DNA-PK. DNA-PK autophosphorylates
to signal further recruitment and processing of the DSB as well as its subsequent
release. (b) Evaluation of DNA repair kinetics of CHO-K1 (wild type), xrs-6 (Ku80-
/-), and irs-20 (DNA-PKcs-/-) exposed to 100 Gy IR. All cell types and repair times
conducted on a single CometChip with data representing median comet tail lengths
(pm) from at least 50 comets. Error bars represent standard deviations of three in-
dependent experiments. Symbols indicate a significant difference compared to wild
type according to Student's t-test: *p < 0.05, **p < 0.005.
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Figure 4-4: Comparison of Neutral CometChip to 7-H2AX Assay. Wild type
(circles) and DNA-PKcs-/- (squares) were exposed to 100 Gy IR. (a) All cell condi-
tions and repair time points were conducted in triplicate wells of a single CometChip.
Comet tail length (pm) values were normalized to peak wild type damage. Irs-20 cells
displayed significantly different repair kinetics from CHO-K1 (P < 0.005). (b) Repair
kinetics were measured in triplicate over eight hours using a Western blot version of
the -y-H2AX assay.
168
00Cl)CO
C.)
W
0
0O
U)
U1)
U)D
60
40
20
0QL.
n=3 * p < 0.05
**p < 0.005
* p < 0.0005
*
* *
* *
4'~ *
0 MD c C 7- NJ T- M U -
Z z m -E 'c 't o 0 '
o : Rd * r-o <
z t 0 C0
0. < 0
z
a
Figure 4-5: Evaluation of Relative Repair from 100 Gy IR after 1 hr Ex-
posure to DNA-PK Inhibitor Library. CHO-K1 (wild type) cells pre-incubated
for 1 hr in 50 pM of each inhibitor. All conditions and controls, xrs-6 (Ku80-/-) and
irs-20 (DNA-PKcs-/-) assayed in triplicate wells. Data and error bars represent av-
erages and standard deviations of three independent experiments. Symbols indicate
significance compared to wild type (DMSO) according to Student's t-test: *p < 0.05,
**p < 0.005, ***p < 0.0005.
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Figure 4-6: Well-to-well Variability of Traditional Comet Assay and Arrayed
Cell CometChip using TK6 Cells Exposed to 100 Gy IR. (a) Median of 30
traditional neutral comets from ten slides. Median comet length: 70 pm; Coefficient
of variance: -20% (b) Median of at least 30 microwell comets from 96 wells of
CometChip. Median: 105 pm; Coefficient of variance: ~15%.
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Figure 4-7: Comparison of CometChip to Traditional Neutral Comet Assay.
(a) Comparison of comet morphologies resulting from 100 Gy IR. (b) Percent total
DNA in tail: R' = 0.30 (CometChip) and R2 = 0.42 (Traditional). (c) Olive tail
moment: R2 = 0.88 (CometChip) and (G2 = 0.63 (raditional). (d) Tail length (m):
R2 = 0.99 (CometChip) and R2 = 0.85 (Traditional).
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Table 4-1. DNA-PK inhibitors
ICso(nM)b Relative d
Compound Other Major Targets DNA-PK P13K mTOR Inhibition (%)
PI-103 ATR, ATM, PI3K, P1100/y, 2 8 20 100
P13KC2a/3, mTORC1/2, hsVP534
Compound 401 mTOR 280 >100000 5300 100
LY290042 c Pl3K, P1100/y, CKII, mTOR 360 1.4 2500 100
NU7441 c P13K, mTOR 14 5000 1700 79
Wortmannin PI3K, PLK1, mTOR 150 2-5 1000 68
NU7026 c 230 >100000 13000 50
DMNB 15000 14
a,b Data compiled from manufacturer (Tocris) c (Leahy, 2004) d Relative inhibition values calculated from Fig.4-5
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Chapter 5
Conclusions
This thesis represents the foundational work surrounding the engineering and char-
acterization of the CometChip, a method to pattern single cells in agarose for high
throughput analysis of DNA damage and repair using the well-established comet assay
protocol. The CometChip was shown to have equivalent sensitivity compared to the
standard comet assay, while increasing throughput by at least an order of magnitude
and reducing experimental noise. Furthermore, the CometChip can be imaged auto-
matically and continuously without the requirement of a slide feeder and the number
of analyzable comets in each image is improved by the spacing of the microwell ar-
ray. We developed an automated software suite that exploits the defined spacing of
the array to objectively select comets and utilizes the fixed head size, provided by
the microwell geometry, to accurately determine comet parameters. Additionally, the
microwell array provides the ability to evaluate DNA damage in cell aggregates and
the potential to include multiplexed labeling for parallel analysis of multiple single
cell endpoints (e.g. viability). The 96-well version of the assay can be integrated with
standard high throughput screening (HTS) and imaging technologies for automated
analysis of multiple cell types, chemical conditions, and repair time points on a single
device. The CometChip has applications in both epidemiology, such as determin-
ing the consequences of harmful exposures and identifying susceptible populations,
and clinical practice, such as determining tumor sensitivities and guiding treatment
strategies.
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We used the CometChip to compare repair kinetics of damage induced by a range
of chemical agents, each revealing a distinct repair profile. By using model agents
with known spectra of lesion induction, we calculated the kinetic half lives for four
major DNA repair pathways, which varied considerably from as fast as 15 min for
base excision repair (BER) of oxidized damage, 1 hr for non-homologous end join-
ing (NHEJ), 4 hr for nucleotide excision repair (NER), to more than 10 hours for
interstrand crosslink repair (ICLR). We used these repair profiles as standards for
evaluation with deficiencies in repair from a specific chemical exposure being detected
as deviations from the corresponding standard repair curve.
We evaluated glioblastoma cell lines with known deficiencies in alkyladenine gly-
cosylase (AAG) and polymerase beta (Polo) and found that only when cells were
both over-expressed (OE) in AAG and knocked-down (KD) in Pol# did an accumula-
tion of BER intermediates result in response to alkylation damage. This emphasizes
that it is the coordinated effort of multiple repair proteins that is important to main-
taining balance in the BER pathway. It would be interesting to probe the system
further with a range of MMS concentrations to determine whether imbalances might
be concentration dependent. For example, at higher doses, cells overexpressing AAG
may saturate Pol# activity. Understanding such thresholds may be important for
optimizing therapeutic dosing regimens.
We successfully employed the CometChip for detection of XPG deficiencies in
NER, however, the mechanistically rich repair profiles expected for XPG deficient
and catalytically inactive XPG mutant cells were not revealed. This is likely because
not all lesions in the 4-Nitroquinoline 1-oxide (4NQO) spectrum are substrates for
NER and the resulting 4NQO repair profile is therefore dictated by multiple repair
processes. By using a dose range of ultraviolet (UV) radiation, which is known to
produce mostly single strand breaks (SSBs) and pyrimidine dimers, and evaluating
repair after three hours, when BER can be expected to be complete, the theoretical
repair profiles predicted by the Dual Incision Hypothesis emerged. This is an exam-
ple of how the increased throughput and improved reproducibility provided by the
CometChip can enable an informed user to exploit the versatility of the comet assay
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for detection of numerous lesions and repair profiles. We plan to evaluate a set of
more than ten other transgenic human fibroblast cell lines with mutations in other
key NER enzymes (e.g. XPF and XPA). The data may provide further details of the
NER mechanism.
In another modality of the comet assay, cells can be exposed to ionizing radiation
(IR) in order to determine the extent of interstrand crosslinking. We adapted this
protocol to the CometChip and identified the critical role of a NER deficiency (XPF-
/-) in interstrand crosslink repair (ICLR). In addition, we showed that a deficiency
in XPB, the NER helicase associated with XPF, did not have an effect on ICLR. It
would be interesting to similarly evaluate the NER deficient human fibroblast cell
lines from the Laboratory of Dr. Orlando Schsrer, in order to determine the roles of
other NER proteins and protein functions in human ICLR. The CometChip can also
be used to evaluate efficacies of ICL agents or evaluate sensitivities of tumor cells.
Lastly, we evaluated double strand break (DSB) repair through adaption of the
neutral comet assay on the CometChip. The use of a Cobalt-60 gamma irradiator
( 120 Gy/min) and ability to assess repair of multiple cell types on a single CometChip
enabled the efficient detection of deficiencies in two critical NHEJ proteins, confirm-
ing the specificity of the assay for DSBs. The CometChip represents one of the only
platforms available for direct measurement of DSBs and DSB repair kinetics, provid-
ing a relatively inexpensive and fast method of measuring DSB repair capacity, which
could be used to assess patient sensitivity and tumor resistance.
It is conceivable that a specific DNA repair profile can be obtained for numerous
other genotoxic agents. A cell sample could then be challenged with an established set
of chemicals in order to produce a DNA repair signature that could reveal biological
insights such as lesion sensitivities and repair deficiencies. Similarly, an uncharacter-
ized genotoxic compound could be screened against a small set of transgenic cells in
order to better understand its chemical mode of action. We demonstrated that even
with a limited number of model cell lines and DNA damaging agents, mechanistically
rich repair profiles can be obtained, providing insight into multiple pathways of repair,
revealing a range of genetic deficiencies.
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The use of the CometChip in detecting DNA repair deficiencies serves as proof
of principle for its use in evaluating small molecule inhibitors of DNA repair pro-
teins, which have emerged as a promising new target in cancer management. We
used the CometChip to assess potential inhibitors of AP Endonuclease (APE). The
screen of three inhibitors provided results that were consistent with the literature,
supporting this approach as a secondary measure of the efficacy of APE inhibition.
However, this application of the assay was not ideal, because inhibitor efficacy was
detected as a dose dependent comet signal assumed to be formed by an accumulation
of spontaneous abasic sites. In contrast, the use of the neutral CometChip provides
a more direct application for screening DNA repair inhibitors. We screened seven
inhibitors of DNA-PK and two control cell lines with deficiencies in DNA-PK on
a single CometChip in triplicate. We found a range of DSB inhibition efficiencies
that appeared to correlate with known inhibition parameters. The detection of such
deficiencies is a niche application for the CometChip, as the '7 -H2AX assay, which
has become a standard in DSB detection, measures a signal that is dependent on
DNA-PK and other proteins and is therefore limited in its ability to measure DSB
repair kinetics. That is not to say that the -y-H2AX assay does not provide useful
information. In fact, the marriage of the two assays may provide a wealth of new
information in screens of other PI3KKs or HDAC inhibitors or studies involving the
effects of chromatin structure on DSB repair kinetics.
The studies described in this thesis support the use of the CometChip in many
settings ranging from the straight forward application of genotoxicity testing to more
elaborate investigations into the biological mechanisms of DNA repair. In addition,
many of the experiments were conducted partially as a technical proof of principle
and therefore have uncovered numerous avenues for deeper analysis, which in turn
may require additional technical advancements. For example, one reoccurring theme
is how to best interpret repair profiles of BER in experiments such as the screen of
glioblastoma lines in Chapter III. Without knowledge of relative enzyme activities,
the WT, AAGOE, and Pol#KD cells would be interpreted as having identical repair
capacities, which we know is not the case due to the accumulation of repair intermedi-
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ates in AAGOE/Pol3KD cells. One way to fully realize the alkylation damage burden
and true extent of repair is through the implementation of post-lysis enzymes (i.e.
AlkA, FPG, T4EndoV) to convert base lesions (Collins, et al., 1997). The CometChip
may be favorable for such applications, as enzyme treatment could be applied using
the 96-well format. This addition to the CometChip tool set would enable increased
sensitivity of DNA damage quantification and provide another layer of analysis into
DNA repair capacity.
Ultimately, we want to provide an assay that is useful in both a variety of clinical
and population studies. It will therefore be necessary to develop protocols for analysis
of primary cells. We have successfully assayed human lymphocytes and nasal epithe-
lial cells for baseline levels of damage. We have also conducted proof of principle
experiments using a variety of murine tissues, including thymus, spleen, hepatocytes,
etc. Most recently, we demonstrated an ability to detect MMS induced damage in
freshly harvested thymus cells. These results are encourgaging, however, in most
cases it will be important to freeze samples and store them before conducting exper-
iments. The effects of such freezing protocols must therefore be explored. Another
barrier to the use of primary cells is potential contamination of the comet signal by
dead or apoptotic cells, which may represent a large fraction of the sample population
in some tissues. One strategy we are pursuing is to develop microwell registration
algorithms in order to multiplex viability endpoints with comet analysis, such as
fluorescent live/dead stains. The CometChip could then be imaged before analysis
and comets resulting from dead/apoptotic cells could be eliminated during analysis.
These algorithms may also be applied for selection of fluorescently labeled cells (e.g.
with a fluorescent antibody), which could be an important method for analyzing het-
erogeneous cell popluations. Together, these technological improvements may enable
DNA damage measurements of primary samples with improved resolution that have
the potential to become a new standard in DNA damage analysis.
This thesis work sits at the interface of engineering and biology, demonstrating
the ability of engineering approaches to significantly improve existing biological as-
says. So while we initiated the project with a tool that resembled the standard comet
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assay, the current version of the CometChip enables analysis of multiple cell samples,
multiple chemical conditions, and multiple repair time points on a single device, and
integrates with standard high throughput screening technologies, providing a plat-
form for drug discovery and genotoxicity screening. Furthermore, the CometChip is
the first device to enable simultaneous evaluation of multiple DNA repair pathways,
which is important both in characterizing chemical exposures and also for detection
of repair deficiencies. The use of microwells not only improves throughput and re-
producibility, but may also permit new applications, such as multiplexing endpoints
and including internal standards for further reduction of variability between exper-
iments. Other technological improvements can also be envisioned, such as the use
of materials with greater stability and more uniform consistency than agarose or the
application of various electrophoresis techniques to enhance signal resolution. Lastly,
improvements to the analysis software may reveal new parameters that provide more
information, such as about cell cycle, or the distribution of damage levels among a
sample population. At the heart of the CometChip technology lies the microwell ar-
ray, an approach whose elegance will enable the continued evolution of the CometChip
as a high throughput platform for DNA damage and repair analysis.
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Appendix A
Protocols
A.1 Photolithography
TRL SU-8 (Purple) Process on 4" Silicon
1) Dehydrate wafer at 180C for 5m on hotplate 1
2) Spin SU-8 2050 @ 3500 rpm for 30s on SU8spinner
3) Prebake wafer @ 65C for 2m on hotplate 2
4) Softbake wafer @ 95C for 7.5m on hotplate 1
5) Expose wafer for 20s on EV1 with transparency mask using 5s intervals and 15s
delay
6) Prebake wafer @ 65C for 2m on hotplate 2
7) Postbake @ 95C for 5m on hotplate 1
8) Develop SU-8 using PM Acetate
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A.2 CometChip
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High Throughput Assays for
Detection of DNA Damage
Engelward Laboratory
Genome Repair and Damage Detection (GRDD) team
updated Sumnmer 2011
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Creating a CometChip
Materials:
Normal Melting Point (NMP) Agarose (invitrogen; Catalog No. 15510-027)
Low Melting Point (IMP) Agarose
Dulbecco's Phosphate Buffered Saline 1X (GIBCO)
GelBond* Film (Lonza; Size: 85 x 100 mm, Catalog No. 53734)
PDMS tamp (Provided by Engeiward Lab)
Square petri dish (VWR: Catalog No. 25378-047)
Bottomless 96-well plate (Greiner Bo-One: Reference 655000)
1.5" Binder Clips
Glass plate
3
Boil agarose and Place gelbond
* Prepare molten 1% NMP agarose in PBS by bringing solution to a boll
- Cut and place GelBond* paper hydrophilic side facing up in petri dish
7PS: 1) Use ~2mL of 1% agarose to seal the gelbond to the dish surface
2) Water will bead on surface of hydrophobic side
4
Pour agarose and set PDMS mold
- See chart to determine amount of NMP agarose
- Add molten 1% NMP agarose
- Immediately set PDMS mold on top of agarose s
1, 2.
3. 4
Remove PDMS mold
- Allow agarose to gel (3-5min), then add 10mL PBS on top of gel/mold
* Carefully remove PDMS stamp from gel using tweezers to peel from the corner
Inspect microwells for quality control
6
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Remove Gel
- Remove gelbond with gel from dish and discard excess gel
- Label back of gelbond using permanent chemical resistant marker (VWR)
Clamp 96-well Plate
- Set gel on glass plate and press bottomless 96-well plate upside-down into it
- Clamp all four sides of 96-well plate to glass using 1.5 binder clips
5. 4 -
Load Cells
- Add 100ul of each single cell suspension (>100,000 cell/mt) to each well of plate
- Cover plate with gelbond to prevent evaporation of media during Incubation
- Allow microwells to load for at least 30min In 37C Incubator
Remove Excess Cells
- Remove plate from incubator* and aspirate media from each well
- Remove 96-well plate and gently rinse with PBS to remove excess cells
*TIp: Use microscope to ensure that>70% wells contain cells.
Apply Overlay
- Overlay gel with 37C 1% Low Melting Point Agarose
- Allow to gel In refrigerator for five minutes
Dosing and Repair
- If multiple chemical conditions or repair time points are to be conducted, replace
the 96-well plate by carefully aligning the wells to exact location.
- Use a marker to cirde the backside of 2-3 wells to help with realignment
- 96-well plate should slip back Into position with minimal force.
12
Electrophoresis Buffer
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Alkaline Assay
Materials:
Buffers
Lysis Buffer
Electrophoresis Buffer
Neutralizing Buffer
TE Buffer
Electrophoresis chamber and Power Supply
SYBR Gold Stain (Invitrogen: Catalog Number S11494)
13
Alkaline Lysis Buffer
&%Agebee~bmw T" ekt" 0WebChe"i d an w eAL t L .0 L 4 L
woncenkn in shiwn (ghnol}
108 M NNoEWA 31 1"g 37.3g 74.89 14.g
1OinMTeb00ee 121.1 GAiee 1.2its lA42e 1a4g
[also"d 00 us-nalysinaisedl
Working solution: 1% Trton X-100
1%1Trton X-100 Directly belor ueadd 1mL Tlton X-1O per 100mL buffer
Stock Solution Preparation:
1) Dissolve crystalline substances half of the desired end volume
2) Adjust the pH to 10: add NaOH until cloudy solution becomes dearer (~pH 9.8)
3) Fill with distilled water to final volume
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Neutralization Buffer
11 me ee *ef ip TeWuleme i* we
112114 606g 1211g 2 4 .1
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1m d40 100.ml 200m 400ml
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Alkaline Comet Assay
- Remove 96-well plate and submerge gel in 4C alkaline luisfI r for lhr or
overnight
* Tape each gel In electrophoresis chamber with double-sided tape
- Fill chamber with 4C alkaline electrophoresis bufer to volume that covers gels
- Allow 40min for alkaline unwinding .
* Run electrophoresis at 1V/cm and 300 mA for 30 min at 4C
*Adjust level of electrophoresis buffer in chamber to achieve 300 mA current
17
183
Neutral Assay
Materials:
Buffers
Lysis Buffer
Electrophoresis Buffer
Neutralizing Buffer
TE Buffer
Electrophoresis chamber and Power Supply
SYBR Gold Stain (Invitrogen: Catalog Number S11494)
18
Neutral Lysis Buffer
Neutral LyuIs Stock Solution (pH 9.5) Total Volume of Lysis Buffer
clwmical nd nal MW 0.5L 1.0L 2.0L 4.0L
concentration In solution (/mol
2.SMNaO 58A 73.1g 146.1g 292.2g 5a4Ag
100 M 0rA 372.2 I. g 37.22 74.Sg 14a.s g
10 mM l.Sa) 122.1 0.6061 1.211 2A42 4 4.8" g
1%N4rWrlswcoine N/A 5g log Og 40g
Stock Solution Preparation:
1) Dissolve crystalline substances half of the desired end volume
2) Adjust the pH to 9.5
3) Fill with distilled water to final volume
Working solution: 0.S%Triton X-100 and 10 DMso
Directly befor, use add: -0.5msL'ton X-100 per 100mL buffer
- 1OnL DM50 per 1OmL butler 19
Neutral Electrophoresis Buffer
Neutral Assay Electrophoresis Buffer Is TME at pH 8.5
TBE Solution (pH .5) Total Volume of LysIs luffer
Chemical nd final MW 0.5 L 1.0 L 2.0 L 4.0 L
concentration In solution (g/mol)
2 mM Na EDTA 372.2 0.372g 0.744 g 1.4881 2.976g
90 mM Ibis (Base) 121.1 5.45 g 10.9g 21.8 g 43.6 g
90 mM Boric AcId 61.83 2.78 1 S.S6 g 11.13 g 22.26 g
Stock Solution Preparation:
1) Dissolve crystalline substances half of the desired end volume
2) Adjust the pH to 5.5
3) Fill with distilled water to final volume
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Neutralization Buffer
w .mo a s w . q T*WV~w*M.a...
Tr4AM I uw wm s #.x I L 2L[4L
Crypteme Ton 1 14 6 G 121 1g 223g 404.S1g
CrstnneTrs117.88 7?.g 1S7.Sg 316.2g 830Ag
Adjust the pH to 7.5 with either HC1 (35%) or 3M NoOH
Worn solution: Premar directly beforeus
s Tiff-W 7e Tta Valuing of ftl 14000
.. na..on I
,Is 100.L 200L 1400mL
0Ina-d o
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Neutral Comet Assay
* Remove 96-well plate and submerge gel In 43C neutralesis for 3 hours
- Can refrigerate overnight in lysis solution after 3 hours
- Remove lysis buffer and rinse with neutral electoohoresis (E) for 2 x
1 hour at room temperature
- Tape each gel In electrophoresis chamber with double-sided tape
- Fill chamber with 4C TBE to volume that just covers gels
- Allow gel to sit in chamber at 4C for 30 minutes
* Run electrophoresis at 0.6 V/cm and 6mA for 1 hour at 4C
*Adjust level of electrophoresis buffer In chamber to achieve 6 mA current
22
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Fluorescent Imaging
- Neutralize gpis In neutralstion buffer for 3 x 5min at 4'C
- Store gels hydrated In TE buffer at 4'C until Imaging
e Stain gels with DNA stain of choice (i.e.SYBR Gold, Ethidlum Bromide, etc.)
" Image using fluorescent microscope and 1oX objective
H202 DsResponse 23
Data Analysis with MATLab:
(1) Stack Images as .tIff using ImageJ (httI:/rsbwebnIh.zoV/1l
(2) Open Matlab
(3) Type "gulcometanalyzer.m" Into the Command Window
(4) Click Browse and select the folder containing your .tiff Images
(5) Select Image flies to analyze
(6) Set parameters (Default Is for 40um PDMS stamp)
* Head diameter: 40 Array spacing: 240
* Image rotation: 0 (tall to the right)
(7) ANALYZE
Data output as text files In directory folder
getcometdata.m can be used to extract data (median/std) from text files
Type "getcometdata(U)" Into Command Window and select directory
24
ImageJ
Microscope images (.tiff) must be converted to stacks for MatLAB analysis
Download for free: htp://rsbweb.nih.gov/ii
11 0 'A -\ A 11110 - .4 -S5I I i-wlmilf-
1) Open all tiff images for a single analysis
condition
2) Convert Images to Stack
"' ~ 3) Save as tiff (in directory to be analyzed)
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Screenshot of Output Textfile
ob-..0w U .et .. t 5.2 49s
1604d $01 4 9N. 01A "I I"P C 4 "
96.233 1.457) 9.8W OAMW 21.13
93.3464 5.333 0.4 U3. 01J6
V54m ..44P 'Z41, 14.e1m 4.11
%.3m7 6.%57n A.W 1611111 22.ASO
452ZW Of 0."79 I'99 mW 29.4W
9.1m4 6:7=1 9.91 6.911 32.
X3.54 3146'4 9.3rW 4.4W11 19.2m5
Data exported as .txt files
Import .txt files into excel or MATLab for analysis
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Credits
Design of CometChip: David Wood and David Weingeist
Oversight of protocol development: David Weingelst
Photodocumentation: Kelly Schulte
Questions and Concerns:
Contact David Weingeist (dmw555@mit.edu)
Appendix B
MatLAB Code
B.1 guicometanalyzer.m
i function varargout = guicometanalyzer(varargin)
2 % GUICOMETANALYZER M-file for guicometanalyzer.fig
3 % GUICOMETANALYZER, by itself, creates a new GUICOMETANALYZER or .
raises the existing singleton*.
4 %
5 % H = GUICOMETANALYZER returns the handle to a new ...
GUICOMETANALYZER or the handle to the existing singleton*.
6 %
7 % GUICOMETANALYZER('CALLBACK',hObject,eventData,handles,...) 
...
calls the local function named CALLBACK in GUICOMETANALYZER.M
with the given input arguments.
8 %
9 % GUICOMETANALYZER('Property', 'Value',...) creates a new
10 % GUICOMETANALYZER or raises the existing singleton*. Starting ..
from the left, property value pairs are applied to the GUI ...
before guicomet analyzer-OpeningFcn gets called. An ...
unrecognized property name or invalid value makes property ...
application stop. All inputs are passed to ...
guicometanalyzerOpeningFcn via varargin.
1 %
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12 % *See GUI Options on GUIDE's Tools menu. Choose "GUI allows ...
only one instance to run (singleton)".
13 %
14 % See also: GUIDE, GUIDATA, GUIHANDLES
15
16 % Edit the above text to modify the response to help guicometanalyzer
17
18 % Last Modified by GUIDE v2.5 29-Sep-2009 10:28:21
19
20 % Begin initialization code - DO NOT EDIT
21 guiSingleton = 1;
22 gui-State = struct('guiName', mfilename,
23 'guiSingleton', gui-Singleton,
24 'gui-OpeningFcn' , ...
@guicometanalyzerOpeningFcn, ...
25 'gui-OutputFcn ' , @guicometanalyzer-OutputFcn, ...
26 'guiLayoutFcn', [] ,
27 'guiCallback', [])
28 if nargin && ischar(varargin{l})
29 gui-State.guiCallback = str2func(varargin{l});
3o end
31
32 if nargout
33 [varargout{1:nargout}] = guiamainfcn(gui-State, varargin{:});
34 else
35 gui-mainfcn (gui.State, varargin{: });
36 end
37 % End initialization code - DO NOT EDIT
38 end
39
40 % Executes just before guicometanalyzer is made visible.
41 function guicomet analyzer-OpeningFcn (hObject, eventdata, handles, ...
varargin)
42
43 handles.output = hObject;
44
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45 % Initialize handle objects
46 handles.SelectedFiles = 1;
47
48 % Update handles structure
49 guidata(hObject, handles);
50
51 end
52
53 % Outputs from this function are returned to the command line.
54 function varargout =guicometanalyzerOutputFcn(hObject,
eventdata, handles)
55
56 % Get default command line output from handles structure
57 varargout{l} = handles.output;
58 end
59
60 % Executes on button press in pushbuttonl.
61 function pushbuttonlCallback(hObject, eventdata, handles)
62
63 analysisok = mwcometanalyzer(handles);
64
65 guidata(hObject,handles)
66 end
67
68 function editl-Callback(hObject, eventdata, handles)
69 end
70
71 % Executes during object creation, after setting all properties.
72 function editlCreateFcn(hObject, eventdata, handles)
73 if ispc && isequal(get(hObject,'BackgroundColor'),
74 get(0,'defaultUicontrolBackgroundColor'))
75 set(hObject,'BackgroundColor','white');
76 end
77 end
78
79
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8o function edit22-Callback(hObject, eventdata, handles)
81 end
82
83 % Executes during object creation, after setting all properties.
84 function edit2-CreateFcn(hObject, eventdata, handles)
85
86 if ispc && isequal(get(hObject,'BackgroundColor'),
87 get(O,'defaultUicontrolBackgroundColor'))
88 set(hObject,'BackgroundColor','white');
89 end
90 end
91
92 function edit3_Callback(hObject, eventdata, handles)
93 end
94
95 % Executes during object creation, after setting all properties.
96 function edit3_CreateFcn(hObject, eventdata, handles)
97 % Hint: edit controls usually have a white background on Windows.
See ISPC and COMPUTER.
98 if ispc && isequal(get(hObject,'BackgroundColor'),
99 get(0,'defaultUicontrolBackgroundColor'))
100 set(hObject,'BackgroundColor','white');
lio end
102 end
103
104 function edit4-Callback(hObject, eventdata, handles)
1o5 end
106
107 % Executes during object creation, after setting all properties.
108 function edit4-CreateFcn(hObject, eventdata, handles)
109 if ispc && isequal(get(hObject,'BackgroundColor'),
110 get(0,'defaultUicontrolBackgroundColor'))
il set(hObject,'BackgroundColor','white');
112 end
113 end
114
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115 function edit5-Callback(hObject, eventdata, handles)
116 end
117
118 % Executes during object creation, after setting all properties.
119 function edit5-CreateFcn(hObject, eventdata, handles)
120
121 if ispc && isequal(get(hObject,'BackgroundColor'),
122 get(O,'defaultUicontrolBackgroundColor'))
123 set(hObject,'BackgroundColor','white');
124 end
125 end
126
127 % Executes on button press in pushbutton2.
128 function pushbutton2_Callback(hObject, eventdata, handles)
129
130 FileDirectory = uigetdir('C:\Documents and Settings\');
131 set(handles.edit6,'String',FileDirectory);
132 dirlist = dir(fullfile(FileDirectory, '*.tif'));
133 [filenames,dummyvar] = sortrows ({dirlist.name}');
134 set(handles.listboxl,'String',filenames);
135 handles.FileDirectory = FileDirectory;
136 guidata(hObject,handles)
137 end
138
139 % Executes on selection change in listboxl.
140 function listboxlCallback(hObject, eventdata, handles)
141
142 handles.SelectedFiles = get(hObject,'Value');
143 guidata(hObject,handles);
144 end
145
146 % Executes during object creation, after setting all properties.
147 function listboxlCreateFcn(hObject, eventdata, handles)
148
149 if ispc && isequal(get(hObject,'BackgroundColor'),
150 get(0, 'defaultUicontrolBackgroundColor'))
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151 set(hObject,'BackgroundColor','white');
152 end
153 end
154
155 function edit6-Callback(hObject, eventdata, handles)
156 end
157
158 % Executes during object creation, after setting all properties.
159 function edit6_CreateFcn(hObject, eventdata, handles)
160 if ispc && isequal(get(hObject,'BackgroundColor'),
161 get(O,'defaultUicontrolBackgroundColor'))
162 set(hObject, 'BackgroundColor','white');
163 end
164 end
165
166 % Executes on button press in pushbutton3.
167 function pushbutton3_Callback(hObject, eventdata, handles)
168
169 FileNames = get(handles.listboxl,'String');
170 handles.SelectedFilenames = FileNames(handles.SelectedFiles);
171 set(handles.listboxl,'String',handles.SelectedFilenames);
172 set(handles.listboxl,'Value',1:length(handles.SelectedFiles));
173 guidata(hObject,handles);
174 end
175
176 function edit7_Callback(hObject, eventdata, handles)
177 end
178
179 % Executes during object creation, after setting all properties.
180 function edit7-CreateFcn(hObject, eventdata, handles)
181 if ispc && isequal(get(hObject,'BackgroundColor'),
182 get(0,'defaultUicontrolBackgroundColor'))
183 set(hObject,'BackgroundColor','white');
184 end
185 end
186
190
187 %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
188 function analysisok = mwcmetanalyzer(handles)
189 % Function mwcometanalyzer This function analyzes images of ...
microwell comets that are in a grid.
190 %
191 % David K. Wood and Drew Regitsky Modified 2/19/09
192 %
193 % Inputs:
194 %
195 % FileDirectory [] - tells the program where to look for comet ...
images. If no directory is set, the program will allow the ...
user to browse for the appropriate folder.
196 % convfac [0.64] - sets the pixel to distance conversion ...
factor for the imaging microscope and is used to calculate ...
comet parameters. Units are microns/pixel. Default is for a ...
1OX objective.
197 % objective [10] - sets the magnification of imaging for ...
writing to output file.
198 % hdthresh [0.15] - sets the threshold used to detect the ...
beginning of a comet in the analysis routine.
199 % tailthresh [0.02] - sets the threshold used to detect the end
of a comet in the analysis routine
200 % headdia [40] - approximate size of microwells. Units are ...
pixels.
201
202 %% Assign parameters from handles structure
203
204 tempvar = get(handles.edit2,'String');
205 hdthresh = str2double(tempvar);
206
207 tempvar = get(handles.edit3,'String');
208 tailthresh = str2double(tempvar);
209
210 tempvar = get(handles.edit4,'String');
211 convfac = str2double(tempvar);
212
191
213 tempvar = get (handles.edit5, 'String');
214 objective = str2double(tempvar);
215
216 tempvar = get(handles.edit7,'String');
217 headdia = str2double(tempvar);
218
219 tempvar = get(handles.edit9,'String');
220 imagerot = str2double(tempvar);
221
222 tempvar = get(handles.editlO,'String');
223 scale-intensity = str2double(tempvar);
224
225 tempvar = get(handles.editl2,'String');
226 PIXELSPACING = round(str2double(tempvar)/convfac);
227 %Spacing between comets in array
228
229 tempvar = get(handles.editll,'String');
230 CROPOFFSET = round(str2double(tempvar)/convfac);
231 %X-offset for cropped comet picture to include tail (positive
to the left)
232
233 tempvar = get(handles.editl3,'String');
234 MINCOMETAREA = round(str2double(tempvar)/convfac^2);
235 %Minimum number of pixels in object for it to be a comet
236
237 tempvar = get(handles.editl4,'String');
238 NearestNeighbors = str2double(tempvar);
239
240
241 FileDirectory = handles.FileDirectory;
242 filenames = handles.SelectedFilenames;
243
244
245 %% Select files for analysis
246
247 if isempty(FileDirectory) % if no directory is specified open gui
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248 FileDirectory = uigetdir;
249 end
250
251 NumFiles = length(filenames); % total number of selected files
252
253 %% Analysis Loop
254
255 h = waitbar(O,'Analyzing File 0 of 0 (0%)'); % initialize waitbar
256 % Begin looping through files
257 for fileID = 1:NumFiles
258
259 % Set Parameters for finding comets in images
260 CROPWIDTH = round(PIXELSPACING*0.9);
261 %Width of cropped comet picture to output
262 CROPHEIGHT = round(CROPWIDTH/2);
263 %Height of cropped comet picture to output
264
265 %Set default values for comet analysis parameters
266 if isempty(convfac)
267 convfac = 0.64; % 0.64 microns/pixel for 1OX objective
268 end
269 if isempty(objective)
270 objective = 10; % 1OX objective
271 end
272 if isempty(hdthresh)
273 hdthresh = 0.15; % 15% of peak intensity
274 end
275 if isempty(tailthresh)
276 tailthresh = 0.02; % 2% of peak intensity
277 end
278 if isempty(headdia)
279 headdia=40; % 40 pixels
280 end
281
282 % File housekeeping
283 filename = fullfile (FileDirectory, filenames{fileID});
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284 % assign placeholder variable
285 display(filename); % Show user what file is being analyzed
286 fileinfo = imfinfo(filename);
287 Nimages = length(fileinfo); % how many frames in tif
288 clear fileinfo % clear unused variable
289
290 %Open file for comet data and write initial info to it
291 fidO = fopen([filename(l:length(filename)-4),'.txt'],'wt');
292 fprintf(fid0,'%s \n', ['Size Calibration: ',num2str(convfac),'
micron/Px']);
293 fprintf(fidO,'%s \n', ['Objective: ',num2str(objective),'X']);
294 fprintf(fidO,'\n');
295 fprintf(fidO,'%s \t %s \t %s \t %s \t %s\n',
296 '%Head DNA','%Tail DNA','OTM (um)','Tail Len. (um)',
297 'Comet Len. (um)');
298
299 % Initialize number of comets in file
300 cometsInFile = 0;
301
302 % Update wait bar to include number of frames in file
303 waitbar(0,h, ['Analyzing File 'num2str(fileID)
304 ' of 'num2str(NumFiles) ' (0%)']);
305 % Begin looping through image frames in tif
306 for nimage = 1:Nimages
307 % Update waitbar at each frame
308 waitbar(nimage/Nimages,h, ['Analyzing File ...
',num2str(fileID),
309 ' of ',num2str(NumFiles),...
310 ' (',num2str(round(nimage/Nimages*100)),'%)']);
311 % Read in image from file
312 cometimage = imread(filename,nimage)/scale-intensity;
313 cometimage = imrotate(cometimage,imagerot); %rotate image
314 % Find comet in images using findcomets function
315 [temp-objs,NumComets] = ...
findcomets(cometimage,MINCOMETAREA,
316 PIXELSPACING,NearestNeighbors);
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317 % Analyze identified comets ...
using runcometanlaysis ...
function and save data to fidO
318 if NumComets == 0
319 NumAnalyzed = 0;
320 else
321 NumAnalyzed = ...
runcometanalysis(cometimage,temp-objs,NumComets,CROPWIDTH,...
322 CROPHEIGHT,CROPOFFSET, convfac, hdthresh,tailthresh,headdia, fidO);
323 end
324 clear cometimage % clear comet image
325 cometsInFile = cometsInFile + NumAnalyzed; % update ...
num. comets
326 end
327
328 % Housekeeping and cleanup
329 fclose(fid0); % close data file
330 clear fidO I % clear file I/O and image
331 display(['Total number of ANALYZED comets in images:
332 ,num2str(cometsInFile)]);
333 end
334 close(h) % close waitbar
335 analysisok = 'Analysis OK'; % assign dummy output
336 end
337
338 function [ObjectsInfo,NumComets] = findcomets (I,MINCOMETAREA,
339 PIXELSPACING, NearestNeighbors)
340
341 bwim = im2bw(I,graythresh(I));
342 % Create bw image using otsu thresholding method
343 labmat = bwlabel(bwim); % Create label matrix from bw image
344 labdata = regionprops(labmat);
345 % Get area and location of objects in label matrix
346
347 %% Sort Objects by size
348 ObjectsInfo = zeros(length(labdata),2); % initialize matrix
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349 NumComets = 0; % initialize number of comets
350 % Loope through objects, keeping only objects that are larger ...
than the
351 % minimum allowed area
352 for nobjects = 1:length(labdata)
353 if labdata(nobjects).Area > MINCOMETAREA && ...
labdata(nobjects).Centroid(l) > 20 &&
labdata(nobjects).Centroid(2) > 20 &&
labdata(nobjects).Centroid(2) < size(bwim,l)-20 &&
labdata(nobjects).Centroid(l) < size(bwim,2)-20
354 NumComets = NumComets +1;
355 ObjectsInfo(NumComets,:) = labdata(nobjects).Centroid;
356 else
357 ObjectsInfo(end,:) = [];
358 end
359 end
360
361 if NumComets > 1
362 %% Sort objects by nearest neighbor distance
363 % Calculate distances between objects and create square ...
matrix of distances
364 distances = pdist(ObjectsInfo);
365 ObjDist = squareform(distances);
366 clear distances
367
368 % filter objects based on distance relative to PIXELSPACING ...
parameter
369 uniquekeepers = [];
370 for nmult = 1:NearestNeighbors
371 [keepers{nmult}(:,l),keepers{nmult}(:,2)] =
372 find(ObjDist < nmult*PIXEL-SPACING+25 & ObjDist > ...
nmult*PIXELSPACING-25);
373 uniquekeepers = [uniquekeepers;unique(keepers{nmult})];
374 % only keep unique objects
375 end
376 uniquekeepers = unique(uniquekeepers);
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377 NumComets = length(uniquekeepers);
378 temp-objects = ObjectsInfo(uniquekeepers,:);
379 clear ObjectsInfo
380 ObjectsInfo = round(temp-objects); % round to intgr values ...
for indexing
381 else
382 NumComets = 0;
383 ObjectsInfo = [];
384 end
385
386 end
387
388 function NumAnalyzed = runcometanalysis(OrigCometImage,
389 ObjectsInfo,NumComets,CROPWIDTH,CROPHEIGHT,
390 CROPOFFSET,convfac,hdthresh,tailthresh,headdia,fidO)
391
392 cometdata = -ones(NumComets,5);
393 XCENT = 1;
394 YCENT = 2;
395 NumAnalyzed = 0;
396 for numcomet = 1:NumComets
397 cropRect = ...
[ObjectsInfo(numcomet,XCENT)-CROPWIDTH/2+CROPOFFSET,...
398 ObjectsInfo(numcomet,YCENT)-CROPHEIGHT/2,CROPWIDTH,CROPHEIGHT];
399 CropCometImage = imcrop(OrigCometImage,cropRect);
400 if ...
size(CropCometImage,l)*size(CropCometImage,2)
401 (CROPWIDTH+1)*(CROPHEIGHT+1)
402 [cometdata(numcomet,1),cometdata(numcomet,2),cometdata(numcomet,3),
403 cometdata(numcomet,4),cometdata(numcomet,5)]=
404 analyzecomet(CropCometImage,convfac,hdthresh,tailthresh,headdia);
405 end
406 if cometdata(numcomet,4) > 0
407 fprintf(fid0,'%7.4f \t %7.4f \t %7.4f \t %7.4f \t %7.4f \n',
408 cometdata(numcomet,:));
197
409 NumAnalyzed = NumAnalyzed+1;
410 end
411 clear CropCometImage
412 end
413 end
414
415 function [headdna,taildna,otm,taillength,cometlength] =
416 analyzecomet(cometim,convfactor,hdthresh,tailthresh,headdiameter)
417
418 % Funtion analyzecomet is used to calculate various comet ...
parameters from
419 % an image of a comet.
420 %
421 % David K. Wood May 2008
422 %
423 % inputs: cometim - image of comet convfactor - pixel to distance ...
conversion for objective/camera combination used for imaging ...
(pixels/micron)
424 % hdthresh - % of peak intensity where comet begins tailthresh -
% of peak intensity where comet ends headdiameter - diameter ...
of head in pixels
425 %
426 % outpus: headdna - % dna in comet head taildna - % dna in comet ...
tail otm - olive tail moment in microns taillength - length of ...
comet tail in microns cometlength - total length of comet in ...
microns
427
428
429 %% Calculate Background
430 backgndwidth = round(0.1*length(cometim(:,l)));
431 % make background 10% of total image width
432
433 background = sum(cometim(1:backgndwidth,:))/backgndwidth;
434 % background is the total average intensity in each column from ...
the top 10% of the image
435 cometsum = sum(cometim) /length (cometim(:, 1) )-background;
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436 % cometsum is the average intensity in each column minus the ...
background
437 % Reverse polarity of comet image cometsum = cometsum([end:-1:1]);
438
439 %Default comet params to -1: this will indicate that these comets ...
have not been analyzed and should not be written to data file
440 headdna = -1;
441 taildna = -1;
442 otm = -1;
443 taillength = -1;
444 cometlength = -1;
445
446 %% Define Comet Head and Tail
447 indices = find(cometsum > hdthresh*max(cometsum)); %col. where ...
comet begins
448
449 if numel(indices) > 0 && indices(l) < 0.5*length(cometsum)
450 % if beginning found, assign location to startx
451
452 startx = indices(1);
453 indices = find(cometsum(startx:end) < tailthresh*max(cometsum));
454 % find column where comet ends
455
456 if numel(indices) > 0 % if end found, assign location to endx
457
458 endx = indices(l)+startx-1;
459
460 clear indices % clear unused variable
461
462 %Find head/tail division
463 temp-htx = startx + headdiameter; % approximate with head ...
diameter
464
465 % Search for division by looking for minimum of first ...
derivative around approximate head diameter
466 startsearch = round(temp-htx*0.9);
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467 endsearch = round(temp-htx*1.1);
468 [trash,headtailx] = ...
min(diff(cometsum(startsearch:endsearch)));
469 headtailx = startsearch+headtailx; % assign value to ...
headtailx
470 clear trash temp-htx startsearch endsearch
471
472 if headtailx < endx
473 % if head is not longer than tail, calculate comet ...
parameters
474
475 %Round indices to nearest integer
476 headtailx=round(headtailx);
477 endx=round(endx);
478 startx=round(startx);
479
480 % tail center-of-mass
481 tailcom = ...
sum(cometsum(headtailx+l:endx).*(headtailx+1:1:endx))
482 /sum(cometsum(headtailx+l:endx))*convfactor;
483 % head center-of-mass
484 headcom = ...
sum(cometsum(startx:headtailx).*(startx:l:headtailx))
485 /sum(cometsum(startx:headtailx))*convfactor;
486 % percentage dna in comet head
487 headdna = sum(cometsum(startx:headtailx))
488 /sum(cometsum(startx:endx))*100;
489 % percentage dna in comet tail
490 taildna = sum(cometsum(headtailx:endx))
491 /sum(cometsum(startx:endx))*100;
492 otm = (tailcom-headcom)*taildna/100; % olive tail ...
moment (um)
493 taillength = (endx-headtailx)*convfactor; % tail ...
length (um)
494 cometlength = (endx-startx)*convfactor; %comet length
(um)
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495
496 %% This code is for debugging
497 % 1
498 figure subplot(2,1,1) imshow(cometim) line([startx startx], [1
499 length(cometim(:,l))],'Color','w') line([headtailx headtailx], [1
500 length(cometim(:,l))],'Color','r') line([endx endx],[1
501 length(cometim(:,1))],'Color' ,'b') subplot(2,1,2)
502 plot ((comet sum) /max (comet sum))
503 %}
504 end
sos end
506 end
507 end
508
509 function editl4_Callback (hObject, eventdata, handles)
510 end
511
512 % Executes during object creation, after setting all properties.
513 function editl4-CreateFcn(hObject, eventdata, handles)
514 if ispc && isequal(get(hObject,'BackgroundColor'),
515 get (0, 'defaultUicontrolBackgroundColor'))
516 set (hObject, 'BackgroundColor', 'white');
517 end
518 end
519
520 function edit9_Callback (hObject, eventdata, handles)
521 end
522
523 % Executes during object creation, after setting all properties.
524 function edit9-CreateFcn(hObject, eventdata, handles)
525
526 if ispc && isequal (get (hObject, 'BackgroundColor'),
527 get (0, 'defaultUicontrolBackgroundColor'))
528 set (hObject, 'BackgroundColor', 'white');
529 end
530 end
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531
532 function editll-Callback(hObject, eventdata, handles)
533 end
534
535 % Executes during object creation, after setting all properties.
536 function editll-CreateFcn(hObject, eventdata, handles)
537
538 if ispc && isequal(get(hObject,'BackgroundColor'),
539 get(0,'defaultUicontrolBackgroundColor'))
540 set(hObject,'BackgroundColor','white');
541 end
542 end
543
544 % Executes during object creation, after setting all properties.
545 function editl0-CreateFcn(hObject, eventdata, handles)
546 if ispc && isequal(get(hObject,'BackgroundColor'),
547 get(0,'defaultUicontrolBackgroundColor'))
548 set(hObject, 'BackgroundColor','white');
549 end
550 end
551
552 function editl2_Callback(hObject, eventdata, handles)
553 end
554
555 % Executes during object creation, after setting all properties.
556 function editl2_CreateFcn(hObject, eventdata, handles)
557
558 if ispc && isequal(get(hObject,'BackgroundColor'),
559 get(0,'defaultUicontrolBackgroundColor'))
560 set(hObject,'BackgroundColor','white');
561 end
562 end
563
564 function editl3-Callback(hObject, eventdata, handles)
565 end
566
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567 % Executes during object creation, after setting all properties.
568 function editl3_CreateFcn (hObject, eventdata, handles)
569
570 if ispc && isequal (get (hObject, 'BackgroundColor'),
571 get (0, 'defaultUicontrolBackgroundColor'))
572 set (hObject, 'BackgroundColor', 'white');
573 end
574 end
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